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CHAPTER 1 
INTRODUCTION 
 
1.1 Pre-invasive lesions of the breast 
The normal human breast is a complex organ composed of thousands of small 
clusters of glands called lobules that are lined by specialized epithelial cells which 
produce milk. The milk is drained by collecting ducts that join to form larger ducts finally 
terminating in the nipple.  The collecting duct branches extensively and ends into 
terminal ductal lobular unit (TDLU), the smallest functional unit of the breast.  A typical 
terminal ductal lobular unit is composed of a lobule and a terminal duct with its multiple 
end ductules or acini.  The duct and TDLU are lined by two layers of cells, the innermost 
luminal epithelial layer and outer layer of myoepithelial cells.  Uncontrolled proliferation 
of neoplastic epithelial cells in the ducto-lobular network gives rise to preinvasive 
lesions.    Histologically, the preinvasive lesions are classified into two categories: 
lobular and ductal subtypes.  Although both types of lesions arise in the TDLU, they 
differ in the cell morphology.  The lobular lesions consist of small, non polarized, loosely 
cohesive cells that resemble luminal cells of breast acini, while the ductal lesions 
consist of cells that are more similar to the cells of normal breast ducts.  The 
preinvasive lesions culminating to lobular neoplasia are atypical lobular hyperplasia 
(ALH) and lobular carcinoma in situ (LCIS) whereas flat epithelial atypia (FEA), atypical 
ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) constitute the preinvasive 
lesions of ductal subtype.  In US, majority of newly diagnosed cases (approximately 
80%) of preinvasive and invasive breast cancer are of ductal type (Sgroi 2010).                                                                                                                                                       
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1.2 Ductal carcinoma in situ 
Ductal carcinoma in situ (DCIS) results from proliferation of the transformed epithelial 
cells in the ducts of the breast.  The malignant epithelial cells accumulate in the lumen 
of the duct but remain confined therein without breaching the basement membrane 
(Pinder and Ellis 2003).  This in situ, non-invasive stage may further progress to 
invasive breast cancer in some patients.  The proportion of DCIS lesions that will 
progress to invasive disease is unpredictable and the latency of disease progression is 
highly variable.  There has been a gradual change in the perception about DCIS in the 
scientific community and DCIS is now recognized as a separate specific pathologic 
entity from invasive ductal cancer (IDC) and is considered as an immediate non-obligate 
precursor to IDC (Schnitt, Silen et al. 1988; Allred, Mohsin et al. 2001) . 
 
1.2.1 Epidemiology of DCIS 
Prior to 1980, DCIS was rarely detected and was only usually diagnosed when it 
formed a large palpable mass in the breast.  With the introduction of nationwide 
mammographic screening, DCIS became the most rapidly increasing subset of breast 
carcinomas.  The incidence of DCIS rose from 1.87 per 100,000 women in 1973-1975 
to 32.5 per 100,000 in 2005 (Virnig, Wang et al. 2010).  Figure 1.1 represents the trends 
in incidence of DCIS in the pre and post mammography era.  Currently, more than 
60,000 patients are diagnosed with DCIS each year in the US (Lari and Kuerer 2011).  
At present, DCIS accounts for 20-45% of all newly detected cancers in females 
undergoing breast screening (Sakorafas, Farley et al. 2008).  The incidence of DCIS in 
women younger than 30 years is rare and the incidence is low in those younger than 40 
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years.  The risk of getting DCIS progressively increases from age 40 to 50 years and 
then more slowly after age 50 years and stabilizes after age 60 years.  
 
1.2.2 Diagnosis of DCIS 
DCIS is usually an asymptomatic disease and is most commonly detected as 
microcalcifications in screening mammography.  These calcifications may manifest as 
fine linear branching, pleomorphic, clustered or rounded in appearance (Evans 2003).  
The mammographic findings are then further confirmed with biopsy of the breast tissue.  
In some cases, calcifications may develop only in part of the DCIS lesion and a large 
part may be occult in mammography.  Hence, mammography may underestimate the 
pathologic extent of disease, especially in patients with multifocal disease.  Magnetic 
resonance imaging (MRI) is more sensitive in diagnosing DCIS than mammography 
(92% versus 56%) and the number of missed DCIS cases with MRI is far fewer than 
those missed with mammography (Kuhl, Schrading et al. 2007).  However, the use of 
MRI alone in diagnosis is not advocated because of its moderate specificity in detection 
of DCIS (Lehman 2010). 
  
1.2.3 Classification of DCIS 
Early attempts to classify DCIS were based on gross and histological features of the 
lesions such as size and shape of cells, microscopic growth pattern, rate of growth and 
degree of cellular necrosis.  The most aggressive form was referred to as ‘comedo-type’ 
with characteristic central necrosis and surrounding large, irregular proliferating cells 
(Figure 1.2).  All other DCIS lesions were classified as ‘non-comedo’ type as the 
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structure was less necrotic and the cells look smaller with more normal appearance.  
These non-comedo lesions were further categorized according to their growth pattern 
into following different types:  Cribriform (appearing to have small holes or pores), 
papillary (appearing to have fingerlike projections), micropapillary (showing smaller 
fingerlike projections) and solid (cells filling up the lumen completely).  However, certain 
DCIS lesions do not fit in any of the above categories and they have a more complex 
growth pattern and cellular features.  These were collectively grouped as ‘mixed type’.  
The histomorphological classification described above has limited clinical utility as it 
does not address intra-tumoral diversity of DCIS lesions.  This traditional classification 
focuses on cellular arrangement and does not reflect the biologic potential of individual 
lesion.  More recent classification approaches are based on numerical scoring and 
nuclear grade, which reflect cell differentiation and growth rate.  In this system, the 
DCIS lesions are graded as well differentiated (grade1), moderately differentiated 
(grade 2) and poorly differentiated (grade 3) depending upon the extent of differentiation 
of cells (Figure 1.2).  It is important to note that there is no accepted standard method of 
grading and this classification method also has limitations with regard to intra-tumor 
heterogeneity in individual DCIS cases.   
In the current clinical practice, for prognosis and treatment decisions, a fairly 
reproducible classification system called Van Nuys Prognostic scoring index (VNPI) is 
widely used (Silverstein, Lagios et al. 1996).   VNPI scores take into account several 
quantifiable parameters of DCIS.  This pathologic classification combines the following 
four factors: overall tumor size, clear surgical margin width, nuclear grade and age of 
the patient.  Scores of 1 (best) to 3 (worst) are assigned for each of the four factors and 
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then summed up to give an overall VNPI score ranging from 4 to 12.  Patients are then 
subgrouped according to the overall score into three risk categories. Those with high 
nuclear grade lesions are grouped into the worst prognostic category (group 3) and 
patients having non-high-grade lesions (nuclear grade 1 or 2) are then categorized as 
group 2 (intermediate group) or group 1 depending upon the presence or absence of 
necrosis respectively (Figure 1.3). 
 
1.2.4 Evolution and progression of DCIS 
 
Presently, there are two major proposed models which aim to explain the origin and 
evolution of breast tumorigenesis.  The stochastic model, also known as clonal 
evolution model, postulates that any breast epithelial cell may be the target of an 
initiating event and the cancer process evolves further with cumulative genetic, 
epigenetic and phenotypic changes combined with selection over a period of time.  The 
other model namely the cancer stem cell model hypothesizes that the cell of origin may 
be either a breast stem cell itself or any progenitor cell (Wicha, Liu et al. 2006; Kakarala 
and Wicha 2008).  
Several models have also been proposed to describe the progression of breast 
carcinoma.  These models are based on epidemiological, morphological and 
immunohistochemical studies.  The traditional linear model of breast cancer progression 
hypothesizes that the progression occurs sequentially in stages from normal epithelium 
to invasive carcinoma via non-atypical and atypical hyperplasia and in situ carcinoma.  
Genomic and transciptomic studies provide further support to this multistep progression 
model.  The classic ‘ductal’ model proposed by Wellings and co-workers suggests that 
Flat Epithelial Atypia (FEA), Atypical Ductal Hyperplasia (ADH) and Ductal carcinoma in 
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situ (DCIS) are non-obligate precursors of invasive ductal carcinoma (IDC).  The 
postulates of this classic theory are that DCIS is a direct precursor of IDC and ADH is a 
direct precursor to low grade DCIS (Wellings and Jensen 1973).  Page and colleagues 
proposed an alternative linear multistep model resembling the classic ‘Wellings ductal’ 
model and include in their model, usual ductal hyperplasia as the precursor of ADH 
(Page, Dupont et al. 1985).  This alternative model has been contested however in the 
light of immunohistochemical and genomic findings that indicate that usual ductal 
hyperplasia has a distinct immunohistochemical and molecular profile from FEA. 
Other models reflect different views from these linear theories about the evolutionary 
pathways of DCIS and IDC.  ‘Non-linear’ and ‘branched’ models describe DCIS as a 
progenitor of IDC and propose that different grades of DCIS progress to different grades 
of IDC.  A ‘parallel’ model of progression of DCIS and IDC has been proposed by 
Sontag and Axelrod (Sontag and Axelrod 2005), which suggests that DCIS and IDC 
diverge from a common progenitor cell and progress independently through different 
grades in parallel.   This model corresponds very well with the pathological observations 
with regard to heterogeneity of DCIS and IDC lesions.  A theoretical view of intra-
lesional or inter-lesional heterogeneity in DCIS is depicted in the Figure 1.4.  The DCIS 
lesion may be homogenous or heterogeneous in terms of different nuclear and cell 
sizes, coexisting different molecular subtypes, and genetic and epigenetic alterations 
(Berman, Gauthier et al. 2010).  The parallel model, however, calls into question the 
rationale of doing mammographic screenings to detect IDC at an early stage and also 
the current treatment strategy for DCIS to prevent the progression to IDC. 
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1.2.5 Genomic analyses and expression profiling of DCIS 
To date, there have not been many studies of DCIS as compared to IDC but it seems 
likely that the same chromosomal regions are amplified with comparable frequencies in 
DCIS as occurring in IDC.  Simpson et al. showed that a loss of 16q results in low grade 
DCIS whereas high grade DCIS is characterized by amplification in 17q12 region 
(Simpson, Gale et al. 2005).  Comparative genomic hybridization (CGH) analyses of 
DCIS and IDC lesions also confirm the above findings (Buerger, Otterbach et al. 1999).  
They show that low and intermediate grade DCIS are characterized by chromosomal 
loss of 16q whereas 1q gain and 11q loss occur at higher frequency in intermediate 
grade DCIS.  High grade DCIS, however is more complex in terms of these alterations 
as characterized by losses in 8p, 11q, 13q and 14q,  gains in the 1q, 5p, 8q and 17q 
and amplifications of 17q12  (ERBB2) and 11q13 (cyclin D1).  Loss of heterozygosity 
(LOH) studies in preinvasive breast lesions by O’Connel and colleagues revealed 
chromosome 16q as a common LOH hot spot in ADH as well as in low grade DCIS 
(O'Connell, Pekkel et al. 1998).  Molecular cytogenetic analysis by CGH of several 
preinvasive and invasive breast cancer cell lines revealed that most common gains are 
found at 8q, 1q, 7q, 3q and 7p and losses occur at Xp, 8p, 18q and Xq (Forozan, 
Veldman et al. 1999).   
Over the past few years, tremendous technological development has occurred that 
has enabled researchers to interrogate the molecular events occurring at the 
preinvasive stages of breast cancer.  Tissue micro-dissection coupled with high 
throughput genomic and proteomic technologies have broadened our comprehension of 
the biology of DCIS.  These technologies have provided useful molecular 
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characterization of DCIS lesions and have identified distinct facets of premalignant 
progression.  Several gene expression profiling studies of DCIS have been carried out 
using a combination of laser capture micro-dissection and microarrays (Ma, Salunga et 
al. 2003; Schuetz, Bonin et al. 2006; Castro, Osorio et al. 2008; Vincent-Salomon, 
Lucchesi et al. 2008; Emery, Tripathi et al. 2009; Muggerud, Hallett et al. 2010).  Serial 
analysis of gene expression found that the most dramatic transcriptome change occurs 
at the transition from normal epithelium to DCIS rather than from DCIS to invasive 
cancer (Porter, Lahti-Domenici et al. 2003).  This is supported by phenotypic and 
genomic analyses demonstrating that the molecular heterogeneity of breast ductal 
carcinomas is already established in in situ lesions (Vincent-Salomon, Lucchesi et al. 
2008), and also from studies of co-existing DCIS and IDC (Castro, Osorio et al. 2008).  
Increase in tumor grade and presence of necrosis have been associated with greater 
gene expression variability and distinct transcriptional signatures (Adeyinka, Emberley 
et al. 2002; Ma, Salunga et al. 2003).  Hannemann et al. identified a gene expression 
classifier of 35 genes that differed between DCIS and IDC and a panel of 43 genes 
which further distinguished well and poorly differentiated DCIS (Hannemann, Velds et 
al. 2006). 
 
1.2.6 Molecular markers of DCIS 
Molecular profiling is being gradually integrated with histogical observations to 
improve risk stratification and for selection of appropriate therapy for patients with DCIS.  
Based on combination of molecular and morphological features with genomic and 
immunohistochemical data, most preinvasive and invasive lesions are stratified into 
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those following either a low grade molecular pathway or a high grade molecular 
pathway as depicted in Figure 1.5.  The low grade molecular subtype is characterized 
by loss of 16q, gains of 1q and expression of estrogen (ER) and progesterone (PR) 
receptors and the lesions of this subtype are referred to as ‘luminal’.  Furthermore, 
depending upon the absence or presence of Her-2, they are classified as luminal A or 
luminal B, respectively.  The high grade variety has gain of 11q13, loss of 13q, 
amplification of 17q12 and infrequent expression of ER and PR.  Lesions with these 
molecular and gene expression signatures are referred to as ‘basal’ or ‘Her-2’ 
depending upon the absence or presence of Her-2 expression, respectively.  Some of 
the important molecular markers mentioned above and others that have previously been 
identified in patients with DCIS are described in further detail below.   
Her-2/neu:  
The Her-2/neu gene encodes for an proto-oncoprotein, c-erbB2, a tyrosine kinase 
receptor.   Her-2/neu amplification plays an important role in initiation rather than in 
progression of ductal carcinoma (Allred, Clark et al. 1992) and its overexpression 
predicts local recurrence (Han, Nofech-Mozes et al. 2012).  
Estrogen receptor (ER): 
Estrogen receptor (ER) expression is inversely related to the grade of DCIS lesions 
(Kuerer, Albarracin et al. 2009) and targeting DCIS that express ER with tamoxifen 
significantly reduces risk of subsequent breast cancer by 40%–50% (Allred, Anderson 
et al. 2012).   
Progesterone receptor (PR): 
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Similar to ER, Progesterone receptor (PR) expression also has an inverse 
relationship to nuclear grade and its presence is associated with expression of ER and 
lack of comedo-necrosis in DCIS (Claus, Chu et al. 2001; Barnes, Boland et al. 2005).   
Cyclin D1: 
Cyclin D1 is an important regulator of cell cycle and cyclin dependent kinases. 
Amplification of cyclin D1 is observed in 10-18% cases of DCIS (Simpson, Quan et al. 
1997; Vos, Ter Haar et al. 1999).  There have been conflicting reports on the correlation 
between expression of cyclin D1 and ER (Oh, Choi et al. 2001; Lebeau, Unholzer et al. 
2003).  Studies also report that there is no correlation between cyclin D1 expression 
and risk of local recurrence (Millar, Tran et al. 2007). 
c-myc: 
c-myc is a proto-oncogene that regulates cell growth and proliferation.  Although 
increased c-myc expression is associated with poor prognosis in IDC, its role in 
preinvasive lesions is not clear.  There have been conflicting reports regarding the 
amplification of c-myc gene in the premalignant lesions of the breast.  No c-myc 
amplification was observed in DCIS in two independent studies (Vos, ter Haar et al. 
1999; Robanus-Maandag, Bosch et al. 2003), whereas other groups reported c-myc 
amplification in the DCIS lesions (Watson, Safneck et al. 1993; Aulmann, Bentz et al. 
2002).  Altintas et al. reported that high expression of c-myc in DCIS did not predict 
local recurrence (Altintas, Lambein et al. 2009). 
Bcl-2: 
Bcl-2 is a protein regulating apoptosis and has been shown to be an independent 
prognostic marker in early stages of breast carcinoma.  It is present in the whole 
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continuum of breast lesions from FEA, ADH to well-differentiated DCIS (Siziopikou, 
Prioleau et al. 1996; Meteoglu, Dikicioglu et al. 2005).  The expression of Bcl-2 
gradually decreases as lesions become more aggressive (Mustonen, Raunio et al. 
1997).   
P53: 
P53 is a tumor suppressor gene and regulates transcription and repression of a 
number of genes.  Inactivating mutations of p53 have been observed in a large 
percentage (40%) of high grade DCIS, whereas low grade DCIS do not exhibit any 
alterations, and the frequency of these mutations is very low (5%) in the intermediate 
grade lesions.  (Walker, Jones et al. 1997; Done, Eskandarian et al. 2001).   
Ki67: 
Ki67 is a cell cycle associated nuclear protein and is commonly used as a 
proliferation marker.  The expression levels of Ki67 in DCIS have been reported as 10-
15% (Barnes, Khavari et al. 2005).  ADH and well differentiated DCIS lesions generally 
have low expression of ki67 whereas poorly differentiated lesions have high ki67 
expression levels.   
E-cadherin: 
E-cadherin is a tumor suppressor gene. It is an important molecular marker for 
differential diagnosis of low grade DCIS, which stains characteristically positive for E-
cadherin, from the lobular lesions that are exclusively negative for E-cadherin (Vos, 
Cleton-Jansen et al. 1997; Jacobs, Pliss et al. 2001). 
Vascular Endothelial Growth Factor (VEGF): 
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VEGF is an angiogenic factor and high expression levels in DCIS have been 
observed (Viacava, Naccarato et al. 2004).  Hieken et al. suggest that increase in VEGF 
expression correlates with the biologic aggressiveness of DCIS lesions (Hieken, Farolan 
et al. 2001).  E-cadherin has also been shown to be associated with the expression 
levels of VEGF-A and VEGF-C that contribute to angiogenic process in DCIS (Gotte, 
Kersting et al. 2007). 
A direct positive relationship has been observed for the expression of ER, PR, and 
Bcl-2 (Provenzano, Hopper et al. 2003).  Ringberg et al. (Ringberg, Anagnostaki et al. 
2001) suggest that a molecular signature with lack of ER and PR, Her-2 over-
expression, accumulation of p53, and high ki67 expression is a strong predictor of local 
recurrence rate in DCIS.  In a retrospective study of DCIS cases, DCIS lesions that 
were positive for p16, COX-2, and Ki67 expression were significantly associated with 
risk of subsequent invasive cancer whereas DCIS lesions that either lacked ER but 
were positive for ERBB2 and Ki67 or that lacked COX2 and were positive for p16 and 
Ki67 were associated with recurrence of DCIS (Kerlikowske, Molinaro et al. 2010). 
There are conflicting reports on the status of other molecular markers such as TGFβ, 
p16, p27, p21 and it is currently hard to interpret the roles of these molecules in the 
context of DCIS progression.  Efforts are ongoing in the field towards deciphering the 
molecular events associated with progression of DCIS.  Lu et al. identified that 14-3-3-
sigma in conjunction with ERBB2 promotes the progression of DCIS to IDC (Lu, Guo et 
al. 2009).  Qi et al. analyzed micro-RNA expression patterns in the preinvasive and 
invasive lesions of the breast.  They found a consistent increase in the expression of 
miR-21 along with its targets (PTEN, PCCD4 and TMI) at each successive stage (Qi, 
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Bart et al. 2009).  A comprehensive systematic review of the studies done on the 
biological markers of DCIS over the past 10 years has been compiled by Lari and 
Kuerer (Lari and Kuerer 2011).  The authors concluded that there is an unmet need to 
identify important prognostic and predictive markers in DCIS and the study of 
biomarkers is still in its infancy in DCIS as compared to IDC. 
1.3  Goals and significance of the present study 
The goal of most expression studies in DCIS has been to characterize molecular 
features of the lesions that are likely to progress to invasive cancer from those that 
remain indolent.   Most research efforts have focused towards understanding the 
progression of DCIS to invasive breast cancer; however, current knowledge of earlier 
events in the breast tumorigenesis remains limited.  It is imperative to identify the 
underlying molecular and genetic changes that drive transition from normal breast 
epithelium to preinvasive lesions of DCIS.  In the present study, our aim was to 
determine and compare the gene expression profiles of normal mammary epithelial 
cells and different DCIS models.  Results from this study may help in elucidating key 
genes and pathways involved in the premalignant process and may help to establish 
clinical biomarkers and define constituents of networks and pathways that contribute to 
the DCIS pathology.  
We hypothesize that there will be a common set of genes highly differentially 
expressed between normal mammary epithelial cells and different models of DCIS, and 
that the products of these genes may be potential targets for preventing the 
premalignant progression.  
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Specific Aim 1: To determine the expression changes that are common to multiple DCIS 
models in comparison to normal mammary epithelial cells by whole genome microarray 
analysis. 
Specific Aim 2: To validate the results obtained from microarray studies using other 
platforms such as next generation sequencing, real time polymerase chain reaction 
(qRT-PCR) and western blotting.  
Specific Aim 3: To characterize the molecular pathways of selected genes and their role 
in premalignant progression.  
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Figure 1.1: Trends in the incidence of ductal carcinoma in situ (DCIS) and 
invasive breast cancer (1975-2005). The incidence of DCIS rose from 1.87 per 
100,000 women in 1973-1975 to 32.5 per 100,000 in 2005 (Adapted from Virnig et al. 
JNCI, 2010) 
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Figure 1.2: Classification scheme of DCIS lesions. (Upper Panel) Based on 
histomorphological features, DCIS lesions are categorized into following types A) 
Comedo B) Cribriform C) Solid D) Micropapillary E) Papillary F) Mixed; (Lower Panel) 
Based on the extent of differentiation of cells, the lesions are graded as well 
differentiated (grade1), moderately differentiated (grade 2) or poorly differentiated 
(grade 3). (Adapted from Allred DC, JNCI Monographs, 2010) 
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Figure 1.3: Classification of DCIS lesions by modified Van Nuys prognostic 
scoring index (VNPI).   VNPI score combines the following four factors: overall tumor 
size, clear surgical margin width, nuclear grade and age of the patient.  Patients are 
grouped according to the overall score into three risk categories. Patients with high 
nuclear grade lesions are grouped into the worst prognostic category (group 3) and 
those with non-high-grade lesions (nuclear grade 1 or 2) are then categorized as group 
2 (intermediate group) or group 1 depending upon the presence or absence of necrosis 
respectively. (Adapted from Silverstein MJ, Oncologist, 1998) 
Non high grade  
nuclear grades 1 or 2 
High grade  
nuclear grade 3 
Necrosis absent Necrosis present 
       DCIS 
Group 3 
   Group 1 Group 2 
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Figure 1.4: A hypothetical model depicting heterogeneity in DCIS lesions.  The 
DCIS lesions may be homogenous or heterogeneous based on different nuclear, cell 
sizes and coexisting different molecular subtypes.  The two ducts represent theoretical 
heterogeneity between different DCIS patients (interlesional) or between two different 
regions in a DCIS lesion in the same patient (intralesional).  (Adapted from Berman et 
al., Cancer Prev. Res., 2010) 
. 
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Figure 1.5:  Classification of invasive ductal breast cancer based on distinct 
genetic and molecular profiles.  Lesions are stratified into following either low grade 
molecular pathway or high grade molecular pathway.  A) The low grade lesions are 
characterized by loss of 16q, gains of 1q and expression of estrogen (ER) and 
progesterone (PR) receptors.  B) The high grade lesions have gain of 11q13, loss of 
13q, amplification of 17q12 and infrequent expression of ER and PR.  The luminal A 
and luminal B subtypes mainly follow the low grade like gene-expression pathway and 
are generally indolent whereas high grade like pathway is followed by the aggressive 
subtypes like Her-2 and basal.  (Adapted from Sgroi DC, Annu. Rev. Pathol. Mech. Dis., 
2010)   
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 MATERIALS 
Disulfiram and Riluzole were generous gifts from Drs Angelika Burger and David 
Gorski respectively (Karmanos Cancer Institute, Detroit, MI).  Ham’s F-12 nutrient 
mixture (F-12), Dulbecco’s modified Eagles medium/Ham’s F-12 nutrient mixture 
(DMEM/F12), bovine serum albumin (BSA), hydrocortisone, dimethyl sulfoxide (DMSO), 
4-hydroxybenzaldehyde and valproic acid were purchased from Sigma (St. Louis, MO).  
Phosphate-buffered saline (PBS), horse serum, epithelial growth factor (EGF), insulin, 
and 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Trizol® 
were purchased from Invitrogen (Carlsbad, CA).   Mammary Epithelial Media 171 
(M171) and Mammary Epithelial Growth Factor Supplement were from Cascade 
Biologics (Portland, OR).  Fetal bovine serum (FBS) was from Hyclone (Logan, UT). 
Trypsin/EDTA solution, and penicillin-streptomycin were from Cellgro (Herndon, VA).  
Cultrex™ rBM was from Trevigen (Gaithersburg, MD).  Total RNA prepared from human 
mammary epithelial cells was obtained from Cell Applications (San Diego, CA).  Primary 
antibodies used for western blotting were mouse anti-GAPDH (EMD Chemicals, 
Darmstadt, Germany) and goat anti-ALDH5A1 (sc-70007, Santa Cruz Biotechnology, 
Santa Cruz, CA), with horseradish peroxidase-conjugated secondary antibodies and 
enhanced chemiluminescence detection as previously described (Li, Chow et al. 2010). 
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2.2 METHODS  
2.2.1 Cell Lines and Culture 
MCF10A and MCF10.DCIS cell lines were obtained from the Cell Lines Resource 
(Karmanos Cancer Institute, Detroit, MI) and maintained as monolayers in DMEM/F12 
containing 5% horse serum, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 50 U/ml 
penicillin, and 50 µg/ml streptomycin (and 5 ng/ml EGF only for MCF10A) at 37°C and 
5% carbon dioxide as previously described (Li, Chow et al. 2010).  SUM102 and 
SUM225 cell lines were a generous gift from Dr. Stephen Ethier (Karmanos Cancer 
Institute, Detroit, MI) and were maintained as monolayers in Ham’s F-12 containing 5% 
fetal bovine serum, 5 µg/ml insulin and 1 µg/ml hydrocortisone, 50 U/ml penicillin, and 
50 µg/ml streptomycin.   
In the in vitro three dimensional (3D) overlay culture with reconstituted basement 
membrane (rBM) protocol, single cells were seeded onto culture dishes previously 
coated with rBM (Cultrex®) and were overlaid with media containing 2% rBM (assay 
medium) as described previously (Li, Mullins et al. 2008; Sameni, Cavallo-Medved et al. 
2009; Li, Chow et al. 2010).  The 3D rBM overlay culture system described was 
modified to provide uniform culture conditions for all the cell lines by use of M171 media 
with Mammary Epithelial Growth Factor Supplement.  The final supplemented media 
contained bovine pituitary extract, 0.4% v/v; bovine insulin, 5 µg/ml; hydrocortisone, 0.5 
µg/ml; and recombinant human epidermal growth factor, 3 ng/ml, 50 U/ml penicillin and 
50 µg/ml streptomycin.  In brief, for 3D culture, each 60-mm dish was coated with 200 µl 
of ice-cold rBM and incubated at 37°C for 20 minutes to allow the rBM to solidify.  A 
trypsinized, single cell suspension containing 1x106 cells in the supplemented 171M 
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medium with 2% (v/v) rBM was added dropwise on top of the coated plate and 
incubated at 37°C for 30 minutes to let the cells attach to the rBM.  Then, 5 ml of the 
assay medium were added, and the cells were cultured at 37°C and 5% CO2.  The 
medium was changed every 4 days.  
 
2.2.2 Harvest of 3D structures  
MCF10A, MCF10.DCIS, SUM102 and SUM225 cells were grown in 3D rBM overlay 
culture for 12 days with change of media every 4 days.  Structures were harvested from 
rBM by repeated washes with ice-cold PBS supplemented with 5 mM EDTA.  In brief, 
after the removal of culture media, the structures were washed once with cold PBS and 
then scraped using a rubber policeman in ice-cold PBS containing 5mM EDTA.  The 
resulting gel-sol mixture of structures and rBM in PBS was then collected from the 
culture dishes into 15-ml Falcon tubes, and incubated on ice with gentle rocking for 45 
minutes to allow solubilization of rBM.  The structures were then pelleted by 
centrifugation at 100 x g for 5 minutes.  After removal of the supernatant, the pellet was 
then washed in PBS-EDTA and the above steps were repeated for the final collection of 
structures in the pellet. 
 
2.2.3 RNA extraction and purification 
Total RNA was extracted from MCF10A, MCF10.DCIS, SUM102 and SUM225 
samples using a combination of TRIZOL TM and ethanol precipitation.  In brief, the 
harvested structures of MCF10A, MCF10.DCIS, SUM102 and SUM225 were lysed for 
extraction of RNA by adding 1 ml TrizolTM per 60-mm culture dish.  Each lysate was 
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passed through a sterile 1 ml pipette tip several times and 0.2 ml of chloroform was 
added followed by vigorous shaking by hand for 15 seconds.  After incubation at room 
temperature (RT) for 2-3 minutes, the samples were centrifuged at 12,000 x g for 15 
minutes at 4°C, again followed by incubation for 2-3 minutes at RT.  The upper aqueous 
phase thus obtained was then transferred to a new tube and 0.5 ml of isopropanol was 
added, mixed and the samples were incubated for 10 minutes at RT and then 
centrifuged at 12,000 x g for 10 minutes at 4oC.  Following removal of supernatant, the 
RNA pellet was washed with 80% ethanol.  The samples were vortexed for 10 seconds 
to dislodge the RNA pellet from the side of the tube and then centrifuged for 5 minutes 
at 7,500 x g at 4°C.  The supernatant was discarded and the RNA pellet was air dried 
for 10 min.  The pellet was then dissolved in 50µl RNase free water by passing the 
solution through a sterile 200 µl pipette tip and was incubated for 15 minutes at 55-60oC 
to facilitate complete dissolution.  An additional purification step was included in the 
protocol to ensure elimination of any genomic DNA by an on-column DNase treatment 
of all the RNA samples using the RNase-free DNase Kit (from Qiagen).  The integrity 
and quantity of RNA in the samples was determined using NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and Agilent 2100 
Bioanalyzer (Agilent Technologies).  
 
2.2.4 Differential interference contrast (DIC) imaging  
MCF10A, MCF10.DCIS, SUM102 and SUM225 cells were grown on 12 mm Cultrex-
coated round coverslips and cultured in 24-well plates.  Coverslips were briefly washed 
with PBS at 37°C and incubated in 4% paraformaldehyde, pH 7.5 in PBS for 20 minutes 
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to fix the cellular structures followed by 3x washes with 0.75% glycine in PBS.  Then the 
coverslips were placed in a 35-mm dish with PBS and imaged with a confocal 
microscope (LSM 510; Zeiss) using 10x objective as described (Li, Mullins et al. 2008).  
 
2.2.5 Imaging and quantification of structures 
 
The structures were fixed and imaged as described above.  Tile-scan mode was 
used to obtain a 4 × 4 phase contrast tile image covering the entire area of the 
coverslip.  The images were then converted into tagged image file (.tif) files using the 
software provided by Zeiss.  The diameters of the structures were measured from at 
least 100 structures for each sample using Adobe Photoshop version CS2 software 
(Adobe Systems, Mountain View, CA).  
 
2.2.6 Affymetrix microarray analysis 
Specific protocols as described in the GENECHIPTM expression analysis technical 
manual were followed.  RNA was labeled using Affymetrix's standard one-cycle 
amplification and labeling protocol. The labeled cRNA was then hybridized to Affymetrix 
Human U133A 2.0 GeneChips, which were scanned using a GeneChip Scanner.  The 
raw array data was processed by Affymetrix GeneChip Operating Software (GCOS) to 
obtain detection calls and signal values.  Each complete probe array image was stored 
in a separate data file.   
 
2.2.7 Pathway analysis  
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The probe sets differentially expressed in the three DCIS samples versus MCF10A 
samples were used for network analysis.  Data sets containing probe set identifiers and 
fold changes were uploaded into Ingenuity’s software [Ingenuity Pathway Analysis 
(IPA); http:// www.ingenuity.com.  The IPA program searches the Ingenuity Pathway 
Knowledge Base for interactions (known from the literature) between the uploaded 
genes and all other genes in the database and generates a series of networks.  Fisher’s 
exact t-test was used to assign statistical significance and each network’s score 
displayed as -log (p value).   The common differentially expressed genes from mRNA-
Seq data were also uploaded to WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) 
to seek the associated significant pathways. 
 
2.2.8 Next generation sequencing  
Libraries of template molecules for high throughput DNA sequencing were prepared 
using Illumina mRNA Sequencing Sample Preparation Kit.  First, using Sera-Mag oligo 
(dT) beads, mRNA molecules were purified from total RNA.  Then the purified mRNA 
samples were fragmented under elevated temperature conditions.  Subsequently, first 
strand cDNA synthesis was done from the cleaved RNA fragments using reverse 
transcriptase and random primers.  This was followed by second strand synthesis using 
DNA polymerase I and RNaseH (using SuperScript II from Invitrogen).  These cDNA 
fragments were then subjected to repair end process with T4 DNA polymerase and 
Klenow.   The 3’ ends were then adenylated to prepare for adapter ligation.  After paired 
end ligation of adapters, the samples were purified on 1.2% agarose recovery 
FlashGelTM.  The library of products of desired size (150-200bp) was then selected for 
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further enrichment with 15 cycles of polymerase chain reaction (PCR) amplification.  
After validation of library using DNA 1000 chip (on Agilent Technologies 2100 
Bioanalyzer), the samples were run on an Illumina Genome Analyzer GAIIx (Illumina, 
San Diego CA, USA) for 76 cycles for sequencing.  All libraries were subject to single-
end sequencing.  Image analysis and base calling were performed using the Firecrest 
and Bustard modules of genome analyzer pipeline software (Illumina Pipeline software 
v. 1.6.0).  Sequencing reads were aligned to human reference genome (hg18).  
Alignments were performed with Novoalign (Novocraft Technologies SdnBhd, v. 
2.05.43) using default parameters and only unique alignments were considered for 
further analysis. 
 
2.2.9 Genomatix analysis 
2.2.9.1 Clustering: The next generation sequencing (NGS) analyzer from Genomatix 
(www.genomatix.de) was applied to cluster the alignments based on the distribution of 
aligned reads.  NGS analyzer parameters were set as following: (1) the size of sliding 
window as 100bp, (2) the minimum number of reads per cluster (τ) were calculated from 
the dataset applying a Poisson distribution. 
2.2.9.2  Gene ontology pathway analysis: The differentially expressed genes were 
uploaded to Genomatix Pathway System (GePS) for gene ontology and canonical 
pathway analysis. GePS uses information extracted from public and proprietary 
databases to display canonical pathways or to create and extend networks based on 
literature data. The output (term of gene ontology or canonical pathway) is coupled with 
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a p-value.  By default, P-value < 0.05 is used as threshold to define significantly 
enriched terms. 
2.2.9.3 Common framework mining and enrichment analysis: Frameworker (Genomatix) 
was employed to mine common framework of elements from a set of genes’ promoter 
sequences. These elements are usually transcription factor binding sites.  Common 
frameworks are defined as all the elements (TF sites) that occur in same order and in a 
certain distance range in all (or a subset of) the input sequences. The parameters used 
to mine the common frameworks were: (1) Maximum distance variance between two 
elements as 20bp (2) the distance between two elements as 10-200bp.   
 
2.2.10 Real-time quantitative PCR assay (qRT-PCR) 
First-strand cDNA was synthesized from total RNA using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA).  The qRT-PCR 
reactions were carried out using diluted cDNA, 150 nM of each primer, and SYBR 
Green master mix (Applied Biosystems, Foster City, CA) in 20 µl reactions on a 
StepOnePlus™ Real-Time PCR System.  Each sample was run in triplicate in separate 
wells for the target gene and three reference genes:  hypoxanthine 
phosphoribosyltransferase 1 (HPRT1); β-actin (ACTB); and β-glucuronidase (GUSB).  
The average of three threshold cycle (Ct) values for the target and reference genes was 
used to determine the level of expression relative to the control.  Delta-delta Ct method 
was used for data analysis.  Primer pair sequences for the genes selected for 
quantification are listed in Table 2.1. 
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2.2.11 Cell lysis  
Cell lysates for western blotting were made in RIPA lysis buffer composed of 50 mM 
Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 0.5% sodium deoxycholate, pH 7.4 
supplemented with protease and phosphatases inhibitors (1 mM PMSF, 1 mM sodium 
orthovanadate, 1 mM sodium fluoride, 50 nM okadaic acid, 8 µg/mL aprotinin, 8 µg/mL 
pepstatin and 8 µg/mL leupeptin). 
 
2.2.12 Immunoblot analysis  
Cell lysates were prepared from the harvested 3D structures by addition of lysis 
buffer as described previously (Li, Chow et al. 2010).  The lysates were briefly sonicated 
on ice, heated at 100°C for 5 minutes, separated by SDS-PAGE, transferred to 
nitrocellulose membranes for immunoblotting.  The blots were quantified using Fujifilm 
LAS-3000 System.   
 
2.2.13 Cell viability and proliferation assays  
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye 
reduction assay in 96-well microplates was used to determine cell viability. Cells (1x104) 
were plated in each well previously coated with Cultrex in a total volume of 200 µl of 
growth media.  The wells were then treated with serial dilutions of drug and vehicle 
control for 3 days.   After 3 days of drug treatment, MTT was added and further 
processed for absorbance as previously described (Li, Chow et al. 2010).  After 
normalizing the absorbance values for blank and vehicle controls, the data were 
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analyzed using GraphPad Prism version 5.0 by non-linear regression (curve fit) to plot 
sigmoid dose-response curves.  The mRFP-expressing variants of MCF10.DCIS and 
SUM102 were grown in 3D rBM culture on coverslips with exposure to drug or vehicle 
controls for 8 days.  To test for reversibility of growth inhibition, cultures were harvested 
after the 8-day treatment, and the cells re-plated in fresh growth media after dilution of 
the rBM.  The cultures were continued in 2D without rBM for ten days in the absence of 
inhibitors and then cells were counted.  
 
2.2.14 Statistical analysis  
Microarray Expression Data Analysis 
 
Affymetrix arrays were analyzed using the manufacturer’s reader software and the 
supplied scanner software.  Data analysis was done in three stages.  First, expression 
intensities were calculated for each gene probed on the array for all hybridizations (X in 
total) using the MAS5 algorithm in the Affymetrix package supplied with R-Bioconductor.  
Second, the intensity values were quality controlled and normalized: quality control was 
carried out by using the MAS5 P/M/A flag.  Genes only ever scored as ‘A’ absent were 
removed from the analysis.  All the arrays were then normalized using the 
normalize.quantiles routine also from the Affymetrix package in Bioconductor. This 
procedure accounted for any variation in hybridization intensity between the individual 
arrays.  Finally, these normalized data were imported into GeneSpring and analyzed for 
differentially expressed genes.  The groups of biological replicates were described to 
the software and significantly differentially expressed genes determined on the basis of 
t-tests and fold difference changes in expression level.  For other data analyses, the 
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results were plotted as the mean ± SEM.  Statistical analysis was performed using 
Graph Pad Prism version 5.0a (Graph Pad Software Inc., San Diego, CA).  Statistical 
significance was determined using Student’s t-test. 
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Gene of interest Primer Sequence 
TIMP-3 
Forward: ACGCTGGTCTACACCATCAAGCAGA 
Reverse: GACGCGACCTGTCAGCAGGTACTGG 
GFPT-1 
Forward: GTTGGCACAAGGCGAGGTAGCC 
Reverse: AAGGCAGGTTGTGCTGTCCACAC 
S100P 
Forward: CGATATTCGGGCAGCGAGGGC 
Reverse: CTTTTCCACTCTGCAGGAAGCCTG 
RHOB 
Forward: CCGGGAGAGAGCTAGGCCGAGT 
Reverse: GGATCGGCGGCTTTGTGCGTA 
FOXO3 
Forward: TTCGCTGGCCGCACGTCTTCAG 
Reverse: GGAGAGTTGGTTATCCCGGGCCG 
MET 
Forward: CTTTGCCAGTGGTGGGAGCACA 
Reverse: AGCGATGTTGACATGCCACTGTAA 
IRS1 
Forward: GGAGTGCACCCCTGAACCGC 
Reverse: GGTCTTCATTCTGCTGTGATGTCCA 
ALDH5A1 
Forward:  GCATAGCCACACCCATTCATT 
Reverse: CCAACTATTCAACTCTGCCAAGAA 
GLUL 
Forward: CTCGCTCTCGCGGCCTAGCTTT 
Reverse: CCTGAGGCAGGGACATGTACACC 
GLUD1 
Forward: AGCTTTGGCTTCTCTGATGACAT 
Reverse: ACCCCCAAACGGCACAT 
CASP2 
Forward: CCCACCGTTGAGCTGTGACTACGA 
Reverse: GGCTTCACCTGAAGGCAGACAGG 
DUSP5 
Forward: ATGACCAGGGTGGCCCAGTTGAA 
Reverse: CGGAGGTCCGTCGGGAGACATT 
PAK1 
Forward: CAGGACAGGAGGTGGCCATTAAGC 
Reverse: CCACAGCTCATCTCCCACGAGG 
GFPT2 
Forward: CCTGCTCCTTGCCCATAGTAAA 
Reverse: CCCACTTGAAACTACTCTCTTGCA 
GUSB 
Forward: CCAAAAAGTGCAGCGTTCCT 
Reverse: ACCTGGTTTCATTGGCAATCTT 
ACTB 
Forward: ACCGAGCGCGGCTACA 
Reverse: CTTAATGTCACGCACGATTTCC 
HPRT-1 
Forward: CGTCTTGCTCGAGATGTGATG 
Reverse: GAGCACACAGAGGGCTACAATG 
 
Table 2.1: Primer pair sequences of genes quantified for expression levels by real 
time PCR.  Specific primer pairs for the candidate genes were designed based on 
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sequences from Ref-Seq and meeting the following criteria:  amplicon length: 50-150 
bases; optimal primer length: 20 bases; melting temperature (Tm): 58-60oC; percentage 
of GC content: 30-80%; no more than 2 G/C residues in the last 5 nucleotides at the 3’ 
end and one of the primer in the pair should span exon-exon junction.  The specificity of 
the primers was then determined by a National Center for Biotechnology Information 
Blast search and University of California, Santa Cruz (UCSC) in silico PCR tool. 
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CHAPTER 3 
 
WHOLE GENOME EXPRESSION ANALYSIS BY MICROARRAY REVEALS A 
COMMON SET OF GENES HIGHLY DIFFERENTIALLY EXPRESSED IN DIFFERENT 
MODELS OF DCIS IN COMPARISON TO NORMAL MAMMARY EPITHELIAL CELLS 
 
3.1 BACKGROUND AND RATIONALE 
 
Global analysis of gene expression by microarrays has been extensively used in 
studying invasive breast cancer.  This approach is now being increasingly used to 
advance the understanding of premalignant breast disease as well.  Microarrays provide 
gene expression information in a high throughput manner and thus provide 
unprecedented opportunities to identify the unique transcriptional fingerprint associated 
with each stage of the disease progression.   
Here, we employed Affymetrix microarrays to identify transcriptional signatures of 
normal mammary epithelial cells and DCIS samples of different origins to elucidate 
candidate genes that may be contributing to premalignant progression.  We have used 
MCF10A cell line as a model for non-tumorigenic human mammary epithelial cells 
hereinafter referred to as ‘normal’.  MCF10A cells are a spontaneously immortalized 
human breast epithelial line exhibiting normal phenotype by most criteria (Debnath, 
Muthuswamy et al. 2003).  For instance, MCF10A cells do not form xenografts in 
immunodeficient mice (Soule, Maloney et al. 1990), and they model normal mammary 
epithelia as they form acini with apicobasal polarity and generate functional glandular 
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structures when grown in three-dimensional (3D) culture in reconstituted basement 
membrane (rBM) (Debnath, Mills et al. 2002).  MCF10A cells were derived from a 
patient with fibrocystic breast disease who underwent reduction mammoplasty (Soule, 
Maloney et al. 1990).  In addition to MCF10A, we employed different DCIS models of 
various origins in the present study.  One model of DCIS is MCF10.DCIS, which is 
isogenic with MCF10A and derived by sequential passage in vitro and in vivo of lesions 
that were derived from MCF10A cells transfected with H-Ras (Dawson, Wolman et al. 
1996).  In immunodeficient mice, MCF10.DCIS cells initially form lesions characterized 
as comedo DCIS and about 50% of the mature lesions later progress to invasive ductal 
carcinoma (IDC) (Miller, Santner et al. 2000; Strickland, Dawson et al. 2000).  The other 
two independent DCIS cell lines were derived from individual patients: SUM102 (Sartor, 
Dziubinski et al. 1997) and SUM225 (Yang, Albertson et al. 2004).  SUM102 cells were 
isolated from a patient diagnosed with extensive ductal carcinoma in situ with areas of 
micro-invasion.  SUM225 cells were derived from a chest wall recurrence in a patient 
previously diagnosed and treated for DCIS.   
Pre-clinical therapeutic identification and development has mostly been based in 
conventional cell culture systems on plastic dishes.  We have conducted all the 
experiments in the present study using in vitro three dimensional (3D) organotypic 
culture models with reconstituted basement membrane (rBM).  The model used in our 
lab is based on a 3D overlay culture system that was adapted by Brugge et al. for 
analysis of oncogene-induced changes in MCF10A cells (Debnath, Muthuswamy et al. 
2003).  In the 3D rBM overlay protocol, single cells are seeded onto coverslips or 
culture dishes previously coated with polymerized rBM (Cultrex® or Matrigel®) and are 
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overlaid with media containing 2% rBM when the cells have attached.  The rationale 
and advantages of using this model system are described in detail below.  
  The growth of mammary epithelial cells in two dimensional (2D) monolayers on 
tissue culture plastic does not reproduce the molecular and morphologic features as 
they exist in normal tissue microenvironment.  The 2D monolayers lack structural 
architecture and thus apical-basal polarity of single cells or ductal structures formed by 
populations of epithelial cells are not replicated in these models (Debnath and Brugge 
2005).  In contrast, the 3D cultures with rBM more closely resemble the in vivo situation 
with regard to cell polarity and its environment, which in turn influence cell behavior and 
gene expression.  Cancer cells grown in three dimensional (3D) matrices, such as 
reconstituted basement membrane (rBM), have been proposed to exhibit responses 
and resistance to drugs that are closer to those observed in vivo (Hebner, Weaver et al. 
2008; Horning, Sahoo et al. 2008; Li, Chow et al. 2010).  In vitro 3D culture systems 
recreate the fundamental features of glandular epithelium in vivo and provide a 
structurally appropriate context for studying breast cancer progression (Kim, Stein et al. 
2004).  Also, the heterogeneity in 3D culture may be far more realistic than homogeneity 
in 2D monolayers as the 3D culture is composed of cells with different phenotypes such 
as proliferating, non-proliferating and necrotic cells, which is more similar to the in vivo 
situation (Kim, Stein et al. 2004).  We used novel and tractable models of DCIS in an in 
vitro 3D rBM overlay culture system originally developed to study morphogenesis and 
oncogenesis of MCF10A cells (Debnath, Muthuswamy et al. 2003).  The 3D rBM 
overlay cultures are a better mimic of the in vivo environment than cells grown on plastic 
dishes (Kenny, Lee et al. 2007) and also provide a source for high quality RNA with 
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avoidance of the contribution of stromal cell RNA.  Thus, we employed the in vitro 3D 
culture model as opposed to conventional 2D model to conduct all our experiments for 
studying the premalignant progression from non-transformed mammary epithelial cells 
to DCIS.    
  
3.2 RESULTS 
 
3.2.1 Normal mammary epithelial cells and premalignant DCIS models exhibit 
phenotypic differences in 3D overlay cultures 
Our lab has further developed the in vitro 3D rBM overlay culture model originally 
developed in Brugge’s laboratory to study breast cancer progression.  Premalignant and 
malignant variants of parental MCF10A have been previously cultured in our lab in 3D 
laminin-rich rBM to analyze different signaling pathways and progression events (Li, 
Mullins et al. 2008).  We compared 3D rBM overlay cultures of the three DCIS models 
(MCF10.DCIS, SUM102 and SUM225) to parallel cultures of MCF10A cells as a model 
for human mammary epithelial cells.  All cultures were grown under uniform conditions 
with identical growth factors and supplements.  After 12 days in 3D rBM overlay culture, 
the MCF10A cells form a uniform population of acinar structures as previously 
described (Debnath, Mills et al. 2002; Li, Mullins et al. 2008) whereas the three DCIS 
models form larger and less uniform structures (Fig. 3.1). 
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3.2.2 High quality RNA yields from normal mammary epithelial cells and different 
models of DCIS grown in 3D cultures 
Using high quality and intact RNA is crucial for successful microarray experiments.  
We first standardized the protocol for extracting RNA from cells grown in 3D culture and 
optimized different experimental variables such as cell number, growth media and 
culture time for obtaining adequate yields of RNA for analysis.  To minimize variability 
and facilitate interpretation of microarray results in an unbiased manner, we isolated 
RNA from biological triplicates for each of the cell lines.  The quality and integrity of all 
the RNA samples were determined using the Agilent Bioanalyzer.  Profiles generated 
on the Bioanalyzer provide quantitative information on the concentrations and ribosomal 
ratios (28S/18S).  The Bioanalyzer software generates electropherograms that allow 
visual inspection of RNA integrity.  The RNA integrity number (RIN) takes into account 
the entire electrophoretic trace and measures RNA quality on a scale of 1 to 10 with 1 
being the most degraded and 10 being the most intact profile.  All the RNA samples 
extracted from the 3D cultures of normal mammary epithelial cells and different models 
of DCIS were of high quality.  The average RIN values of the RNA samples were in the 
range of 8.85-9.7.  All the samples conformed to the standards required for Affymetrix 
microarray analysis (RIN value > 5 or 28S/18S ratio > 1.5).  In one of the MCF10.DCIS 
samples (sample1), RIN value was not computed by the software due to non-critical 
anomaly during sample preparation.  However, considering the ribosomal ratios 
28S/18S (> 1.5) the sample quality was considered to be suitable for subsequent use 
for microarray experiment.  The results of RNA quality are depicted in the 
electrophoresis gel image and electropherograms in Figures 3.2a and 3.2b respectively.   
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3.2.3 Whole genome Affymetrix microarray identifies differentially expressed 
genes 
In collaboration with Applied Technology Genomics Center (at Wayne State 
University) and Sanford Burnham Institute (San Diego, California), we performed 
microarray analysis of the RNA samples extracted from biological triplicates described 
in the section above.  We employed Affymetrix GeneChip® Human Genome U133A 2.0 
Arrays, which represent 14,500 well-characterized human genes.  The GeneChip®  
analyzes the expression level of 18,400 transcripts and variants and is comprised of 
more than 22,000 probe sets. 
The gene expression profiles by hierarchical clustering for microarray data are shown 
in Figures 3.3a and b.  These results indicate that the three premalignant DCIS samples 
cluster more closely to each other than to normal MCF10A samples.  In between these 
clusters the biological replicates cluster to their equivalent in all four sample types.  The 
reproducibility between the biological triplicates and magnitude of changes (on log2 y-
axis scale) for the pair-wise comparison of MCF10.DCIS and MCF10A is illustrated in 
Figure 3.4.   
As hypothesized, results from Affymetrix microarray analysis reveal a number of 
genes (290) which are consistently differentially expressed between MCF10A and the 
three models of DCIS we tested.  Of these 290 genes, 137 were up-regulated and 153 
genes were down-regulated in all the three DCIS as compared to MCF10A.  Using a p-
value of 0.05 and cut-off of 1.5-fold change, we obtained 157 differentially expressed 
genes (Figure 3.5).  The genes up regulated more than 10- fold in DCIS included 
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aldehyde dehydrogenase 5A1 (ALDH5A1); major histocompatibility complex, class II, 
DQ beta 1 (HLA-DQB1); RAB25 member of RAS oncogene family, G protein-coupled 
receptor 56 (GPR56); butyrylcholinesterase (BCHE); B-box and SPRY domain 
containing (BSPRY); keratin 7 (KERT7); integrin beta 2 (ITGB2); fibroblast growth factor 
1 (FGF1) and immediate early response 3 (IER3) whereas genes showing more than 
10-fold decrease in DCIS included dual specificity phosphatase 1 (DUSP1); alcohol 
dehydrogenase 1B (ADH1B); periostin (POSTN); aspartoacylase (ASPA); chemokine 
(C-X-C motif) receptor 4 (CXCR4); insulin growth factor-like family member 2 (IGFL2); 
podoplanin (PDPN); decorin (DCN) and nidogen 1 (NID1).  The genes with largest fold 
change in expression identified in the list of those differentially expressed are 
summarized in Table 3.1. 
 
 
3.2.4 Ingenuity pathway analysis of microarray data reveals biological pathways 
and functions of differentially expressed genes 
To gain an overview of biological processes in which these differentially expressed 
genes are involved, we performed gene set enrichment analysis using Ingenuity 
pathway analysis (IPA) software.  The network-eligible IDs proceeded into the pathway 
analysis by comparing the network-eligible genes with the Ingenuity Pathways Analysis 
Knowledge Base (IPAKB), which is a curated database that contains numerous 
scientific findings extracted from hundreds of thousands of journal articles, textbooks, 
and other data sources and many canonical pathways derived from those scientific 
findings.  The significance (p-values) of the association between the dataset and the 
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canonical pathway is measured by comparing the number of specific genes of interest 
that participate in a given pathway to the total number of occurrences of those genes in 
all pathway annotations that are stored in the IPAKB.  The p-value indicates the 
probability that the association between the genes in the dataset and the canonical 
pathway is explained only by chance. 
Gene annotation and pathway analysis showed dysregulation of many important 
genes and pathways.  The canonical pathways associated with these differentially 
expressed genes include glutamate metabolism, PXR/RXR activation, IGF-1 signaling, 
integrin signaling and fatty acid biosynthesis (Figure 3.6).  The most significant network 
revealed by IPA analysis showed the presence of enzymes involved in glutamate 
metabolism.  The pathway includes 4 focus genes namely aldehyde dehydrogenase 5 
family member 1 (ALDH5A1), glutamine–fructose-6-phosphate transaminase 2 
(GFPT2), glutamate dehydrogenase 1 (GLUD1), and glutamate ammonia ligase (GLUL) 
(Table 3.2).  
The major functions of the differentially expressed genes were related to 
hematological disease, infection mechanism, cellular development, embryonic 
development and gastrointestinal disease (Table 3.3).  Functional annotation of the 
differentially expressed genes revealed enrichment of genes involved in various 
processes such as cell growth and proliferation, cell-cell signaling and interaction, cell 
death, cell morphology, cellular assembly and organization.  The genes found to be 
associated with cell growth and proliferation and cell development are ADAM 
metallopeptidase with thrombospondin type 1 motif, 5 (ADAMTS5); adaptor-related 
protein complex 1, sigma 2 subunit (AP1S2); ArfGAP with SH3 domain, ankyrin repeat 
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and PH domain 2 (ASAP2); cyclin D1 (CCND1); cell cycle progression 1 (CCPG); 
collagen, type IV, alpha 1(COL4A1); collagen, type IV, alpha 2 (COL4A2); diazepam 
binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) (DBI); extended 
synaptotagmin-like protein 2 (ESYT2); family with sequence similarity 102, member A 
(FAM102A); fibulin 1(FBLN); follistatin (FST); hemoglobin, epsilon 1(HBE1); huntingtin 
(HTT); mannosidase, alpha, class 1A, member 1 (MAN1A1); mitogen-activated protein 
kinase 8 (MAPK8); MyoD family inhibitor domain containing (MDFIC); midkine (neurite 
growth-promoting factor 2) (MDK); opioid receptor, kappa 1(OPRK1); periostin 
(POSTN); phosphopantothenoylcysteine decarboxylase (PPCDC); protein tyrosine 
phosphatase, receptor type, F(PTPRF);  solute carrier organic anion transporter family, 
member 2A1(SLCO2A1); small VCP/p97-interacting protein (SVIP); transglutaminase 1 
isoform (TGM1); thrombospondin, type I, domain containing 7A (THSD7A); wingless-
type MMTV integration site family, member 5B (WNT5B); WW and C2 domain 
containing 1 (WWC1); zinc finger homeobox 3 (ZFHX3) and zinc finger protein 655 
(ZNF655).  Several genes known to be dysregulated in ovarian adenocarcinoma were 
also found in our differential list of genes; namely apolipoprotein E (APOE); ATPase, 
aminophospholipid transporter, class I, type 8B, member 1 (ATP8B1); CXXC finger 
protein 5 (CXXC5); fibroblast growth factor 18 (FGF18); low density lipoprotein receptor-
related protein 8 (LRP8); met proto-oncogene (hepatocyte growth factor receptor) 
(MET); tissue inhibitor of metalloproteinases 3 (TIMP3) and vascular endothelial growth 
factor A (VEGFA).  Consistent with what we would expect to find, many differentially 
expressed genes were implicated in cancer (Figure 3.7 and Table 3.4).   
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3.3 DISCUSSION 
Based on microarray findings, a 70-gene predictor for breast cancer was identified by 
Van’t veer et al. that is now currently available commercially as MammaprintTM (van 't 
Veer, Dai et al. 2002).  Another test, Oncotype DX assay, utilizes expression analysis of 
21 genes for risk stratification and prognosis of breast cancer patients (Ishibe, Schully et 
al. 2011).  Two long term large scale randomized trials (Trial Assigning Individualized 
Options for Treatment [TAILO]Rx and Microarray In Node- Negative and 1 to 3 Positive 
Lymph Node Disease May Avoid Chemotherapy [MINDACT]) are underway to 
determine the clinical utility for Oncotype DX and MammaprintTM tools.  With regard to 
DCIS, a study by Adeyinka et al. identified 69 genes that were expressed at significantly 
different levels between low and high-grade DCIS (Adeyinka, Emberley et al. 2002).  
Another study compared 12,000 transcripts in a larger cohort of samples including ADH, 
DCIS, and IDC and found gene expression profiles to be highly similar in DCIS and IDC, 
but a signature of 85 genes separated DCIS and IDC (Ma, Salunga et al. 2003).  A 
diagnostic and prognostic application of microarrays in ovarian cancer has been 
reported by Kim and colleagues (Kim, Skates et al. 2002).  A previous microarray study 
in ovarian cancer reported up regulation of osteopontin gene in cancer samples 
compared to normal samples (Wong, Cheng et al. 2001).  In the clinical study by Kim et 
al., a similar up regulation in osteopontin protein concentrations was found in plasma 
samples of ovarian cancer patients as reported in microarray findings by Wong et al.  
This reflects the potential of microarrays in identifying biomarkers of disease, which 
after proper validation may be used in the clinical setting.   
43 
 
 
In the present study, our aim was to gain an insight into transcriptional signatures of 
various DCIS models using microarrays and to identify genes marking the transition 
from non-tumorigenic mammary epithelial cells to premalignant lesions.  Obtaining high 
quality gene expression data from formalin fixed paraformaldehyde embedded (FFPE) 
samples is quite challenging due to variation in fixation and extraction procedures, and 
also the age of samples.  Here, we used an in vitro 3D overlay culture model to 
circumvent the technical issues associated with microscopic clinical specimens.  In the 
first part of research, our major focus was to establish and standardize the protocols to 
obtain high quality RNA samples from cell cultures grown in 3D rBM.  We minimized 
variability issues by adopting uniform procedures for cell culture conditions, RNA 
extraction and subsequent processing of samples.  The RIN values and 
electropherograms of all the samples reflect high quality RNA samples and their 
suitability for microarray analysis.    The profile plot for gene expression in MCF10A 
replicates and MCF10.DCIS replicates corroborates the quality and reproducibility of the 
biological replicates.   
The hierarchical clustering of samples indicates robustness of microarray data as the 
three DCIS models cluster together and separate from normal MCF10A samples.  We 
have applied stringent criteria for identification of differentially expressed genes 
common to the three DCIS models in comparison to MCF10A.  The observation that 
MCF10.DCIS has more genes common with MCF10A as compared to either SUM102 
or SUM225 is consistent with the fact that MCF10.DCIS and MCF10A are isogenic.   
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3.3.1 Down-regulation of matrix assembly genes 
We observed more than tenfold down regulation in expression levels of various 
genes involved in regulation of matrix assembly such as NID1 (Nidogen-1), DCN 
(decorin),  and POSTN (periostin).  Nidogens provide structural stability to basement 
membrane by connecting laminin and collagen IV networks.  They interact with various 
integrins and play an important role in cell adhesion.  Loss of nidogen expression 
weakens the basement membrane and favors invasion.  A study by Ulazzi and co- 
workers reported that loss of NID1 expression observed in colon and gastric tumors is 
due to aberrant methylation in NID1 promoter (Ulazzi, Sabbioni et al. 2007).  Nidogen-1 
was also found to be significantly under-expressed in a gene expression analysis in 
embryonic stem cell-cloned blastocysts implicating its aberrant expression in 
developmental disorders in embryos (Jincho, Sotomaru et al. 2008).  Genome-wide 
association study identified nidogen 1 (NID1) as a susceptibility locus to melanoma risk 
(Nan, Xu et al. 2011). 
Another down-regulated gene that we observed in our microarray analysis is 
periostin.  It is a matricellular cell adhesion protein that interacts with multiple cell-
surface receptors like integrins.  There have been conflicting reports on the role of 
periostin in tumor development and progression.  Kim et al. have suggested its role as a 
suppressor of invasion and metastasis in the progression of bladder cancer (Kim, 
Yoshioka et al. 2005).  They observed down regulation of periostin expression in high-
grade bladder tumors.  However, many studies report the role of periostin over-
expression in promoting tumor invasiveness.  Over-expression of periostin has been 
observed in various malignant tumors such as metastatic breast cancer (Contie, 
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Voorzanger-Rousselot et al. 2011), metastatic ovarian cancer (Zhu, Fejzo et al. 2010) 
and high-grade prostate cancer (Tischler, Fritzsche et al. 2010).  In a recent study, Ben 
et al. reported that periostin may be involved in the progression and invasion of 
pancreatic cancer (Ben, Jin et al. 2011).  We have observed marked down-regulation of 
periostin expression in our premalignant DCIS models.  This may be explained by the 
fact that periostin up-regulation is related to the tumor aggressiveness in most cancers 
and DCIS is a pre-invasive stage of breast cancer. 
Decorin (DCN) modulates the activity of transforming growth factor β and plays an 
important role in the process of tumor growth and progression.  It acts as a tumor 
suppressor gene and its de novo gene expression suppresses the malignant phenotype 
of human colon cancer cells (Santra, Skorski et al. 1995).  Down-regulation of decorin 
expression leads to increased proliferation in intestinal epithelium and decorin over 
expression in colorectal cancer cells inhibits cancer cell proliferation and migration (Bi, 
Tong et al. 2008; Bi, Pohl et al. 2012).  In an independent study by Mlakar et al., the 
authors observed under-expression of DCN and another gene (SLC26A3) in colorectal 
tumors (Mlakar, Berginc et al. 2009).  In our study, we found down-regulation of DCN, 
which may imply its contributory role in to the events driving the premalignant 
progression in DCIS. 
 
3.3.2   Signaling pathways and networks 
One approach to interpret the microarray results is to analyze each gene separately, 
and then draw conclusions at the pathway level by combining results on individual 
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genes in the pathway.  However, in view of the complexities of cancer, we know that 
causative genes and proteins do not operate in isolation and it may be more relevant to 
study their interactions (Barros and Offenbacher 2009).  Hence, we employed a network 
modeling approach, Ingenuity pathway analysis (IPA), and uploaded our microarray 
data into IPA to define the molecular networks and pathways associated with our 
differentially expressed genes.  The microarray analysis showed that a subset of 
differentially expressed genes in DCIS is strongly linked to glutamate metabolism, 
suggesting a possible molecular link between this pathway and premalignant breast 
disease.  Glutamate receptors mediate a diverse array of cellular signaling responses 
and their over-expression has been observed in several malignancies.  For example, 
metabotropic glutamate receptor (Grm) has been reported to be over expressed in 
invasive breast cancer (Speyer, Smith et al. 2012).  Furthermore, Wei et al. did whole 
exome sequencing of patient matched normal and melanoma samples and reported 
that the ionotropic glutamate receptor gene, GRIN2A, was the most highly mutated of all 
the genes.  Using cell signaling pathway analysis, they identified glutamate signaling to 
be the most significant pathway implicated in melanoma (Wei, Walia et al. 2011).   
Another biological pathway associated with differentially expressed genes in our 
dataset was integrin signaling.  We observed more than 10-fold up-regulation of ITGB2 
(also known as CD18 or Mac1) gene in all DCIS models.   Inhibition of CD18 has been 
shown to enhance tumor response to radiation therapy (Ahn, Tseng et al. 2010).  The 
authors showed that tumors were more sensitive to irradiation when grown 
in CD18 hypomorphic mice.  Further, when CD18 hypomorphism was partially rescued 
by reconstitution with the wild-type bone marrow, the tumors recovered resistance to 
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irradiation.  We also observed down regulation of integrin alpha 9 (ITGA9) which has 
previously been reported to be deregulated in non small cell lung cancer (Anedchenko, 
Dmitriev et al. 2008) and premalignant cervical lesions   (Mitra, Mazumder Indra et al. 
2010).  The role of frequent alterations in ITGA9 and other genes (RBSP3 and hMLH1) 
in early dysplastic lesions of head and neck has been characterized by Ghosh and co-
workers (Ghosh, Ghosh et al. 2010). 
Our pathway analysis of microarray data revealed activation of Retinoid X receptor 
(RXR) pathway as one of the significant biological pathways in which differentially 
expressed genes are involved.  Retinoid X receptor (RXR) is a combinatorial partner for 
about one third of the 48 human nuclear receptor superfamily members.  It acts as a 
master regulator of nuclear receptor signaling pathways involved in the control of cell 
growth and differentiation (Tanaka and De Luca 2009).  In a study using several breast 
cancer cell lines, Bonofigolo and co-workers demonstrated that ligand activation of 
peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor 
(RXR) induces antiproliferative effects (Bonofiglio, Cione et al. 2009). 
Many genes involved in lipid metabolism and fatty acid biosynthesis were found to be 
altered in our premalignant DCIS samples.  We observed up-regulation of 
sphingomyelin phosphodiesterase, acid-like 3B (SMPDL3B), stearoyl-CoA desaturase 
(SCD), lipase member I (LIPI), low density lipoprotein receptor related protein 8 (LRP8), 
acyl-CoA oxidase 1, palmitoyl (ACOX), insulin induced gene 1 (INSIG1) and down- 
regulation of apolipoprotein E (APOE) and acetyl-CoA carboxylase beta (ACACB) 
genes.  These findings suggest that alteration in lipid metabolism may be a key driving 
force in the early events of premalignant progression.  A recent comprehensive 
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lipidomics study conducted in human breast cancer tissues by Hilvo and colleagues 
provides further support to our observations (Hilvo, Denkert et al. 2011).  They 
investigated the global lipid profiles of breast cancer tissues and found that the products 
of de novo fatty acid synthesis were increased in tumors as compared to normal breast 
tissues.  These lipids were associated with cancer progression and their concentration 
was highest in estrogen receptor-negative and grade 3 tumors.  They observed high 
expression of several lipid metabolism regulating genes such as ACACA (acetyl-CoA 
carboxylase α), ELOVL1 (elongation of very long chain fatty acid-like 1), FASN (fatty 
acid synthase), INSIG1 (insulin-induced gene 1), SCAP (sterol regulatory element-
binding protein cleavage-activating protein) and SCD (stearoyl-CoA desaturase) in their 
study. 
The presence of genes related to insulin-like growth factor (IGF) signal 
transduction pathway in our differential genes list emphasizes the importance of 
targeting the IGF pathway in breast cancer.  The prevailing view is that targeting the 
IGF pathway in triple-negative breast cancers is not of any benefit as their growth is not 
IGF-responsive.  However, a recent report by Davison et al. shows that IGF stimulates 
cell proliferation and promotes cell survival in triple-negative breast cancer cells 
(Davison, de Blacquiere et al. 2011).  In MCF7 breast cancer cells, IGF-1 confers 
increased invasive potential and induces activation of TGF-β1 leading to epithelial to 
mesenchymal transition (Walsh and Damjanovski 2011).  Over expression of insulin-like 
growth factor 1 (IGF-1) and its receptor (IGF-1R) has also been reported in low-grade 
serous ovarian carcinoma (King, Zu et al. 2011).  Studies of IGF-1R inhibitors are 
currently ongoing in pancreatic, gastroesophageal, hepatocellular and colorectal 
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cancers.  Clinical trials with IGF-1R inhibitors in patients with Ewing sarcoma have 
shown significant anti-tumor activity (Golan and Javle 2011).   
In summary, we have identified several important genes that are differentially 
expressed in DCIS as compared to normal epithelium in this microarray study.  Further 
characterization of genes that show significant changes in expression in DCIS in 
comparison to non-transformed MCF10A will provide important clues and directions for 
our next in depth studies.  The present study also clarifies pathway networks that 
function in premalignant lesions of DCIS.  The results demonstrate that glutamate 
metabolism, IGF-1 signaling, integrin signaling and fatty acid metabolism are 
significantly associated with the early neoplastic changes.  Further experimental 
investigations are required to elucidate the consequences of these biological pathways 
and their relevance in driving early premalignant changes in breast tissue.  Those data 
could provide biomarkers and could lead to the development of novel efficacious targets 
to treat premalignant progression of breast cancer.   
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Figure 3.1: Different morphologic characteristics of non-transformed mammary 
epithelial cells and DCIS models grown in 3D rBM overlay culture. Differential 
interference contrast (DIC) images of 12-day 3D rBM overlay cultures of MCF10A, 
MCF10.DCIS, SUM102, and SUM225 cells.  Scale bar, 200 µm.  
51 
 
 
 
 
Figure 3.2a: Electrophoresis gel image of RNA samples extracted from biological 
triplicates of MCF10A, MCF10.DCIS, SUM102 and SUM225 cultured in 3D.  The 
cells were grown in 3D overlay cultures in 171 media with mammary epithelial growth 
supplements for 12 days.  The purity and integrity of RNA samples was determined 
using Agilent Bioanalyzer 2100 using the Eukaryote Total RNA Nano assay. 
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Figure 3.2b: Electropherograms of RNA samples extracted from biological 
triplicates of MCF10A, MCF10.DCIS, SUM102 and SUM225 cultured in 3D.  The 
purity and integrity of RNA samples is depicted by RIN values and was determined by 
Agilent Bioanalyzer 2100.  
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Figure 3.3a: Cluster dendrogram of microarray samples: Unsupervised hierarchical 
clustering of 12 samples shows that the normal MCF10A and the three models of DCIS 
have low correlation coefficient.  In the dendrogram the length of the branches between 
two elements reflect their degree of relatedness.  The three DCIS cluster together and 
separately from normal MCF10A.  The biological replicates cluster together within each 
sample subtype.  
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Figure 3.3b Gene expression profiles by hierarchial clustering.  Heatmap showing 
expression profiles of MCF10A and MCF10.DCIS, SUM102 and SUM225 samples 
using > 54000 probes.  The green color represents relative gene over-expression while 
the red color indicates relative gene under-expression. 
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Figure 3.4: Profile plot of normalized gene expression in paired analyses of 
MCF10.DCIS versus MCF10A.  Each line represents an individual gene product, with 
the values in MCF10A triplicates shown at left and those in MCF10.DCIS shown at right.  
Red indicates transcripts that are decreased, yellow indicates that are unchanged and 
blue indicates that are increased. 
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Figure 3.5: Differentially expressed genes between MCF10A and the three DCIS 
models. Venn diagram showing the overlap between the genes expressed by the 
different models of DCIS: MCF10.DCIS, SUM102 and SUM225 as compared to the 
MCF10A model of non-tumorigenic mammary epithelial cells. 
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Figure 3.6: Significant canonical pathways associated with the differentially 
expressed genes.   Probe sets identified as differentially expressed in all models of 
DCIS were uploaded into Ingenuity Pathway Analysis software.  A Fisher's exact test 
was used to test the statistical significance with a significance level of 0.05. 
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Figure 3.7: Significant biological processes and pathways associated with the 
differentially expressed genes.  Probe sets identified as differentially expressed in all 
models of DCIS were uploaded into Ingenuity Pathway Analysis software. A Fisher's 
exact test was used to test the statistical significance with a significance level of 0.05. 
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Table 3.1: The genes with the largest fold change in expression identified in the 
list of those differentially expressed by microarray.  The values represented in the 
second column are the fold changes in expression (with a p-value of < 0.05) in all 
models of DCIS over those expressed in normal MCF10A model. The red arrows 
indicate up regulation in expression and green arrows indicate down regulation in 
expression. 
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Table 3.2:  List of molecules in glutamate metabolism pathway.   Arrows pointing 
up (in red) and down (in green) indicate up and down regulation of genes respectively.  
The values are the fold change values with a p-value of < 0.05 in all models of DCIS as 
compared to normal MCF10A. 
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ID Molecules in Network Score Focus Molecules Top Functions 
1 
C1q, C1S, caspase 3/7, COL6A1, collagen, CSN, 
DCN, DUSP1, EHF, Fibrinogen, FOXP1, GAS6, 
GFPT2, HLA-DQB1(includes others),HOX A2, Hsp 
27, IgG , IL1, IL33, IL1RAP, Immunoglobulin, ITPKB, 
MAP3K5*, MAPK8IP3, MERTK, NFκB(complex), 
PDPN, RRBP1*, Sapk, SH3RF1*, TFAP2C, TLE6, 
TNFRSF12A, TRAF4 
43 25 
Hematological 
disease, 
infection 
mechanism 
2 
ACACB, ADAMTS5, AMPK, BICD1, BTG3, 
CLEC11A, DYNC1I1, Erk1/2, Fcer1, Fgf, FGF1,FGF 
18, H1F0, HDL, HTRA1, IRS1, Mek, MET, NTN4, 
p70S6k, PLC gamma, POSTN, PP2A, RAB4A, 
RAB4AB* RHEB,PRKAG2,  Rsk, SCD*, SOCS6*, 
TGFB2, TIMP3*,UNC5, UNC5B, UNC5C 
40 24 
cellular 
development, 
embryonic 
development, 
gastrointestinal 
disease 
3 
A4GALT, ABLIM2, AP1S2, Caspase, CD70, 
CHEMOKINE, COTL1, CROT, Cyclin E, F Actin, 
FBXW7, Gpcr, HIP1, HNRNPC, Hsp90, Ige, 
IL12(complex), IL6R, Interferon alpha, Jnk, KIF23, 
LRRK2, MHC ClassII(complex), Mmp, NEDD4, NOV, 
PYHIN1, RAPGEF6, SCN8A, SHROOM3, SNX33, 
SREK1, STAT, TJP3, Trypsin 
33 21 
cell cycle, 
cellular 
assembly and 
organization 
4 
14-3-3, Alp, Alpha Actinin, BRCA2, CES2*, CXCR4, 
DBNDD1, FKHR, Foxo, FOXO1*, FOFO3, GRB10, 
ID1, ID3, IER3, IGF1R, Laminin, MAP2K1/2, MEGF10, 
NEXN, P85(pik3r), PCSK5, PDGF BB, PDLIM1, 
PI3K(complex), POU2AF1, PTK6, PXR ligand-PXR-
Retinoic acid_RXRα, Rar, SLCO1A2, Smad, 
STAT5A/B, TM4SF1*, VEGFA* 
30 20 
cellular growth 
proliferation, cell 
death, skeletal 
and muscular 
development 
and function 
5 
26sProteasome, Akt, Ap1, APOE*, ARHGEF9, BGN, 
CDKN2C, CDON, CLMN, COL2A1, Collagen type I, 
Collagen(s), Creb, CyclinA, Estrogen receptor, 
FKBP1B, GMNN, GPSM2, HOXA7*, Iκb, INSIG1*, 
LDL, LRP8*, NEDD9, P38 MAPK, PDCD4*, Pro-
inflammatory Cytokine , Rb,Rxr, SLC12A2, Tgf beta, 
TLL1, TP73, Ubiquitin, Vegf 
26 18 
cardiovascular 
disease, 
organismal 
injury and 
abnormalities, 
cancer 
6 ACOT2, ACOX1, AQP8, BHMT, C14orf147, CHDH*, 
COPS8, COPS7A, COPS7B, CYP3A43, CYP4F2, 
25 17 lipid 
metabolism, 
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CYP7B1, CYP8B1, ETNIκ2, GSTM4, HNF4A, 
HSPH1*, KLF15 MGST3, MREG, NAT8, PLD2, 
PPP1R11, PPP1R3C, PPP2R5B, RORA, SLC25A24, 
SLC35D1, SLCO1A2, SRSF11, SSFA2, SULT1A1, 
TMEM43, TRIP11, ZBTB45 
small molecule 
biochemistry, 
endocrine 
system 
development 
function 
7 
ACER3, ATP2A1, BDNF, Ca2+, CDCA2, CDK1, 
CHAF1B, DCN*, DEFB103A/DEFB103B, EFCAB4B, 
EGR2, ERK1/2 FZD2, GABRA5, GCGR, GLP2R, 
IDI1*, IL4, KCNA3, KISS1R, LAT2, LTB4R2, MATK, 
MMP12, NRG1, NXPH4, OBFC2A, ORAI1, POSTN, 
SLAIN1, SOX 13, TAC1, TGM1, TMED5, ZNF33B 
23 16 
cell death,  
hypersensitivity 
response 
8 
ATP8B1, ATP8B2, ATP9A, BAMBI, C1S, CD2AP, 
COL6A1, DOCK8*, FGA, FOXC1, FZD2, KRT17, LSR, 
MG2+-ATPase,  OSM, PDLIM5, PDPN, PKIG, PSG1, 
RAB25, RAC1, SERPINB1, SFN, SLC4A11, SNAI1, 
SYNJ2, TAL 1, TGFB1, TNS4, VPS37B, WISP1, 
YWHAB, ZNF266, ZNF395 
23 16 
cellular growth 
and 
proliferation, 
cellular 
development, 
cellular 
movement 
9 
ADAM12, ANKS1B, beta-estradiol, BICD1, CDK18, 
CLDN7, CMTM6, CXCR7, CYP4B1, DLG4, FZD1, 
FZD2, FZD7, GPM6A, GRB2, ID4, KCNJ10, KRT7, 
LEPROT, LPHN1, LRRC1, NOVA1, OPRK1, OPRM1, 
PLEKHA6, PTGER2, PTPN13, PTPRN, PXDN, 
PYG01, SH2D4A, SLC22A5, SNTB2, SPARCL1, 
SSTR2 
21 15 
reproductive 
system disease, 
biliary 
hyperplasia 
10 
ADAMTS5, AP1S2, ASAP2, butyric acid, CCND1, 
CCPG1, COL4A1, COL4A2, DBI, ESR1, ESYT2, 
FAM102A, FBLN1, FST, GAD2, HBE1, HTT, 
MAN1A1, MAPK8, MDFIC, MDK, OPRK1, POSTN, 
PPCDC, PTPRF, SERPING1, SLCO2A1, SVIP*, 
TGM1, THSD7A, tretinoin, WNT5B, WWC1, ZFHX3, 
ZNF655 
20 15 
cellular growth 
and 
proliferation, 
cellular 
development, 
reproductive 
system 
development 
and function 
11 
ADH1A, ADH1B, ADH1C, ALDH16A1, ALDH5A1, 
C/ebp, C1R, C8orf4, CD4, Ck2, DUSP1, EBAG9, 
FAM69B, GLCCI1, GLUL, HAS2, Histone h4, 
HOXA7*, INSM2, MED13, MED31, NOL3, NR3C1*, 
OASL, ONECUT1, PPID, PRR15L, pyridoxal 
19 14 
small molecule 
biochemistry, 
infectious 
diseases, 
cellular function 
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phosphate, RBMS2, RNA polymerase I, SDPR, 
SLC25A2, SUB1, WDR12 
and 
maintenance 
12 APBB2, ASPM, ATF4, CLCN3, CLCN5, Cofilin, 
COL6A1, Collagen type IV, Cytokeratin, DCN*, EGFR, 
FBLN2, FBN1, FNDC3B, FZD2, GLI1, KRT7, LAMC2, 
MTHFD2*, PARP, PARP3, PARP4, PARP8, PARP9, 
PCDH18, POSTN, RIN2, SERPINE2, SESN3, 
SLC23A2, TGFB1, TGFBR3, Tpsab1, WISP1, ZNF226 
19 14 
cellular 
movement, 
connective 
tissue disorders, 
genetic 
disorders 
13 ADAP1, ARHGAP29*, CAP2*, EHD4, EIF4EBP2, 
ERK, ERO1L, Focal adhesion kinase, FSH, G protein 
alphai, G-protein beta,  GLUD1, GPR56*, Gsk3, 
GULP1*, hCG, Histone h3, Insulin, ITGB2, JAM3, Lh, 
Mapk, Nfat (gamily), PDXK, PGGT1B, Pka, Pkc(s), 
RAB3IP, Rac, Ras, Ras homolog, RG53, Sfk, Shc, 
TCR 
18 15 
cell –to-cell 
signaling and 
interaction, 
cellular 
movement, 
hematopoiesis 
 
Table 3.3: Signaling pathway networks involving differentially expressed genes.   
The IPA analysis of differentially expressed genes revealed several statistically 
significant pathway networks.  Each network includes genes from microarray analysis 
as focus molecules and indicated in bold.  The statistical score of > 3 was considered 
significant (p value < 0.01).   
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Molecular and Cellular Functions p-value No. of molecules 
Cellular Growth and Proliferation 3.74E-07 - 1.66E-02 79 
Cell-To-Cell Signaling and Interaction 6.36E-06 - 1.71E-02 34 
Cellular Assembly and Organization 9.93E-05 - 1.71E-02 27 
Lipid Metabolism 1.09E-04 - 1.71E-02 28 
Small Molecule Biochemistry 1.09E-04 - 1.71E-02 40 
Physiological System Development 
and Function 
p-value No. of molecules 
Tissue Development 6.36E-06 – 1.57E-02 45 
Connective Tissue Development  1.18E-05 -  1.71E-02 27 
Skeletal and Muscular System 
Development and Function 
1.18E-05 -  1.71E-02 26 
Tumor Morphology 8.45E-05 – 1.03E-02 19 
Organ Development 1.62E-04 – 1.56E-02 32 
 
Table 3.4: Biological functions associated with the differentially expressed genes.  
The values in the second column represent the statistical significance score (p value) of 
each biological function. The number of molecules represents the number of 
differentially expressed genes in the microarray dataset that are involved with a 
particular biological function. 
 
Diseases and Disorders p-value No. of molecules 
Cancer 2.25E-07 - 1.54E-02 106 
Genetic Disorder 2.06E-06 - 1.71E-02 178 
Neurological Disease 1.94E-05 - 1.71E-02 112 
Cardiovascular Disease 4.56E-05 - 1.71E-02 75 
Reproductive System Disease 9.43E-05 - 1.41E-02 55 
65 
 
 
CHAPTER 4 
 
DEEP SEQUENCING BASED EXPRESSION ANALYSES VALIDATE MICROARRAY 
FINDINGS AND REVEAL NOVEL POTENTIAL TARGETS IN THE PREMALIGNANT 
PROGRESSION OF BREAST CANCER  
 
4.1 BACKGROUND AND RATIONALE 
Microarrays have been the technology of choice for most gene expression studies.  
However, the enormous amount of expression data generated by microarrays requires 
further validation.  The two most common approaches employed by researchers to 
validate the microarray results are: quantitative real time polymerase chain reaction  
(qRT-PCR) and repeating the experiment with another, different microarray platform.  
Here, we have used an advanced approach by employing deep sequencing or next 
generation sequencing (NGS) technologies along with qRT-PCR for validating the 
microarray results.  The major reason for choosing NGS over a different microarray 
platform is because of the clear advantages that these sequencing technologies have 
over microarrays.  The deep sequencing technology does not rely on prior sequence 
information as required for probes used for microarrays.  Identification and quantification 
of gene expression at the whole genome level without a priori sequence knowledge 
provides higher confidence in discovering novel targets and network pathways.   Also, 
as NGS uses sequencing instead of hybridization, there are no cross-hybridization or 
background noise issues.  The NGS data are obtained as countable digital signals that 
can be recorded, quantified, annotated and re-annotated as per the current genome 
databases.  We have used two NGS tools namely Digital Gene Sequencing (DGE) and 
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a more comprehensive technique, RNA-Sequencing (RNA-Seq) in order to confirm our 
array data. 
Ultra high throughput sequencing by DGE allows for detection of differentially 
expressed transcripts especially low abundance transcripts.  It also enables detection of 
rare transcripts, differential polyadenylation and antisense transcription.  DGE uses 3’ 
end tag for transcriptional reads, however, RNA-Seq covers the full length mRNA and 
provides comprehensive transcriptional profiling.  RNA-Seq is particularly useful in 
revealing transcriptional boundaries, novel, rare transcripts and alternative splice 
variants.   Additionally, RNA-Seq provides an insight into post transcriptional 
modifications and re-arrangement events as well.  For example, reads that align to 
exon–exon junctions when mapped to the reference genome indicate splicing events.  
Also, reads containing poly (A) tracts that are not encoded in the reference genome are 
indicative of poly-adenylation.  When the reads contain sequence polymorphisms in 
comparison to the reference genome this may illustrate potential RNA editing events 
(Figure 4.1). 
Currently, there are three NGS platforms available commercially: FLX pyro 
sequencing system (454 Life Sciences); Illumina Genome Analyzer (developed by 
Solexa); and AB SOLiD system (Life Technologies).  The underlying principle in all the 
NGS technologies is same; however, the approaches used to produce sequence reads 
may differ.  In general, a population of RNA molecules is first converted into a cDNA 
library and then after fragmentation, adaptors are ligated to cDNA.  Each molecule is 
then sequenced base-by-base in a high throughput manner.  The sequencing may be 
done from a single end or both ends (paired-end) and data are obtained as short 
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sequences or reads.  The reads are then aligned to a reference genome as well as the 
corresponding genes or assembled de novo to create a transcription map.  We used 
Illumina Genome analyzer for RNA-seq and used single end sequencing (76 cycles) for 
generating sequence reads in the present study.  As described in details below, 
employing deep sequencing not only validated our microarray results but also enhanced 
the depth of gene expression data with identification of novel transcripts and common 
regulatory frameworks.  Furthermore, we validated the microarray expression findings 
and deep sequencing data with another orthogonal tool, i.e., qRT-PCR.  Hence, we 
employed an array of diverse technologies to consolidate and compliment the data 
findings from microarray with the aim of elucidating potential gene targets for further 
characterization. 
 
4.2 RESULTS 
 
4.2.1 Digital Gene Expression (DGE) validates microarray results and identifies 
novel transcripts 
In collaboration with Krawetz lab at the Mott Center at Wayne State University, we 
first confirmed the results from our microarray analysis with Illumina G2A digital gene 
sequencing.  As DGE is very sensitive in detection of low abundance transcripts and of 
small changes in gene expression, we expected that it would not only validate but also 
enrich the expression profiling data from microarrays.  We determined digital gene 
expression of the same RNA samples extracted from MCF10A and the three DCIS 
models as those used for microarray analysis.  The reads expressed from all the 
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samples were mapped to 33,000 genes and then the gene candidates were annotated 
in NCBI map viewer.  We used reads on the sense strand < 500 bp from the 3’ end to 
infer expression and compared all the reads against MCF10A to detect fold changes in 
expression.  We observed that 154 genes of the 290 genes in the Affymetrix list of 
differentially abundant genes generated sufficient signal in the DGE data to assess fold 
change in expression.  In the un-normalized read data, 123 (80%) of the fold change 
values were in the same direction in the DGE data as in the Affymetrix data.  We 
therefore obtained strong qualitative concordance between the Affymetrix microarray 
and Illumina DGE results (Figure 4.2).  We found 79 genes consistently differentially 
expressed between MCF10A model of non-tumorogenic breast epithelial cells and the 
three models of DCIS: MCF10.DCIS, SUM102 and SUM225 (Table 4.1).  The fold 
change in expression levels in DCIS relative to MCF10A of some selected genes 
common to both Affymetrix and DGE analyses are depicted in Table 4.2.  Ontology 
analysis of these 79 differentially expressed genes suggested few common groups, all 
of which were generally weak with respect to multiple hypothesis testing.  The major 
functions associated with these genes were tissue/organ development and fibronectin 
pathways.  Studies are currently ongoing in our lab to investigate the role of fibronectin 
in progression of DCIS to invasive breast cancer.   
Further analysis of digital gene expression data revealed a broad range of antisense 
transcripts and transcripts that are transcribed outside of standard (NCBI 36.3) gene 
models.  Reads from one of the genes, vesicle-associated membrane protein 2 
(VAMP2) or synaptobrevin 2, are shown mapped to the University of California Santa 
Cruz (UCSC) browser to illustrate antisense transcription and transcription far from 3'-
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untranslated regions (UTRs), both of which may be linked to silencing transcripts 
(Figure 4.3).  Analysis of DGE results also revealed truncated transcripts for the gene 
endoplasmic oxidoreductin-1-like (ERO1L).  The data showing truncated transcripts for 
ERO1L is illustrated in Figure 4.4. 
4.2.2 mRNA-Seq reveals unique differentially expressed transcripts and validates 
both microarray and DGE findings 
At the next level of validation, we employed a step forward approach using whole 
transcriptome sequencing or mRNA-Seq for expression profiling of samples from the 
two biological replicates of each of the DCIS models (MCF10.DCIS, SUM102 and 
SUM225) and the MCF10A model of non-tumorigenic mammary epithelial cells.  The 
reads obtained from each sample were grouped to generate clusters and mapped back 
to the genome as well as the corresponding genes.  Using Novoalign software, greater 
than 80% alignment to the reference genome was observed for all the samples.  The 
number of reads and clusters for each of the RNA-Seq samples is shown in Table 4.3.  
Based on a log2 fold change > 2 and adjusted p-value < 0.001, we identified 1,103 
genes in MCF10.DCIS, 2,388 genes in SUM102 and 3,036 genes in SUM225 as 
significantly differentially expressed in comparison to MCF10A.  Volcano plots from 
each individual model are depicted in Figure 4.5.  The number of significant differentially 
expressed transcripts that were common to all the three DCIS models in comparison to 
non-tumorigenic MCF10A were 295 (Figure 4.6, Appendix).  
Among the 295 differentially expressed, 63 genes were significantly up-regulated in 
all three models, 156 genes were down-regulated, and 76 genes showed differential 
expression but their pattern of up and down regulation was not consistent.   
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We also performed hierarchical clustering analysis to assess the relatedness of the 
different DCIS models (MCF10.DCIS, SUM102 and SUM225) and non-transformed 
mammary epithelial cell model (MCF10A).  Unsupervised clustering based on the total 
number of sequence reads shows that the two biological replicates have a very high 
correlation coefficient and that there is also a good correlation between the expression 
profile of the isogenic MCF10A and MCF10.DCIS models (Figure 4.7A).  When 
clustering is based on differentially expressed transcripts (Figure 4.7B), the 
MCF10.DCIS samples are much less correlated with MCF10A samples as compared to 
when total transcripts are considered.  The DCIS models derived from two individual 
patients (SUM102 and SUM225) are more highly correlated when clustering is based on 
differentially expressed transcripts (Figure 4.7B) as opposed to the total number of 
reads (Figure 4.7A). 
   
4.2.2.1 Validation of microarray and DGE results by mRNA-Sequencing 
We compared our microarray and DGE findings with RNA-Sequencing results to see 
whether there is any correlation among the results obtained with different platforms.  We 
observed an overlap in microarray and RNA-Seq results with 238 significantly 
differentially expressed genes observed in common by both the technologies (Figure 
4.8).  We then compared the DGE analysis with the RNA-Seq data and found that 
almost all the DGE data completely confirm with the RNA-Seq data.  The consistency 
analysis between the DGE results and mRNA-Seq results is reported in Table 4.4. 
 
4.2.2.2 Detection of novel differentially expressed transcripts by mRNA-Seq 
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The genes detected by deep sequencing as most significantly differentially over- 
expressed in DCIS in comparison to normal MCF10A include anterior gradient homolog 
2 (AGR2); grainyhead like (Drosophila) (GRHL2);  apolipoprotein D (APOD); chemokine 
(C-C motif) ligand 20 (CCL20); cation transport regulator homolog 1 (E. coli)(CHAC1); 
claudin 4 (CLDN4); lipocalin 2 (LCN2); lipase member H (LIPH); fucosyltransferase 3 
(FUT3) and cAMP responsive element binding protein 5 (CREB5).  The genes which 
were found be significantly down-regulated include alcohol dehydrogenase 1B (class I), 
(ADH1B); RNA, Ro-associated Y5 (RNY5); transforming growth factor, beta-induced 
(TGFBI); podoplanin (PDPN); tolloid-like 1 (TLL1); dermatopontin (DPT); cell adhesion 
molecule 3 (CADM3); aspartoacylase (ASPA); Duffy blood group, chemokine receptor 
(DARC) and  nidogen 1 (NID1).  Some of these genes were also identified by the 
microarray and DGE analyses whereas several other genes are unique to RNA-Seq 
analysis only.  The genes identified by RNA-Seq as significantly differentially over 
expressed or under expressed in all three models of DCIS are depicted with their fold 
change values in Table 4.5. 
 
4.2.2.3 Biological functions and pathways related to differentially expressed 
transcripts  
The transciptomic data obtained from mRNA-Seq analysis of all DCIS and normal 
mammary epithelial cell models were analyzed with IPA software to define which well-
characterized cell-signaling and metabolic pathways could be the most relevant during 
the premalignant progression.  Network pathway analysis showed three statistically 
significant cell signaling and metabolic pathway networks (Table 4.6).  Each network 
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includes the differentially expressed genes as focus molecules along with other related 
genes from the IPA database. The top network relates to connective tissue disorders, 
genetic disorders, dermatological diseases and conditions and includes 74 focus 
molecules or genes with a statistical significance score of 131.  The genes playing a key 
role in this network include but are not limited to A4GALT, ANKRD2, APOE, CCL20, 
CD70, CLDN4, CLDN9, COL17A1, DCN, ELF3, FGFR3, FOXO1, GPR56, LAMB1, 
MMP28, MYL9, NFATC4, NID1, PDGFB, POSTN, RAP1GAP and SERPINF1.  The 
second network functions in cellular development, lipid metabolism and molecular 
transport and includes 43 significantly differentially expressed genes.  Some of the 
focus molecules playing a key role in this network include AGR2, ANKRD13B, APOD, 
ARL14, BSPRY, CADM3, CHAC1, CREB5, DQX1, DPT, FAM65B, GRHL2, JAM3, 
KRT7, LIPH, PDPN, RAB25 and SEPT6.  The third most significant network pertains to 
lipid metabolism, small molecule biochemistry, organismal injury and abnormalities.  
This network involves 26 focus molecules from the differentially expressed list of genes.  
Some of the genes involved in this network are ABTB2, ADH1B, ALDH5A1, ASPA, 
CALML3, CHST2, ETNK2, FUT3, GGT6, HIP1, KCNB1, LRRK2, MMP28, PLCH2, 
RNY5 and SEMA5B. 
IPA also identified major functions and canonical pathways associated with the 
differentially expressed genes.  The canonical pathways include atherosclerosis 
signaling, leukocyte extravasation signaling, tight junction signaling, PTEN signaling and 
glycosphingolipid biosynthesis (Figure 4.9).  Significant molecular and cellular functions 
in which a high number of differentially expressed genes are implicated correspond to 
cell-cell signaling and interaction; cellular movement; cellular organization and 
73 
 
 
assembly; cellular function, maintenance and development (Figure 4.10 and Table 4.7).  
Some of the important genes regulating the processes of cell-cell signaling and 
interactions identified in our data analysis are PDPN, APOE, SCD, CADM3, SFTPD, 
TWIST1, CCL20, SDC3, WISP2, NID1, TNFRSF12A, ELF3, EDN2, LAMB1, POSTN, 
HOXA7, CDH13, FUT3, DARC, TIMP3, TGFBI, DCN, BGN, COL2A1, COL17A1, 
SERPINF1, INPP5D, PDGFB, GPR56, RAP1GAP, CSF1, JAM3 and ZEB2. 
Functional annotation of the differentially expressed genes revealed cancer as the 
most significant disease followed in order of significance by inflammatory disease, 
connective tissue disorders, genetic disorders and dermatological diseases (Table 4.7).   
The analysis emphasized the functions of cell-cell signaling and interaction, cellular 
movement, and cellular organization and assembly and the disease of cancer as 
significantly associated with the DCIS gene signature.   Indeed, many of the significantly 
differentially expressed genes have previously been implicated in cancers other than 
breast (Table 4.8). 
WebGestalt2 (Duncan) and Genomatix GePS were also employed to identify 
biological processes related to the common significant transcripts from the RNA-Seq 
data.   These two other tools independently mine the relationships and thus yield their 
own curated data sets.  The results showed that a large number of the differentially 
expressed genes are involved in cell adhesion, cell proliferation, response to chemical 
and organic stimuli, lipid metabolic processes, organ development and morphogenesis.  
The corresponding biological processes are summarized in Figure 4.11 with the number 
of associated genes and their statistical significance.  Their associated molecular 
functions include protein binding, receptor binding, fibroblast growth factor receptor 
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activity, enzyme regulatory activity, type II transforming growth factor beta (TGFβ) 
receptor binding, platelet derived growth factor binding and glycosaminoglycan binding.   
Classification of the differentially expressed genes from the DCIS models by cellular 
component revealed a striking focus of gene expression changes in the plasma 
membrane and extracellular region (Figure 4.12).  Overlaying GePS also revealed 11 
pathways to be most relevant to the differentially expressed genes in DCIS (Table 4.9).  
These pathways were dominated by signaling events mediated through integrins, 
patched homolog1, fibroblast growth factor, TGFβ, hepatocyte growth factor, signal 
transducer and activator of transcription (STAT) and RhoA.  
 
4.2.2.4 Common framework analysis in the promoters of differentially expressed 
up-regulated genes  
 
We further explored the mRNA-Seq results to gain an insight into common 
frameworks in the promoter regions of differentially expressed genes.  The genes were 
classified into up-regulated or down-regulated.  The up-regulated genes (63) were then 
sub- grouped by biological functions for common framework mining.   Using the 
Genomatix Gene2Promotor program, the promoter regions of the up-regulated genes 
were identified and then screened for common transcription factor binding site (TFBS) 
modules with Genomatix program tools.  From a total of 82,703 promoter sequences in 
the entire human genome, 244 promoter loci were found to be associated with the 63 
up-regulated genes.  Enrichment analysis of common frameworks showed that 
V$STAT-V$PERO-V$RXRF-V$NFKB is highly enriched (254.2 fold) in 4 genes in the 
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entire human genome and 3 of those genes are present in our RNA-Seq data.  These 
genes are ELF3, CCL20 and NFATC4 and the gene not detected by RNA-Seq but 
present in the genome with this framework is IL-9R.  A schematic illustration for this 
common framework binding to the promoters of three genes is represented in Figure 
4.13.  Also, significant enrichment (336.36 fold) was observed for common framework 
consisting of five TFBS elements (RXRF-ZF02-ZF02-PLAG-HDBP) which is present in 
promoter regions of RAP1GAP, SPRY4 and PDGFB genes in the entire human genome 
and all three of these genes are present in our dataset.  The results of common 
framework mining in the promoters of differentially expressed up regulated genes are 
summarized in Table 4.10. 
 
4.2.3 Quantitative real time polymerase chain reaction (qRT-PCR) supports the 
validity of different platforms used for detection of differentially expressed 
transcripts 
Having validated the array results with deep sequencing technologies, we employed 
another independent measure for quantification of transcript abundance namely qRT-
PCR to confirm our findings.  In addition to the microarray data, we also validated the 
expression of select genes identified as differentially expressed by mRNA-Seq analysis 
as well.   
For qRT-PCR validation, we selected candidate genes based on significant fold 
changes in expression observed in both microarray and RNA-Seq analyses and based 
on their association with the identified canonical and biological pathways.  We chose a 
total of nineteen genes that were either identified by both microarray and mRNA-Seq 
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analysis or that were uniquely identified by either analysis.  The venn diagram 
summarizing the genes selected from microarray and RNA sequencing data for qRT-
PCR validation is shown in Figure 4.14.  Since adequate quantification of target gene 
expression relies upon appropriate use of internal reference genes, in all our 
experiments we normalized the expression of our target genes to three housekeeping 
genes (HPRT, ACTB and GUSB).  The qRT-PCR results were in concordance with 
results from the array and sequencing approaches for fifteen of the nineteen genes and 
the results for four of the genes (RHOB, FOXO3, GLUL and MET) are partially 
inconsistent among different platforms.  The overall correlation among the different 
platforms was good with correlation coefficient between microarrays and qRT-PCR 
being 0.82 and that between RNA-seq and qRT-PCR being 0.86.  We observed that the 
qRT-PCR results agreed more closely with the RNA-Seq results than with the 
microarray (Table 4.11).  The expression fold change values of selected genes in 
MCF10.DCIS, SUM102 and SUM225 over MCF10A as detected by microarray, RNA-
Seq and qRT-PCR are compared in Table 4.12.  
 
4.3 DISCUSSION 
In the present chapter, our major objective was to validate the findings from the 
microarray study by using diverse platforms.  We first used digital gene expression to 
obtain the transciptomic profiles of all DCIS and MCF10A samples.  The DGE analysis 
very well confirmed the microarray results as indicated by the strong qualitative 
concordance in the data obtained by the two platforms.  In addition, DGE also unraveled 
many novel differentially expressed transcripts that were not identified by microarray.  
77 
 
 
Two interesting observations in the transcriptome sequencing data command particular 
attention.  Firstly, the presence of antisense transcripts for the gene VAMP2 indicates 
an additional level of transcriptional regulation.  VAMP2 belongs to the family of vesicle 
associated membrane proteins and a recent evidence points to its role in trafficking of 
alpha5beta1 integrin to the plasma membrane, which is crucial in cell adhesion, 
migration and survival (Hasan and Hu 2010). The antisense transcripts observed for 
VAMP2 may be responsible for degradation of the corresponding sense transcripts and 
transcriptional silencing of VAMP2.  Also the antisense transcripts link neighboring 
genes into chains of linked transcriptional units thereby regulating expression 
(Katayama, Tomaru et al. 2005).  Another notable observation in the sequencing data 
was the presence of truncated transcripts for the gene ERO-1L. This gene is known to 
be induced by hypoxia and plays a key role in VEGF secretion (May, Itin et al. 2005).  
The pathophysiological role of truncated form of ERO1L in breast cancer progression 
needs to be elucidated. 
In the DGE data, we obtained fewer reads in MCF10A samples as compared to 
signals from the three DCIS models.  Instead of repeating the experimental run for DGE 
(for 3’UTR regions), we extended our approach by sequencing the full length mRNA 
using mRNA-Seq in order to confirm the findings from digital gene expression as well as 
from microarray.  The global transcriptome profiling by RNA-Seq corroborated both the 
microarray and DGE data as well as revealed many novel differentially expressed 
transcripts in DCIS.  The hierarchical clustering of RNA-Seq samples indicates the 
robustness of the data and the reproducibility of the biological replicates.  The 
observation that MCF10.DCIS has more genes in common with MCF10A than with 
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either SUM102 or SUM225 is consistent with the fact that MCF10.DCIS and MCF10A 
are isogenic. 
 
4.3.1 Differentially Expressed Genes in Models of DCIS  
 The implication of the differentially expressed genes being involved in the processes 
of cell-cell adhesion, cell proliferation and movement signify the importance of 
deregulation of these processes very early in the course of premalignant progression.  
Interestingly, the down-regulated differentially expressed genes with largest fold change 
in expression pertain to the functions of cell adhesion and include CADM3 (cell 
adhesion molecule 3), DPT (Dermatopontin), NID1 (nidogen1) and TGFBI 
(Transforming growth factor beta induced).  The latter is consistent with the previous 
observation that the level of TGFBI decreases in progression from benign breast tissues 
to DCIS and IDC (Calaf, Echiburu-Chau et al. 2008).  TGFBI activates adhesion-
associated signaling and decreases the motility in breast cancer cells both in vitro and 
in vivo.  It also reduces the activation of matrix metalloproteinases (MMPs) 2 and 9, 
which are responsible for the degradation of extracellular matrix (Wen, Partridge et al. 
2011).  
In contrast to decreased TGFBI that has previously been associated with DCIS, 
decreased CADM3, DPT, and NID1 have not previously been linked to breast cancer.  
CADM3 also known as nectin like protein 1 (Necl1) is a cell-cell adhesion molecule and 
has been reported to suppress tumorigenicity in colon cancer cells (Raveh, Gavert et al. 
2009).  Loss of its expression has been detected in various gliomas (Gao, Chen et al. 
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2009).   DPT is involved in cell adhesion and promotes ECM assembly.  Downregulation 
of DPT has been previously observed in oral squamous cell carcinoma and is 
associated with lymph node metastasis (Yamatoji, Kasamatsu et al. 2011).  Decreased 
expression of DPT in hepatocellular carcinoma has also been reported (Li, Feng et al. 
2009).  We also observed greater than tenfold down regulation in expression levels of 
NID1 (Nidogen-1).  Loss of NID1 expression has been observed in colon and gastric 
tumors due to aberrant methylation of NID1 promoter (Ulazzi, Sabbioni et al. 2007), and 
NID1 has been identified as a susceptibility locus for melanoma in a genome-wide 
association study (Nan, Xu et al. 2011). 
Some of the significantly over-expressed genes found in DCIS included AGR2 
(anterior gradient 2), CLDN4 (claudin 4) and LCN2 (lipocalin 2).  The presence of AGR2 
in primary breast tumors is correlated with poor survival (Barraclough, Platt-Higgins et 
al. 2009), and elevated expression of AGR2 is related to treatment failure with 
tamoxifen (Hrstka, Nenutil et al. 2010).  High levels of CLDN4 have been reported in 
basal-like breast cancers (Kulka, Szasz et al. 2009).   In gastric carcinoma, high levels 
of CLDN4 have been found to be significantly associated with MMP-9 expression, which 
in turn can degrade type IV collagen of ECM and facilitate cancer cell invasion (Lee, Wu 
et al. 2008).  In comparison, increased LCN2 promotes breast cancer progression and 
metastasis by facilitating epithelial-to-mesenchymal transition (Yang, Bielenberg et al. 
2009).  The increased expression of LCN2 in our data may be explained by its 
regulation to be under the control of NFKB signaling.  Up-regulation of LCN2 has been 
observed in an NF-KB dependent manner in prostate cancer cells under the conditions 
of ER stress (Mahadevan, Rodvold et al. 2011). 
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Several findings from our sequencing study are in agreement with results from other 
gene expression profiling studies in DCIS.  Down regulation of DST and HTRA1 has 
been associated with progression to invasive breast cancer (Lee, Stewart et al. 2012; 
Wang, Eckert et al. 2012) and was found in our data-set.  Similarly, upregulation of 
GJB2 expression, which is involved in local invasion of breast ductal carcinoma 
(Castellana, Escuin et al. 2012), was also found.  We observed differential gene 
expression of several collagens (1A1, 2A1, L4A6, 7A1,8A1 and 17A1) in DCIS models, 
but not the related family members (e.g.,11A1 and 5A2) that have previously been 
reported to be involved in progression of DCIS to IDC (Vargas, Reed et al. 2012).  
Similar to the findings of comparative microarray analyses of MCF10A and 
MCF10.DCIS trancriptomes (Rhee, Park et al. 2008), we found up regulation of ABTB2, 
CX3CL1, DHRS9, GRHL2, HNMT, KRT6B, KRT7, LCN2, MYEOV, PLEKHF1, SEMA4A 
and TNFRSF12A; down regulation of APOE, C1R, COL4A6, D4S234E, KRT14 and 
PCDH7; and differential expression of several members of various gene families like 
ALDH, CAPN, CCDC, CHST, ITGB, SLC and TMEM. 
 
4.3.2. Signaling pathways and networks 
The integration of differentially expressed genes identified by mRNA-Seq into known 
biological pathways greatly facilitated our comprehension of the complex gene 
expression data.  Involvement of the common differentially expressed genes in various 
signaling pathways such as FGF signaling, TGFβ receptor binding, integrin signaling 
and PDGF binding highlights the cross-talk between these pathways and reiterates the 
complexity of cancer progression.  Thus while the focus on individual genes that were 
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significantly down regulated or over expressed identified many candidates that had not 
previously been considered in the context of breast cancer, the majority of the networks 
and pathways identified from the results were concordant with those that might have 
been predicted. 
The role of FGF signaling has been well characterized in mammary gland 
development and also in progression of breast cancer.  Elevated expression of several 
FGFRs, including FGFR1, FGFR2, FGFR4, and FGFR10 has been previously reported 
in several studies in breast cancer.  A recent study (Sharpe, Pearson et al. 2011) 
reported that FGFR signaling mainly via FGFR2 promotes the growth of triple- negative 
breast cancer.  However, the role of FGFR signaling in the context of DCIS has not 
been studied in depth.  Further characterization of the differentially expressed genes 
involved in FGFR signaling pathway will provide further insights into its role in 
premalignant progression of breast cancer. 
TGF-β plays an important tumor suppressor role in the early phase by preventing 
epithelial cell proliferation or by inducing apoptosis.  The precise role of TGF-β depends 
upon the balance between its canonical and non canonical signaling pathways (Parvani, 
Taylor et al. 2011).  Enrichment of differentially expressed genes in the TGFB signaling 
indicates that this pathway is active during the premalignant stages as well.  A 
significant association between TGFβ and E-cadherin, β-catenin and c-met has been 
observed in DCIS cases progressing to invasive ductal cancer (Logullo, Nonogaki et al. 
2010). 
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Another biological pathway associated with differentially expressed genes in our 
dataset was integrin signaling.  We observed up-regulation of ITGB2 (also known as 
CD18 or Mac1) gene in all DCIS models.   Inhibition of CD18 has been shown to 
enhance tumor response to radiation therapy (Ahn, Tseng et al. 2010).  The authors 
showed that tumors were more sensitive to irradiation when grown 
in CD18 hypomorphic mice.  Further, when CD18 hypomorphism was partially rescued 
by reconstitution with the wild-type bone marrow, the tumors recovered resistance to 
irradiation (Ahn, Tseng et al. 2010).  We also observed down regulation of integrin alpha 
9 (ITGA9), which has previously been reported to be deregulated in several 
malignancies such as non small cell lung cancer (Anedchenko, Dmitriev et al. 2008).  
The role of frequent alterations in ITGA9 and other genes (RBSP3 and hMLH1) in early 
dysplastic lesions of head and neck has been characterized by Ghosh and co-workers 
(Ghosh, Ghosh et al. 2010). 
Collectively, we can infer that these different signaling pathways act in concert to 
drive the premalignant changes in the breast.  The overall pattern of changes 
emphasizes modifications in the interaction of the cells with their environment, with 
major changes in the expression of gene products that localize to the plasma 
membrane and the extracellular region, and alterations in cellular adhesion, motility and 
signaling.  Delineation of the genetic hierarchy and interactions of the various genes 
involved in these pathways may further elucidate their mechanism in governing the 
premalignant progression. 
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4.3.3. Common frameworks as regulatory modules 
In further analysis of our RNA-Seq data, we interrogated the promoters of 
differentially over-expressed genes in DCIS in order to decipher the regulatory 
connections existing among these genes.  A particular physiological process or a 
cellular signal can induce the expression of a distinct set of genes mediated by binding 
of transcription factors to their corresponding binding sites.  These well defined 
regulatory modules present in the promoter regions can influence the expression of 
genes within the same class or may regulate the expression of different unrelated 
genes.  The common promoter structures may explain the functional regulation of 
different co-expressed genes that have no detectable sequence similarity (Werner 
2001).  Hence, we performed in-silico analysis to explore the transcriptional regulatory 
networks that are responsible for the gene expression profiles we observed in our RNA-
Seq study.  We found that a common framework comprising of four transcription factors 
elements namely STAT (signal transducer and activator of transcription), PERO 
(Peroxisome proliferator activated receptor), RXRF (RXR heterodimer binding sites) and 
NFKB (nuclear factor k B) is highly enriched.  This framework may be of particular 
significance and provides a possible explanation of the co-expression of three different 
genes (ELF3, CCL20 and NFATC4).   The identification of coexistence of RXRF and 
PERO is important as RXR physically interacts with PERO or peroxisome proliferator-
activated receptor (PPAR-α) in regulating lipid metabolism and inflammation.  This 
finding is in line with our previous pathway analysis of differentially expressed genes 
that indicated activation of Retinoid X receptor (RXR) pathway and lipid metabolism to 
be one of the most significant biological pathways.  
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ELF3 or E74-like factor 3 (ets domain transcription factor, epithelial-specific) is 
located at chromosome 1q32 in a region, which is known to be amplified in almost 50% 
of early breast cancers.  Protein encoded by ELF3 transactivates Ets-responsive 
promoter elements including that are present in the Her-2/neu oncogene (Chang, Scott 
et al. 1997).  Our findings confirm the previous reports that over-expression of ELF3 
occurs in DCIS samples (Chang, Scott et al. 1997).  ELF3 was shown to differentially 
activate several malignancy-associated gene promoters and regulate cellular survival of 
human mammary cells (Eckel, Tentler et al. 2003).   
A second gene that shares the regulatory motifs with ELF3 for binding of the above 
mentioned four transcription factors is CCL20.  It is interesting to note that CCL20 is 
also among the top 10 significantly differentially expressed genes in our RNA-Seq data.  
It belongs to a large family of chemotactic cytokines that participate in directing 
inflammatory cell migration and in modulating angiogenesis (Kleeff, Kusama et al. 
1999). CCL20 is also known as Macrophage Proinflammatory Human Chemokine-
3alpha (Mip-3alpha/LARC/Exodus) and its expression has been reported to be under 
the direct control of TNF-dependent NF-kappaB activation (Sugita, Kohno et al. 2002).  
Significant up-regulation of CCL20 and its receptor CCR6 was found in pancreatic 
adenocarcinoma and higher expression was associated with the advanced stage of the 
disease (Rubie, Frick et al. 2010).  In a mouse model of colorectal cancer, Liu et al. 
observed that tumor-associated macrophages recruit CCR6+ regulatory T cells and 
promote colorectal cancer by enhancing CCL20 production (Liu, Zhang et al. 2011).  In 
a recent study, the prognostic value of the chemokines CCL19, CCL20 and CCL21 and 
their receptors CCR6 and CCR7 was assessed in non metastatic breast cancer.  The 
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study found that CCR6 (receptor for CCL20), CCL19 and CCR7 expression correlated 
with histologic features of aggressive disease (Cassier, Treilleux et al. 2011).  In an 
another study, expression and secretion of chemokine CCL20 was observed to be 
dramatically increased in breast cancer cells in the presence of adipocyte culture 
medium, which in turn stimulated  metastasis of breast cancer cells.  Interestingly, the 
authors observed that an NF-kappaB blocker completely inhibited adipocyte culture 
medium-induced CCL20 expression (Kim, Baek et al. 2009). This finding underscores 
our observation of predicted transcriptional regulation of CCL20 gene by NFKB.  
The third gene regulated by the common binding of the four transcription factors is 
NFATC4. The product of this gene is a member of the nuclear factors of activated T 
cells and plays an important role in the inducible expression of cytokine genes in T cells, 
especially in the induction of the IL-2 and IL-4.  NFATC4 has been reported to regulate 
peripheral vascular development during embryogenesis.  It is expressed in perivascular 
tissues that influence the development of endothelial cells and vascular smooth muscle 
cells.  Interaction of NFATC4 with ERalpha and ERbeta has been observed both in vitro 
and in mammalian cells.  NFATC4 also acts as negative regulator of adiponectin gene 
expression in obesity and type 2 diabetes (Kim, Kong et al. 2006).  In non small cell 
lung cancer, the expression of NFATC4 was significantly associated with the expression 
of COX-2 (Zhao, Chen et al. 2010).  COX-2 over expression has been previously 
reported in DCIS and is associated with poor prognosis (Sakorafas, Farley et al. 2008).  
A recent study reported that NFATC4 signaling reduces motility of breast cancer cells 
through inhibition of Lipocalin 2 (LCN2) gene expression (Fougere, Gaudineau et al. 
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2010).  In our study, we observed LCN2 as one of the ten most significantly differentially 
over-expressed genes.   
The other common framework that was found to be most highly enriched in our 
comparative promoter analysis comprised of five elements (RXRF-ZF02-ZF02-PLAG-
HDBP) and likely regulates the genes RAP1GAP, SPRY4 and PDGFB.  The protein 
encoded by the gene RAP1GAP is a Rap1 GTPase-activating protein that inhibits the 
RAS superfamily protein Rap1 by facilitating hydrolysis of GTP to GDP.  Down-
regulation of Rap1Gap has been reported to promote cell proliferation and invasion in 
thyroid cancer (Zuo, Gandhi et al. 2010).  The down-regulation of Rap1GAP impairs 
cell-matrix adhesion, but its role in the regulation of cell-cell adhesion is complex and 
not completely understood (Vuchak, Tsygankova et al. 2011).  The observed over-
expression of RAP1GAP in our data is intriguing and requires further investigations to 
characterize the significance of its over-expression in DCIS.  Studies have been initiated 
in our lab to further explore the role of Rap1Gap in premalignant progression of breast 
cancer. 
Another gene co-regulated by the common framework is SPRY4 (sprouty homolog 
4), which is an inhibitor of the receptor-transduced mitogen-activated protein kinase 
(MAPK) signaling pathway.  Sprouty-4 has been shown to inhibit transformed cell 
growth, migration and invasion, and epithelial-mesenchymal transition in non small cell 
lung cancer cells (Tennis, Van Scoyk et al. 2010).  Additionally, SPRY4 has been 
shown to regulate angiogenesis by inhibiting vascular endothelial cell growth factor-
induced extracellular signaling-regulated kinase (ERK) activation.  The expression of 
SPRY4 was found to be increased under the conditions of hypoxia (Haigl, Mayer et al. 
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2010).  In a recently published report, over expression of SPRY4 and its long noncoding 
RNA SPRY4-IT1 was detected in melanoma.  The elevated expression levels of 
SPRY4-IT increased cell growth and decreased apoptosis in melanoma cells (Khaitan, 
Dinger et al. 2011).  The functional relevance of increased expression of SPRY4 that we 
observed in the premalignant DCIS samples needs to be further investigated.  
The third co-regulated gene with RAP1GAP and SPRY4 is PDGFB. The product of 
this gene belongs to the family of platelet derived growth factors that are mitogenic 
factors for the cells of mesenchymal origin.  In breast cancer, high PDGFB expression 
in stroma has been reported to be significantly associated with high histopathological 
grade, estrogen receptor negativity and high HER2 expression (Paulsson, Sjoblom et al. 
2009).  In gastric carcinoma, secretion of PDGFB and expression of its receptor PDGF-
Rβ by tumor-associated stromal cells are involved in mediating lymphatic metastasis 
(Kodama, Kitadai et al. 2010).   
To conclude, here we have used a systematic in silico approach to analyze the genes 
with similar expression patterns by exploring their promoter sequences.  We have 
identified concerted modulation of several genes controlled by binding of transcription 
factors into well conserved common regulatory motifs.  Our data reveal complex 
transcriptional networks in DCIS that may be driving the premalignant progression.  
Further experimental studies will be required to validate the putative crosstalk between 
the co-expressed genes that we have observed in our data.  
Lastly, as the final step of orthogonal validation of our microarray and deep 
sequencing data, we used quantitative real time PCR.  Good correlation between the 
qRT-PCR, microarray and sequencing results indicates the strength of these 
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independent techniques in quantifying the gene expression levels and cross platform 
reproducibility of results.   
In summary, in the present study we were able to confirm the microarray results 
using deep sequencing techniques as well as quantitative real time PCR.  The present 
study also expands the scope of our knowledge on molecular mechanisms, signaling 
pathways and regulatory networks operative in the premalignant progression of breast 
cancer.   Further experimental studies on the novel candidates and the functional 
pathways unraveled in this study may help discover potential biomarkers and develop 
efficacious therapeutic agents. 
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Figure 4.1: Identification of post-transcriptional modifications and 
rearrangements by RNA-sequencing.  A) Reads spanning exon–exon junctions 
indicate splicing events.  B) reads containing poly (A) tracts that are not encoded in the 
reference genome signify poly-adenylation events.  C) reads containing sequence 
polymorphisms as compared to the reference genome indicate editing sites.  (Adapted 
from Marguaret and Bahler, Cell Mol Life Sci., 2010) 
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Figure 4.2: Qualitative concordance between data obtained from Affymetrix 
microarray and Illumina digital gene expression.  In the un-normalized read data, 
123 (80%) of the fold change values were in the same direction in the DGE data as in 
the Affymetrix data.  Each dot on the graph represents a single differentially expressed 
gene. 
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Figure 4.3: DGE signal reads for VAMP2 showing antisense transcription.  Reads 
mapped to UCSC genome browser showing MCF10A & SUM102 sense and antisense 
reads around the gene VAMP2.  Lower signal with more antisense (silencing) reads are 
evident in SUM102 relative to MCF10A.  
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Figure 4.4: Read profiles exhibiting truncated transcripts in the gene ERO1L.  
Reads mapped to UCSC genome browser showing truncated transcripts in SUM102 
relative to MCF10A.  
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A)                                               B)  
         
 
 C) 
 
Figure 4.5: Volcano plots depicting differential expression of genes in various 
DCIS models versus MCF10A.  X-axes represent log2 (fold change) and Y-axes 
denote adjusted p-values for each plot.  Each black dot represents a single gene.  A) 
MCF10.DCIS vs MCF10A; B) SUM102 vs MCF10A; C) SUM225 vs MCF10A.  Note that 
the ranges of the x-axes are variable and the spread of the data for the comparison of 
MCF10.DCIS vs MCF10A is the narrowest. 
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Figure 4.6: Venn diagram of differential expression results showing the overlap 
between the genes expressed by different models of DCIS in comparison to 
MCF10A.  There are a total of 295 genes that are differentially expressed (with a p-
value < 0.001 and log2 fold change ≥ 2) in common to the three DCIS models: 
MCF10.DCIS, SUM102 and SUM225 in comparison to MCF10A. 
95 
 
 
 
 
 
Figure 4.7: Cluster dendrogram of mRNA-Seq samples. Unsupervised hierarchical 
clustering of MCF10A and three DCIS models from the eight RNA-Seq samples  
showing the biological replicates in all groups have high correlation coefficient (A) 
Clustering based on total transcript profile (B) Cluster dendrogram based on 
differentially expressed genes. 
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Figure 4.8: Venn diagram illustrating the overlap between significant genes from 
RNA-Seq (right) and microarray (left). The overlap between the two circles represents 
the common differentially expressed genes detected by both techniques. 
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Figure 4.9: Significant canonical pathways associated with the differentially 
expressed genes.   The list of genes identified as differentially expressed in all models 
of DCIS were uploaded into Ingenuity Pathway Analysis software.  A Fisher's exact test 
was used to test the statistical significance with a significance level of 0.05. 
98 
 
 
 
Figure 4.10: Significant biological processes and pathways associated with the 
differentially expressed genes.  The list of differentially expressed genes in DCIS as 
compared to MCF10A identified by mRNA-Seq analysis was uploaded into Ingenuity 
Pathway Analysis software. A Fisher's exact test was used to test the statistical 
significance with a significance level of 0.05. 
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Figure 4.11: Significant biological processes associated with the differentially 
expressed genes as identified by Genomatix.  The differentially expressed genes in 
all models of DCIS in comparison to MCF10A were analyzed by WebGestalt2 tool.  A 
Fisher's exact test was used to determine statistical significance with a significance level 
of 0.05.  The p-values and the number of genes associated with a particular function or 
process are indicated in bold in the respective boxes.   
100 
 
 
 
Figure 4.12: Cellular components related to significantly differentially expressed 
genes.  The differentially expressed genes in all models of DCIS in comparison to 
MCF10A were analyzed by WebGestalt2 tool.  The p-values and the number of 
differentially expressed genes associated with a particular cellular function or process 
are indicated in bold in the respective boxes.   
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Figure 4.13: Schematic display of genes sharing common regulatory motifs. 
Promoters for three genes (ELF3, NFATC4 and CCL20) contain the common framework 
comprising of four elements V$STAT-V$PERO-V$RXRF V$NFKB. The ‘V$' prefixes to 
the individual matrices are representative of the Vertebrate MatInspector matrix library. 
STAT (signal transducer and activator of transcription); PERO (Peroxisome proliferator 
activated receptor); RXRF (RXR heterodimer binding sites) and NFKB (nuclear factor k 
B). 
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Figure 4.14: Venn diagram showing the genes chosen for validation by qRT-PCR.   
The genes were selected from overlap of microarray and mRNA-Seq results and also 
those detected either by microarray or sequencing only.   
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 AHNAK2 HMG17L1 FOXO1 
ALDH5A1 KRCC1 RPS3 
C1orf62 KRT15 NLGN2 
CCNO ALAS1 SLC7A2 
COL17A1 TACSTD1 PHLDA1 
CYP4B1 VAMP2 MGC4655 
ELF3 ITGB4 ARF5 
ETNK2 SECTM1 GRINA 
GPSM2 NSF MOBKL2B 
HTRA1 DQX1 ZNF395 
LOC100130394 TOX2 CDH3 
LOC401206 IL20RB TTC9C 
LOC642587 RNF126 DUSP6 
MIRN205 HMHA1 DFNB31 
MORF4L1 ANKRD28 PGAM4 
NEBL DPP9 KRT6B 
PDLIM1 FKBP1B LOC440335 
PLEKHA6 LOC100129867 GPR56 
RGS2 ATAD4 ANXA1 
RPL41P2 XPC SFRP1 
SCRN1 RPS4L2 MRPL51 
SESN1 MREG B4GALNT4 
SPRY4 PSMA7 TRAPPC1 
STC2 ID1 LRFN4 
TCEB2 ALS2CL EML3 
TGFBI MXD4 
PIP4K2C HSPH1 
 
Table 4.1: Differentially expressed genes identified by digital gene expression.  A 
total of 79 genes consistently differentially expressed between MCF10A model of 
normal human breast epithelium and the three models of DCIS: MCF10.DCIS, SUM102 
and SUM225. 
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Table 4.2: Comparison of differential expression levels of selected genes by 
Affymetrix and DGE analysis.  The fold change in expression levels in DCIS relative 
to MCF10A are depicted.  
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Sample No. of reads  No. of clusters Clusters/percentage 
MCF10A-2 10,465,483 97,237 8,952,978 (84.6%) 
MCF10A-3 9,158,711 80,872 7,920,391 (86.5%) 
DCIS-2 9,576,827 86,842 7,904,905 (82.5%) 
DCIS-3 7,566,009 82,166 6,390,646 (84.5%) 
SUM102-1 10,052,168 87,122 8,531,282 (84.9%) 
SUM102-2 6,968,895 74,876 5,706,991 (81.9%) 
SUM225-1 9,906,081 92,650 8,404,428 (84.8%) 
SUM225-2 8,337,795 84,549 6,866,336 (82.4%) 
 
Table 4.3: Generation of clusters from the reads obtained by deep sequencing of 
different samples.  Biological duplicates of MCF10A, MCF10.DCIS, SUM102 and 
SUM225 samples were run in the Solexa flowcell.  No. of reads indicates the total 
number of short reads that uniquely aligned to reference genome.  The reads from each 
sample were grouped into clusters using two parameters: 1. window size 100bp; 2. 
number of reads per cluster > 9.  No. of clusters indicates those generated from the 
reads based on Poisson distribution.  The reads that did not group in any cluster were 
considered as background and discarded.  Clusters/percentage indicates reads in 
clusters compared with the total number of reads. 
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Samples RNA-Sequencing Digital gene expression Common 
 
 No. of 
clusters 
No. of mapped 
genes 
No. of 
clusters 
No. of mapped 
genes  
MCF10A 80,872 11,991 206 171 153 
MCF10.DCIS 86,842 11,625 630 586 537 
SUM102 87,122 11,859 926 844 781 
SUM225 92,650 11,857 1,664 1,435 1,288 
  
Table 4.4: Consistency analysis between DGE and RNA-Seq data. The clusters of 
reads generated from MCF10A, MCF10.DCIS, SUM102 and SUM225 samples and 
corresponding number of mapped genes were compared for both the runs.  Most genes 
are consistent between RNA-Seq and DGE.  The genes detected only in DGE 
correspond to the clusters with less number of reads. 
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Top Molecules 
Log Ratio up-regulated Log Ratio down-regulated 
Molecules Exp Value Molecules Exp Value 
AGR2 ↑   5.011 ADH1B ↓    -10 
GRHL2 ↑   4.435 NID1 ↓    -8.728 
APOD ↑   4.239 DARC ↓    -8.382 
CCL20 ↑   4.219 ASPA ↓    -8.323 
CHAC1 ↑   4.161 CADM3 ↓    -8.173 
CLDN4 ↑   3.97 DPT ↓    -8.058 
LCN2 ↑   3.87 TLL1 ↓    -7.994 
LIPH ↑   3.855 PDPN ↓    -7.757 
FUT3 ↑   3.804 TGFBI ↓    -7.586 
CREB5 ↑   3.714 RNY5 ↓    -7.581 
 
Table 4.5: Genes with the largest fold change in expression identified in the list of 
those differentially expressed.  The significantly differentially over-expressed in DCIS 
in comparison to normal MCF10A include anterior gradient homolog 2 (AGR2), 
grainyhead like (Drosophila) (GRHL2), apolipoprotein D (APOD), chemokine (C-C motif) 
ligand 20 (CCL20), cation transport regulator homolog 1 (E. coli) (CHAC1), claudin 4 
(CLDN4), lipocalin 2 (LCN2), lipase member H (LIPH), fucosyltransferase 3 (FUT3)  and 
cAMP responsive element binding protein 5 (CREB5).  The genes which were found be 
significantly down-regulated include alcohol dehydrogenase 1B (class I), (ADH1B), 
RNA, Ro-associated Y5 (RNY5), transforming growth factor, beta-induced (TGFBI), 
podoplanin (PDPN), tolloid-like 1 (TLL1), dermatopontin (DPT), cell adhesion molecule 
3 (CADM3), aspartoacylase (ASPA), Duffy blood group, chemokine receptor (DARC) 
and nidogen 1 (NID1).  The red arrows indicate up regulation in expression and green 
arrows indicate down regulation in expression. 
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ID Molecules in Network Score 
Focus 
Molecules Top Functions 
1 
26s 
Proteasome,A4GALT,Akt,Alp,ANKRD2,Ap1,APOE,BEX2,BG
N,C1q,C1R,CCL20,CD7,CD70,CDH13,CHEMOKINE,CLDN4,
CLDN9,cldn,COL17A1,COL1A1,COL21A1,COL22A1,COL28A
1,COL2A1,COL4A6,COL7A1,collagen,Collagen type 
I,Collagen type IV,Collagen(s),CPE,CSF1,Cyclin 
A,DARC,DCN,DST,EDN2,ELF3,ERK,ERK1/2,FGFR3,FKBP1
B,FOXO1,FSH,FZD2,GLI3,Gpcr,GPR56,GPR61,GPR84,GPR
113,GPR114,GPR144,GPR162,GPR174,GPR180,GPR89A/G
PR89B,GPR89C,Growth hormone,HIST2H2BE,Histone 
h3,Histone h4,HOXA7,ID3,Ifn 
gamma,Ige,IgG1,IgG,IGH@,Igm,IL1,INPP5D,Insulin,Integrin,I
nterferonalpha,Jnk,LAMB1,Laminin,LBH,LCN2,LDL,Lh,LMTK
3,MAPK13,Mapk,MMP28,Mmp,MT1E,MYL9,NFAT 
(complex),Nfat (family),NFATC4,NFkB (complex),NID1,P38 
MAPK,p85 (pik3r),PCDH7,Pdgf (complex),PDGF 
BB,PDGFB,PI3K 
(complex),Pkc(s),POSTN,PPARGC1B,PROCR,Rac,Rap1,RA
P1GAP,Ras,RIN1,RIN2,S100P,S1PR4,SCD,SECTM1,SERPI
NF1,SFTPD,Smad,SPRY4,SPSB1,TAAR8,Tgf 
beta,TGFBI,TGFBR3,TIMP3,TJP3,TLL1,Tnf 
receptor,TNFRSF12A,TNIK,TP73,TWIST1,UCN2,Vegf,VN1R
2,VN1R3,WISP2,ZBTB16ZEB2 
131 74 
Connective 
Tissue 
Disorders, 
Genetic 
Disorder, 
Dermatological 
Diseases and 
Conditions 
2 
ACSL4,ACSM3,ADAMDEC1,ADCYAP1,AGR2,AMACR,ANKR
D13B,ANP32E,APOD,arachidonic 
acid,ARL14,ART3,B3GALNT1,BCAS4,beta-
estradiol,BSPRY,C9orf3,CADM1,CADM3,CCDC64B,CDK18,
CHAC1,CKMT1A/CKMT1B,CLCN2,CLEC2B,Clec2d (includes 
others),CNN2,CORO6,CPXM1,CREB5,DLEU2,DLK2,DPT,DQ
X1,E2F1,Egfbp2,EGR2,ELOVL2,EPGN,ERBB2,FAM105B,FA
M110B,FAM129A,FAM50A,FAM65B,FBXO27,FOS,FRRS1,F
XYD5,G6pd2,GINS1,GLRA1,GLUD2,Gm10077,Gm10155,GR
HL2,heparin,HIST1H2AG (includes 
others),HNMT,HTRA1,ICA1,IL6,IL29,INMT,JAM3,KDELR3,KI
AA0802,KLK11,KRT7,KRT13,KRT14,KRT81,L-alpha-
lysophosphatidylcholine, 
stearoyl,LEPROT,LIPH,LOC729505,LRRN3,LTBP3,MAP4,MA
PK6,MARK4,MED31,MGMT,MIA2,MLXIP,MSGN1,MYC,OMG
,PAQR7,PARD3,PCDHGC3,PDE7A,PDPN,PGLYRP1,PHGD
H,PLA2G2E,PLA2G2F,PLA2G4F,PLSCR1,PMPCB,PPT2,pro
gesterone,PRR15L,PRSS22,RAB10,RAB25,RFX2,RPL17,Rpl
9 (includes 
others),RPLP1,RPS18,SATB1,SBNO2,SCRN1,SDC3,SEMA4
A,SEPT6,SLC13A3,SLC14A1,SLC39A14,SLC7A2,SOD2,SOL
H,SPAG4,SPEG,SPRR3,SQRDL,TDRD6,TERT,TGFB1,Timd
2,TMEM2,TMEM126A,TOX2,TRIM14,UST,YWHAZ,YY2,ZFP
65 43 
Cellular 
Development, 
Lipid 
Metabolism, 
Molecular 
Transport 
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161,ZNF22 
3 
AATK,ABCB9,ABTB2,ACY1,ACY3,ADCK3,ADH6,ADH1B,AL
DH16A1,ALDH1L1,ALDH5A1,ALDH8A1,ANKRD49,APP,AQP
9,AS3MT,ASPA,BCL2L14,BPI,C21orf33,C7orf10,C8orf4,CAL
ML3,CALML4,Casein,CCDC76,CD300C,CDCA7L,CES2,CHS
T2,CHST4,CIDEC,COX11,CSRNP1,CTNNBL1,CWC15,CYP2
6B1,CYP4F3,D4S234E,DDX10,DDX18,DEFA4,DHRS3,DHR
S4,DLEU1,ECD,ECE2,ECI2,EIF4EBP2,ELMOD3,EPB41L4B,
ETNK2,EWSR1,FAM86C,FARSB,FASTKD2,FETUB,FEZF2,F
LRT3,FUT3,FUT4,FZD3,GGT6,GPX2,GRHL1,HGD,HIP1,HM
GN4,HNF4A,HS3ST1,HS6ST1,HSD17B11,IFT122,KCNB1,K
CNQ5,KIF3C,KLF15,LAD1,LGALS12,LRRC8C,LRRK2,MAP7,
MGST2,MMP28,MRPS18B,MSLN,MTF2,NBPF3,NDST1,NDU
FB1,NDUFV1,NLN,NR3C1,NR4A2,OAS3,OASL,OSCAR,OTU
D6B,PAFAH2,PARP4,PHB2,PLCH2,PLEKHF1,PWP1,RABG
GTB,RASL11B,RNY5,RTP3,SAMHD1,SEMA3C,SEMA5B,SE
PX1,SERPINB8,SLC25A20,SLC38A1,SLC5A3,STARD10,ST
T3A,SULT1C2,SUPT4H1,TMEM176B,TNF,TNFRSF21,TPCN
1,TPP2,tretinoin,TRIM15,TRIM35,TROVE2,TSPAN14,VMP1,
WDR37,WNT10A,WTAP,ZBTB11,ZDHHC6,ZNF133,ZNF146,
ZNF318 
32 26 
Lipid 
Metabolism, 
Small Molecule 
Biochemistry, 
Organismal 
Injury and 
Abnormalities 
 
Table 4.6: Signaling pathway networks involving differentially expressed genes.  
Ingenuity Pathway Analysis (IPA) of differentially expressed genes revealed several 
statistically significant pathway networks.  Each network contains focus molecules that 
are obtained from RNA-Seq analysis and are indicated in bold.  The other genes in the 
network are derived from IPA database.  The statistical significance score and top 
functions associated with the molecules in network are also indicated in the table.  
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Molecular and Cellular 
Functions p value 
No. of 
molecules 
Cell-To-Cell Signaling and 
Interaction 1.96E-09 - 1.08E-02 35 
Cellular Movement 1.97E-07 - 1.08E-02 43 
Cellular Assembly and 
Organization 4.44E-06 - 1.11E-02 22 
Cellular Function and Maintenance 4.44E-06 - 8.94E-03 11 
Cellular Development 1.04E-05 - 1.11E-02 53 
Diseases and Disorders p value No. of 
molecules 
Cancer 4.23E-09 - 1.07E-02 71 
Inflammatory Disease 7.96E-07 - 9.89E-03 60 
Connective Tissue Disorders 1.91E-06 - 8.94E-03 42 
Genetic Disorder 3.40E-06 - 1.11E-02 100 
Dermatological Diseases and 
Conditions 4.96E-06 - 8.94E-03 31 
 
Table 4.7: The molecular and cellular functions and diseases and disorders 
associated with the differentially expressed genes derived from RNA-Seq data 
analysis.  The values in the second column represent the statistical significance score 
(p value).  The number of differentially expressed genes in the dataset are indicated in 
the third column. 
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Functions 
Annotation 
p-
Value Molecules 
No. of 
Molecules 
carcinoma 5.06E-06 
ADH1B, AGR2, ALDH5A1, APOD, APOE, BEX2, BGN, C1R, 
CD70, CDH13, COL1A1, COL7A1, CSF1, FGFR3, GPR56, 
HIP1, KRT14, KRT7, LCN2, MAPK13, MSLN, MT1E, MYL9, 
PDPN, POSTN, RAP1GAP, SCD, SERPINF1, TIMP3, TLL1, 
TNFRSF12A, TP73, TWIST1 
33 
malignant 
tumor 
1.93E-
05 
ADH1B, AGR2, ALDH5A1, APOD, APOE, BEX2, BGN, C1R, 
CD70, CDH13, COL1A1, COL7A1, CSF1, DCN, FGFR3, 
FOXO1, GPR56, HIP1, IGH@, KRT14, KRT7, LCN2, 
MAPK13, MSLN, MT1E, MYL9, PDPN, POSTN, RAP1GAP, 
SCD, SERPINF1, TIMP3, TLL1, TNFRSF12A, TP73, TWIST1 
36 
digestive organ 
tumor 
2.57E-
05 
ADH1B, APOE, BGN, COL1A1, CSF1, FGFR3, KRT14, KRT7, 
LCN2, MAPK13, MSLN, PDPN, POSTN, RAP1GAP, SCD, 
TIMP3, TP73, TWIST1 
18 
genital tumor 2.77E-04 
APOD, APOE, C1R, CDH13, COL7A1, CSF1, FGFR3, GPR56, 
HIP1, KRT7, LCN2, MYL9, PDPN, TIMP3, TP73 15 
oral cancer 3.40E-04 
BGN, COL1A1, KRT14, MAPK13, PDPN, S100P 6 
breast cancer 5.23E-04 
AGR2, APOE, BEX2, CD70, CDH13, CLDN4, COL1A1, CSF1, 
ETNK2, FGFR3, FOXO1, HIST2H2BE, KRT14, LCN2, MT1E, 
PDGFB, PDPN, SERPINF1, TLL1, TP73, TSPAN15 
21 
head and neck 
tumor 
5.51E-
04 
ALDH5A1, BGN, FGFR3, KRT14, LAMB1, MAPK13, PDGFB, 
PDPN, POSTN, RAP1GAP, TP73, TWIST1 12 
prostate cancer 5.58E-04 
AGR2, ALDH5A1, APOD, C1R, CDH13, COL1A1, COL7A1, 
CSF1, FGFR3, GPR56, HIP1, KRT7, MYL9, TIMP3, TLL1 15 
prostatic 
carcinoma 
7.39E-
04 
APOD, C1R, CDH13, COL7A1, CSF1, GPR56, HIP1, KRT7, 
MYL9, TIMP3 10 
uterine tumor 7.93E-04 
ADH1B, CDH13, CSF1, DPT, DST, FGFR3, HNMT, SPSB1, 
TIMP3, TP73 10 
benign tumor 8.06E-04 
ADH1B, DARC, DCN, DPT, DST, FGFR3, HNMT, LCN2, 
MAPK13, SCD, SEMA5B, SPSB1, TGFBR3, TNFRSF12A, 
WISP2, ZEB2 
16 
pancreatic 
tumor 
9.05E-
04 
BGN, FGFR3, KRT7, LCN2, MAPK13, MSLN, TWIST1 7 
colorectal 
cancer 
1.15E-
03 
C1R, CLDN4, COL2A1, FGFR3, FUT3, HSD17B11, HTRA1, 
LIPH, MT1E, PDPN, RAP1GAP, SECTM1, SLC2A14, 
TGFBR3, TIMP3, TJP3, TNIK, TWIST1, WISP2 
19 
metastasis of 
lung 
2.15E-
03 
CSF1, LCN2 2 
 
Table 4.8: Significant differentially expressed genes involved in various types of 
cancers. The number of focus genes and the p-values are indicated in the table. 
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Pathways P value 
Integrin signaling pathway 5.99e-03 
Patched homolog 1 (drosophila) 4.54E-04 
Fibroblast growth factor 5.41E-04 
TGF beta 5.43E-04 
Phosphatidylinositol 7.21E-04 
Mothers against dpp homolog 1.68E-03 
Rhoa ras homolog 2.80E-03 
Indian hedgehog v akt murine thymoma viral 
oncogene homolog 1 3.10E-03 
V akt murine thymoma viral oncogene homolog 1 5.55E-03 
Hepatocyte growth factor receptor 5.79E-03 
Signal transducer and activator of transcription 8.94E-03 
 
Table 4.9: Network pathway analysis of differentially expressed genes by 
Genomatix. The genes identified as differentially expressed in all models of DCIS were 
analyzed by Genomatix software.  A Fisher's exact test was used to test the statistical 
significance with a significance level of 0.05. 
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Biological 
Process Common Framework 
No. of 
frameworks 
in 244 
promoters 
No. of 
frameworks 
in human 
promoters 
Enrichment 
Regulation of 
biological 
processes 
KLFS-EGRF-SP1F-CTCF 5 266 6.32 
SP1F-ZF02-EGRF 11 2545 1.45 
Communication 
RXRF-ZF02-ZF02-PLAG-
HDBP 3 3 336.36 
CTCF-EGRF-SP1F-KLFS 3 48 21.02 
CTCF-ZF02-SP1F-KLFS 3 51 19.79 
Regulation of 
metabolic process CFCF-EGRF-SP1F 20 5131 1.31 
Defense 
Response 
V$EBOX-V$NFKB-V$STAF 3 32 31.8 
V$HNF1-V$SORY-V$HAND 3 134 7.6 
V$LEFF-V$ZF02-V$GCMF 3 15 67.8 
V$STAT-V$PERO-V$RXRF 
V$NFKB  3 4 254.2 
 
Table 4.10: Common framework mining in the promoters of differentially up- 
regulated genes. Clustering by biological processes of differentially over expressed 
genes in the DCIS models for promoter analysis.  High enrichment for the common 
frameworks V$STAT-V$PERO-V$RXRF V$NFKB and RXRF-ZF02-ZF02-PLAG-HDBP 
is highlighted in red. 
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 RNA-Seq qRT-PCR 
Gene 
Symbol DCIS SUM102 SUM225 DCIS SUM102 SUM225 
CASP2 -0.79 -0.57 -0.52 -3.09 -2.79 -3.80 
DUSP5 1.38 2.49 3.57 -1.58 2.80 1.88 
GRB7 0.59 2.34 7.64 1.42 11.19 126.47 
PAK1 1.08 1.61 1.16 1.43 4.83 1.60 
GPT2 -0.82 0.71 4.47 -2.16 2.38 48.84 
 
Table 4.11: Comparison of the fold changes in gene expression of various genes 
detected by RNA-Seq and qRT-PCR. The values represent the fold changes in 
MCF10.DCIS, SUM102 and SUM225 compared to expression in MCF10A. The values 
in the table are Log2 (Fold Change), positive value indicates up-regulated, negative 
value indicates down-regulated.  
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 Microarray RNA-Seq qRT-PCR 
Gene Symbol DCIS SUM102 SUM225 DCIS SUM102 SUM225 DCIS SUM102 SUM225 
TIMP3 -4.56 -3.46 -5.05 -5.09 -3.81 -5.38 -9.24 -3.57 -103.54 
GFPT1 1.64 2.57 3.57 0.50 1.15 2.70 3.074 5.063 13.833 
RAB25 6.16 5.62 5.58 2.48 2.07 1.99 5317.75 3630.12 2442.26 
S100P 4.31 5.08 4.63 2.14 3.91 2.89 7.03 47.10 13.91 
IRS1 -3.14 -2.44 -3.38 -3.38 -1.80 -2.97 -3.90 -1.39 -4.32 
GLUL -1.65 -3.18 -1.20 -3.79 -4.95 -2.40 3.78 1.31 4.25 
KLK5 6.74 4.11 4.21 2.48 0.01 0.12 1119.78 288.73 140.49 
MET -1.99 -0.88 -1.69 -1.55 -0.25 -0.43 -4.59 1.19 -4.86 
ITGB4 1.88 -2.73 -4.53 2.11 -3.98 -5.43 4.61 -17.60 -161.43 
FOXO3 -1.29 -0.78 -1.85 -1.29 -0.45 -1.85 -25.32 -5.90 -79.07 
RHOB 1.61 1.54 4.07 0.99 0.87 3.84 -1.95 1.21 4.58 
ALDH5A1 13.00 11.41 20.79 4.60 6.13 6.13 1.32 2.00 1.97 
GLUD1 
-2.78 -2.66 -2.05 -2.68 -2.76 -2.76 -3.39 -2.01 -2.35 
GFPT2 
-1.28 -1.18 -2.47 -20.00 -1.76 -1.76 -26.72 -2.22 -8.00 
 
Table 4.12: Comparison of the fold changes in gene expression of selected genes 
detected by microarray, RNA-Seq and qRT-PCR. The values represent the fold 
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changes in MCF10.DCIS, SUM102 and SUM225 compared to expression in MCF10A. 
The values in the table are Log2(Fold Change), positive value indicates up-regulated, 
negative value indicates down-regulated. 
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CHAPTER 5 
 
ALDH5A1, A KEY ENZYME OF GLUTAMATE METABOLIC PATHWAY, PROMOTES 
CELL GROWTH AND PROLIFERATION IN VARIOUS MODELS OF DUCTAL 
CARCINOMA IN SITU  
 
5.1 BACKGROUND AND RATIONALE 
 
5.1.1 Glutamate metabolism in cancer 
The cancer cells face a major bio-energetic and bio-synthetic challenge to meet the 
ever increasing demands of proliferating cells.  To maintain continual supply of energy 
for growth and proliferation, the cancer cells undergo metabolic reprogramming wherein 
they avoid oxidative phosphorylation and metabolize glucose by aerobic glycolysis even 
in the presence of available oxygen.  This phenomenon, known as ‘Warburg effect’ has 
been long known to researchers and was observed in early 1950s.  In the last decade, 
various studies have reported another important alteration in cancer cellular metabolism 
that is the conversion of glutamine into intermediates for other bio-synthetic pathways. 
Glutamine serves as a source of reduced nitrogen, which is required by the 
proliferating cancer cells to produce nucleotides and non-essential amino acids.  
Glutamine metabolism was observed to be a robust source of Kreb’s cycle 
intermediates, NADPH and non essential amino acid pools in glioblastoma cells 
(DeBerardinis, Mancuso et al. 2007).  Targeting elevated glutaminase activity by small 
molecule inhibitor, 968, inhibits oncogenic transformation in breast cancer cells (Wang, 
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Erickson et al. 2010).   Evidence has emerged that glutamate, the breakdown product of 
glutamine, also acts as a signal mediator in malignant progression.  The excitatory 
neurotransmitter has been known to regulate the growth and proliferation of neurons, 
however the peripheral expression of glutamate receptors points towards other diverse 
biological roles that glutamate may have, apart from its neurotransmitter function.  
Studies have indicated the presence of glutamate receptors in various cancers of 
peripheral tissues such as melanoma (Namkoong, Shin et al. 2007), head and neck 
(Haas, Linecker et al. 2010), pancreatic ductal adenocarcinoma (Herner, Sauliunaite et 
al. 2011), advanced squamous cell carcinoma of larynx (Stepulak, Luksch et al. 2011) 
and triple negative breast cancer (Speyer, Smith et al. 2011).  Aberrant glutamate 
signaling was recently reported as most significant metabolic pathway in melanoma 
(Wei, Walia et al. 2011).  Although a link between glutamate metabolism and 
premalignant breast disease would be a novel connection in the context of DCIS, 
metabolomic profiling of gastric cancer metastases also identified associations with 
glutamate metabolism (Chen, Tang et al. 2010).  
In the light of the published studies and our gene expression profiling studies by 
multiple tools, we sought to further investigate the role of, one of the significantly altered 
pathway associated with the differentially expressed genes in DCIS i.e. glutamate 
metabolism, in promoting premalignant progression.   
 
5.1.2 ALDH5A1 as a Novel Potential Target 
Among the several members of glutamate metabolic pathway (such as aldehyde 
dehydrogenase 5 family member 1; ALDH5A1, glutamine–fructose-6-phosphate 
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transaminase 2; GFPT2, glutamate dehydrogenase 1; GLUD1, and glutamate ammonia 
ligase; GLUL) identified in our list of differentially expressed genes in DCIS, we chose to 
focus on ALDH5A1.  It was selected as an initial target for detailed investigation for 
several reasons.  First, there was a strong gain of expression in all three models of 
DCIS that was revealed by microarray, RNA-Seq and confirmed by qRT-PCR.  Second, 
ALDH5A1 represented a novel transcript that had not previously been associated with 
breast cancer.  Third, there is established pharmacology for inhibition of ALDH5A1 
through two FDA-approved drugs (disulfiram [DSF] (Hellstrom and Tottmar 1982) and 
valproic acid [VPA] (van der Laan, de Boer et al. 1979).  Both are known to be safe for 
chronic use in patients with other disorders but have not previously been considered in 
the context of DCIS. 
 
5.1.3 Experimental Strategy 
If the protein expressed by the over expressed gene contributes to a major metabolic 
pathway or is a key enzyme in biochemical process, then inhibition of its activity should 
lead to change in cell growth and proliferative properties.  Based on this rationale, we 
used different experimental approaches to manipulate the expression levels of 
ALDH5A1 in order to establish the functional significance of its increased expression in 
the models of DCIS. 
We first determined the expression levels of ALDH5A1 at protein level and then 
employed pharmacological inhibition of ALDH5A1 with different commercially available 
inhibitors.  We targeted inhibition of ALDH5A1 by disulfiram, valproic acid and 4- 
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hydroxybenzaldehyde or glutamate release by riluzole in the 3D rBM overlay cultures of 
DCIS models (MCF10.DCIS, SUM102 and SUM225) and MCF10A.   
 
5.2 RESULTS 
 
5.2.1 Increased ALDH5A1 protein expression in all models of DCIS 
Since changes in mRNA level are not always reflective of changes in protein 
expression, so we determined the level of ALDH5A1 protein in MCF10.DCIS, SUM102, 
SUM225 and MCF10A models by immunoblotting.  We observed increased expression 
of ALDH5A1 in all three models of DCIS in comparison to the MCF10A model (Figure 
5.1).   
 
5.2.2 Pharmacological Inhibition of ALDH5A1 
 
5.2.2.1 Effect on cell survival and proliferation  
Next, we sought to determine the effect of treatment of different drugs, on the survival 
and proliferation of MCF10A cells and the three models of DCIS by an adaptation of 
tetrazolium based MTT assay for 3D culture.  The cells in culture were either treated 
with varying concentrations of the individual drug or with the vehicle as control.  We also 
included doxorubicin as a positive control in all the assays.   
 
5.2.2.1.1 Treatment with disulfiram  
121 
 
 
Disulfiram (DSF) is a broad spectrum and irreversible inhibitor of many isozymes in 
the aldehyde dehydrogenase family (Hellstrom and Tottmar 1982).  Treatment with DSF 
significantly inhibited proliferation of 3D rBM overlay cultures of MCF10.DCIS, SUM102 
and SUM225, but had only a modest effect on 3D rBM overlay cultures of MCF10A 
(Figure 5.2).  For example, a concentration of 20 µM DSF significantly (p < 0.001) 
reduced the proliferation of MCF10.DCIS, SUM102 and SUM225 cultures.  The GI50 
values (the concentration of drug that produces 50% inhibition of cell growth) for 
MCF10.DCIS, SUM102 and SUM225 were 4.8 µM, 9.3 µM and 11.6 µM, respectively, 
whereas the GI50 value for MCF10A was 56.9 µM. 
 
5.2.2.1.2 Treatment with riluzole 
Similar to the sensitivity pattern exhibited by the DCIS models to disulfiram 
(MCF10.DCIS > SUM102 > SUM225), we observed that MCF10.DCIS model was more 
sensitive to the growth inhibitory effect of riluzole than the other two SUM models 
(Figure 5.3).  The GI50 value for riluzole in MCF10.DCIS was 10.7 µM whereas the GI50 
values for SUM102 and SUM225 were 20.2 µM and 23.4 µM respectively.  However, 
there was no significant difference in the growth inhibitory effect on SUM102, SUM225 
and MCF10A (GI50 21.3 µM).  
 
5.2.2.1.3 Treatment with valproic acid 
Valproic acid (VPA) is a selective blocker of the ALDH5A1 isoform (van der Laan, de 
Boer et al. 1979) that is increased in the three DCIS models.  VPA is also an inhibitor of 
the histone deacetylases (Gottlicher, Minucci et al. 2001; Phiel, Zhang et al. 2001; Eyal, 
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Yagen et al. 2004).  Treatment with VPA had a minimal effect on the proliferation of 
MCF10A 3D rBM overlay cultures at any of the doses tested, but inhibited proliferation 
of MCF10.DCIS, SUM102, and SUM225 3D rBM overlay cultures in a dose-dependent 
manner (p < 0.05) (Figure 5.4).  In contrast to our observation with disulfiram and 
riluzole, SUM102 had greater sensitivity to growth inhibition by valproic acid followed in 
order by MCF10.DCIS and SUM225. 
 
5.2.2.2 Effect on cellular morphology 
To further evaluate, whether treatment with the above drugs can affect the 
morphology of MCF10A and DCIS models as well, we performed imaging of the cells 
grown on Cultrex pre-coated coverslips and cultured in 3D overlay cultures in the 
presence of varying concentrations of the inhibitors or vehicle as control.      
 
5.2.2.2.1 Treatment with riluzole 
Since in the cell survival and proliferation assays, we observed that riluzole had 
significant effect of MCF10.DCIS model versus a modest effect on proliferation of the 
two SUM models, here we focused on the morphological analyses of MCF10.DCIS and 
MCF10A structures.  However, in addition to MCF10.DCIS, we also tested the effect of 
riluzole on the MCF10.AT1 variant, which is an intermediate in the progression series 
from MCF10A and MCF10.DCIS and represents atypical hyperplasia and also on MDA-
MB-231 cells, which represent invasive breast cancer.  The purpose to include the pre-
DCIS and the post-DCIS stages was to determine whether the effect of riluzole is 
specific to MCF10.DCIS only or it has a wider spectrum of effect.  
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We observed that treatment with riluzole significantly inhibited the growth and altered 
the morphology of MCF10.DCIS and MCF10.AT1 structures at the concentration of 10 
µM (and above).  The control MCF10.DCIS structures showed dysplastic growth and 
the control MCF10.AT1 cells formed hyper-plastic structures lacking any lumen.  
However, the riluzole treated MCF10.DCIS structures looked growth inhibited and less 
irregular.  Similarly, the riluzole treated MCF10.AT1 structures were smaller in size as 
compared to control.  The treatment, however, did not show any observable effect on 
the MCF10A spheroids, which looked similar to the control (Figure 5.5).  Furthermore, 
MDA-MB-231 cells did not exhibit any alteration in morphology upon treatment with 
riluzole.  In order to determine whether riluzole has any effect on the survival and 
proliferation of MDA-MB-231 cells, we then performed MTT assay.   As observed for 
morphological changes, the treatment had no significant effect on growth and 
proliferation of these cells (data not shown). 
Next, with the aim to quantify the changes induced by riluzole treatment on the 
MCF10.DCIS, MCF10.AT1 and MCF10A structures, we performed morphometric 
analysis of the above structures.  Since the MDA-MB-231 cells grow as stellate 
projections bridging multiple cell colonies, the evaluation could not be performed in 
those structures.  The analysis showed that riluzole had modest effect on the growth of 
the MCF10A spheroids whereas it showed concentration dependent reduction in size 
for both MCF10.DCIS and MCF10.AT1 structures.  The size determination of spheroids 
was performed following a blinded protocol by an undergraduate student in the 
laboratory. 
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5.2.2.2.2 Treatment with disulfiram 
We then investigated whether disulfiram has any impact on the morphology of 
MCF10A and MCF10.DCIS structures.  Herein, in addition to MCF10A and 
MCF10.DCIS, we included MCF10.Ca1d cells, which represent invasive breast cancer 
and is the next stage of MCF10.DCIS in the progression series.  We observed that 
disulfiram significantly inhibited the growth of MCF10.DCIS and MCF10.Ca1d structures 
as compared to the growth of MCF10A spheroids.  The control MCF10.DCIS structures 
exhibited hyper-plastic growth with irregular morphology whereas the control MCF10A 
structures showed typical acinar morphology.  The control MCF10.Ca1d cells 
proliferated as large structures exhibiting invasive phenotype. Treatment with disulfiram 
strongly inhibited growth and proliferation of both MCF10.DCIS and MCF10.Ca1d while 
having a scant effect on MCF10A (Figure 5.6).  
  
5.2.2.2.3 Treatment with 4-hydroxybenzaldehyde 
Next, we sought to investigate the treatment effect of another inhibitor of ALDH5A1, 
4-hydroxybenzaldehyde, upon growth and morphology of MCF10A, MCF10.DCIS and 
MCF10.Ca1d cells.  The treatment resulted in inhibition of proliferation of MCF10.DCIS 
and MCF10.Ca1d structures whereas there was lack of any noticeable effect on 
MCF10A spheroids.  The treated MCF10A spheroids had the normal acinar structure 
with similar size as that of control spheroids.  However, the treated MCF10.DCIS 
structures were smaller in size and MCF10.Ca1d structures showed significant growth 
inhibition (Figure 5.7).  We then evaluated the effect of 4-hydroxybenzaldehyde on the 
survival and proliferation of MCF10A and MCF10.DCIS cells using MTT assay.  The 
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MTT results however did not show any significant effect on survival and proliferation of 
either MCF10A or MCF10.DCIS cells.   
 
5.2.2.2.4 Treatment of DCIS variants with DSF and VPA 
As an independent assay for effects on cell growth, we developed variants of 
MCF10.DCIS and SUM102 cells that constitutively expresses monomeric red 
fluorescent protein (mRFP) and treated 3D rBM overlay cultures of these cells.  The 
results show the dysplastic growth of the control and vehicle-treated MCF10.DCIS-
mRFP and SUM102-mRFP cells over a period of eight days.  This growth is essentially 
terminated by inclusion of DSF at ≥ 20 µM (Figures 5.8 and 5.9A).  We also tested VPA 
against the SUM102-mRFP cells and found that ≥ 0.1 mM was sufficient to reduce their 
proliferation (Figure 5.9B).  To test whether these growth inhibitory effects of DSF and 
VPA were reversible, we re-plated the cells in fresh media without drug and assayed 
their ability to re-grow over 10 days (Figure 5.10).  The SUM102-mRFP cells that had 
been treated with 20 or 50 µM DSF showed no ability to re-grow, whereas those that 
had been treated with 5 µM DSF showed minimal re-growth as compared to control, 
vehicle-treated cells.  Treatment with as little as 0.1 mM VPA was sufficient to almost 
completely block re-growth.   
 
5.3 DISCUSSION 
From among the group of differentially expressed gene products in the DCIS models 
that are involved in glutamate metabolism, we selected ALDH5A1 due to its novelty in 
the context of breast cancer and status as an established druggable target.  The gene 
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product of ALDH5A1, also known as succinic semi-aldehyde dehydrogenase (SSDH), is 
involved in the catabolism of neurotransmitter 4-aminobutyric acid (GABA) and is highly 
expressed in brain.  ALDH5A1 belongs to the superfamily of aldehyde dehydrogenases 
(ALDHs) that oxidize aldehydes to the corresponding carboxylic acids. Very little is 
known about ALDH5A1 with regard to cancer, beyond an observation in renal cell 
carcinoma cells that it is regulated by hepatocyte nuclear factor 4alpha (Lucas, Grigo et 
al. 2005).   
In contrast, elevated activity of the ALDHs 1A2, 1A3, 1A7, 3A1, 4A1, 5A1, 6 and 9A1 
has been reported in stem cells (Muzio, Maggiora et al. 2012).  Increased activity of 
ALDH1A1 has been observed in the stem cell populations of multiple myeloma, acute 
myeloid leukemia and malignant mammary cells (Pearce, Taussig et al. 2005; Ginestier, 
Hur et al. 2007).  Breast cancers with stem cells having high expression of ALDH1A1 
have biologically aggressive phenotypes and poor prognoses (Morimoto, Kim et al. 
2009). Down regulation of ALDH1A1 and ALDH3A1 has been shown to reduce cell 
growth and motility in lung cancer cells (Moreb, Baker et al. 2008).  ALDH3A2 is one of 
the 35-gene signature that is reported to discriminate between well- and poorly 
differentiated DCIS (Hannemann, Velds et al. 2006).  Here, in this chapter, we aimed to 
determine the significance of many fold increase in ALDH5A1 expression in ductal 
carcinoma in situ that we observed in our expression profiling data and how that 
contributes towards premalignant progression.   
Whole genome expression analysis by microarrays and sequencing showed 
significant increases in ALDH5A1 expression in the DCIS models that was validated by 
both qRT-PCR and immunoblotting.  Meta-analysis of normalized gene expression 
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profiles in the GeneSapiens "body-wide" microarray database reveals that the median 
level of ALDH5A1 expression is significantly higher in certain cancers (particularly 
glioma and some leukemias and lymphomas).  In the group of breast and reproductive 
cancers, the median expression of ALDH5A1 remains low.  Notably, there are outliers of 
breast cancers classified as ductal and classified as not-otherwise-specified (which 
would include DCIS and IDC, respectively) in which ALDH5A1 is increased in 
expression (Figure 5.11).  
 
5.3.1 Studies with Disulfiram  
The studies with disulfiram (DSF) were undertaken in view of its potential to 
irreversibly inhibit aldehyde dehydrogenases and notably ability to block ALDH5A1 in 
brain slices (Hellstrom and Tottmar 1982).  DSF has been used clinically for several 
decades as a deterrent to alcohol consumption and has recently emerged as a potential 
cancer drug.  Its antitumor activity has been previously reported in both in vitro and in 
xenograft studies of breast cancer cell lines (Chen, Cui et al. 2006; Wickstrom, 
Danielsson et al. 2007), but the possibility that this activity could be due to inhibition of 
the ALDH5A1 isoform was not previously considered.  We observed that DSF at low 
micromolar concentrations was effective in inhibiting proliferation of all three DCIS 
models, while having negligible effect on the MCF10A model of normal breast epithelial 
cells.  Notably, 20 µM DSF had a significant effect on all the DCIS models in 3D rBM 
culture.  This concentration has previously been shown to have no effect on 
MCF10.DCIS cells grown in conventional 2D cell culture unless supplemented with 20 
µM CuCl2 to allow inhibition of the proteasome.   DSF forms complex with the available 
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copper and the drug-metal complex then targets the proteasome resulting in 
accumulation of tumor suppressor proteins and induction of apoptotic cell death (Chen, 
Cui et al. 2006).  In the present study, the copper concentration in the medium used for 
3D culture was approximately 1 nM.  Hence, the observed effect on proliferation is 
unlikely to be due to inhibition of proteasomal activity.  
 
5.3.2 Studies with Riluzole 
Riluzole is an FDA-approved drug for the treatment of amyotrophic lateral sclerosis 
(ALS), which is a motor neuron disease resulting from neurodegeneration in the central 
and peripheral nervous system.  Riluzole functions as a glutaminergic modulating agent 
with complex mechanisms of action.  It inhibits release of glutamate at the presynaptic 
nerve terminals by blocking voltage gated sodium channels (Urbani and Belluzzi 2000).  
It also reduces the glutamate vesicle fusion with the pre-synaptic cell membrane thus 
inhibiting glutamate release (Huang, Song et al. 1997; Wang, Wang et al. 2004).  
Treatment with riluzole was shown to decrease the glutamatergic neuronal excitation in 
SH-SY5Y human neuroblastoma cells (Arun, Moffett et al. 2010).  Riluzole also 
functions in part by blocking the metabotropic glutamate receptor mGluR1 (Speyer, 
Smith et al. 2012).  Riluzole was able to block proliferation of melanoma cell lines 
expressing mGluR1 (Namkoong, Shin et al. 2007) as well as suppress melanoma 
migration, invasion and colony formation (Le, Chan et al. 2010).  Another study showed 
that the combining multi-kinase inhibitor Sorafenib with Riluzole effectively suppressed 
proliferation in melanoma cells (Lee, Wall et al. 2011) .   
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Based on these findings, we chose riluzole to target glutamate signaling in our DCIS 
models and observe the effect of its treatment on cellular proliferation.  We found in our 
study that riluzole inhibited the proliferation of MCF10.DCIS whereas it had less 
significant effect on the MCF10A.  Furthermore, we observed that riluzole treatment 
altered the morphology and reduced the size of MCF10.AT1 and MCF10.DCIS 
structures while having no observable effect on MCF10A spheroids at the same dose.  
Our investigations of riluzole in premalignant breast gain support from a recent study 
that reported the effectiveness of riluzole in reducing tumor volume in mice bearing 
triple negative breast cancer xenografts (Speyer, Smith et al. 2011). 
We also observed in our study that riluzole treatment at low dose did not have 
significant effect on cell proliferation of SUM102 and SUM225 as that observed in 
MCF10.DCIS.  This may be attributed to the different levels of expression of mGluR1 
receptors in the different models of DCIS.  Further investigation into the levels of 
metabotropic glutamate receptors in the different DCIS models may address the 
different sensitivities of these models to riluzole treatment.   
The lack of any effect on MDA-MB-231 cell proliferation in our study is in contrast to 
the findings of Speyer et al. wherein they observed significant inhibition of proliferation 
of these cells by riluzole (Speyer, Smith et al. 2011).   A plausible explanation of this 
discrepancy lies in the doses used for the experiments.  This inhibitory effect on cellular 
proliferation was observed at a much higher dose of riluzole (at 50µM) in their study 
whereas the highest dose used in our study was 30 µM.  Another notable observation is 
that at the effective concentration of 50µM, they also observed inhibition of proliferation 
of non-transformed mammary epithelial cells.  In the present study, however, we have 
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observed differential effect of riluzole at a low dose (10 µM) on proliferation of 
MCF10.DCIS and MCF10A cells.  Overall, these findings are encouraging and suggest 
that riluzole may be a promising new approach in the treatment of DCIS either as a 
single agent or in combination therapy.   
 
5.3.3 Studies with 4-hydroxybenzaldehyde 
4-Hydroxybenzaldehyde (HBA) is a competitive inhibitor of ALDH5A1 (Rivett and 
Tipton 1981) and is a major active constituent of Gastrodiae Rhizoma, a traditional 
herbal medicine used in the treatment of migraine, epilepsy and several neurological 
disorders (Tao, Yuan et al. 2006).  With its given mechanism of ALDH5A1 inhibition, we 
tested this compound in our DCIS models to observe the effect of its treatment on cell 
survival, proliferation and morphology.  It was intriguing to observe that whereas it 
showed significant inhibition of growth with reduction in size of the MCF10.DCIS and 
MCF10.Ca1d structures in the morphology studies, it did not show any significant 
treatment effect in the cell survival and proliferation assays.  This incongruity between 
the observations may be explained by the variation in the duration of treatments for the 
morphology and cell proliferation studies.  The cells were treated with HBA for a period 
of 8 days in the morphology assays whereas for cell proliferation assays they were 
treated for a period of 72 hours.  This might well explain the observed difference 
between the treatment effects of 4-hydroxybenzaldehyde on cell growth, morphology 
and cell proliferation. 
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5.3.4 Studies with valproic acid 
Valproic acid (VPA) is a widely used drug in the treatment of epileptic seizures and 
mania in bipolar disorder.  Other approved indications include the treatment of 
neuropathic pain and as prophylaxis for migraine.  Valproic acid exerts its action by 
potentiating the inhibitory effects of neurotransmitter GABA by several mechanisms.  It 
inhibits GABA degradation and turnover and increases its synthesis (Johannessen 
2000); (Johannessen and Johannessen 2003); (Owens and Nemeroff 2003).  VPA was 
observed to affect the removal of glutamate in the synaptic cleft by up-regulating the 
glial transporter, glutamate-aspartate transporter (GLAST), and decreasing GABA 
transport resulting in increased concentrations of GABA (Ueda and Willmore 2000).   
 VPA inhibits ALDH5A1 with a Ki of ~ 0.5 mM (Whittle and Turner 1981), and this 
activity is important to its anti-seizure activity (Johannessen 2000).  More recently VPA 
has also been found to inhibit histone deacetylases with similar potency (Gottlicher, 
Minucci et al. 2001; Phiel, Zhang et al. 2001; Eyal, Yagen et al. 2004).  Notably, the 
serum concentration of VPA in patients under standard chronic therapy is 0.35 - 0.7 mM 
(Phiel, Zhang et al. 2001).  We have observed in our study that VPA, in a concentration 
dependent manner, inhibits proliferation in all three models of DCIS whereas having a 
minimal effect on the non-tumorigenic breast epithelial cells.  The concentrations of VPA 
that effectively inhibit DCIS proliferation are within the therapeutic range for VPA 
therapy in humans (Phiel, Zhang et al. 2001).  The discovery of VPA inhibition of 
histone deacetylases has provided a rationale for studies to test whether it has anti-
cancer effects, including in the context of breast cancer [e.g., ClinicalTrials.gov: 
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NCT01010854].  The results from our study suggest that inhibition of ALDH5A1 may 
contribute to its anti-tumorigenic activity.   
 
5.3.5 Conclusions 
 To summarize, ALDH5A1, an enzyme of glutamate metabolism, has not previously 
been linked to DCIS.  Two drugs, DSF and VPA, that target ALDH5A1 significantly 
reduced proliferation in all the three DCIS models.  These results taken together with 
the extensive clinical experience and safety profile of both the drugs encourage further 
studies for the potential repurposing in the treatment of DCIS. 
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Figure 5.1:  ALDH5A1 is over-expressed in DCIS models.  Whole cell lysates from 
3D rBM overlay cultures of MCF10A, MCF10.DCIS, SUM102 and SUM225 were probed 
for ALDH5A1 (upper panel) and for GAPDH (lower panel) as a loading control.  
Densitometry indicated that ALDH5A1 levels in the lysates of MCF10.DCIS, SUM102, 
and SUM225 were 2.7, 3.1, and 7.3-fold over that in MCF10A in this representative 
experiment.  In three independent analyses of MCF10.DCIS 3D rBM cultures, the mean 
increase in ALDH5A1 over control was 3.8-fold. 
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Figure 5.2: Effect of disulfiram on the proliferation of MCF10A, MCF10.DCIS, 
SUM102 and SUM225 models.  Cells were incubated for 72 hours with the indicated 
concentrations of drug or with DMSO as a vehicle control and subjected to an MTT 
assay.  Sigmoidal dose-response curves were plotted using nonlinear regression 
analysis.  Data represent the mean ± SEM of three independent experiments (each 
performed in triplicate).   
   
135 
 
 
 
Figure 5.3: Effect of riluzole on cell proliferation of MCF10A, MCF10.DCIS, 
SUM102 and SUM225.  Cells were cultured in Cultrex pre-coated 96 well plates for 72 
hours with the indicated concentrations of riluzole or with DMSO as a vehicle control 
and subjected to MTT assay.  Sigmoidal dose-response curves were plotted using 
nonlinear regression analysis.  Data represent the mean ± SEM of three independent 
experiments (each performed in triplicate).   
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Figure 5.4: Effect of valproic acid on cell proliferation of MCF10A, MCF10.DCIS, 
SUM102 and SUM225.  Cells were incubated for 72 hours with the indicated 
concentrations of valproic acid and subjected to an MTT assay.  Sigmoidal dose-
response curves were plotted using nonlinear regression analysis.  Data represent the 
mean ± SEM of three independent experiments (each performed in triplicate).   
 
137 
 
 
 
 
Figure 5.5: Treatment of MCF10A, MCF10.DCIS, MCF10.AT1 and MDA-MB-231 
three dimensional overlay cultures with Riluzole. Differential interference contrast 
images of MCF10A, MCF10.DCIS, MCF10.AT1 and MDA-MB-231cultured in 3D rBM 
overlay culture in the presence of indicated concentrations of Riluzole or DMSO as a 
vehicle control for 8 days.  DIC images at 10x magnification. Results are representative 
of each experiment performed in triplicates. 
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Figure 5.6: Treatment of MCF10A, MCF10.DCIS and MCF10.Ca1d cells with DSF. 
Differential interference contrast images of MCF10A, MCF10.DCIS and MCF10.Ca1d 
cultured in 3D rBM overlay culture in the presence of indicated concentrations of 
inhibitor or DMSO as a vehicle control for 8 days.  DIC images at 10x magnification. 
Results are representative of two independent experiments performed in duplicates. 
Control  50 µM  100 µM  
MCF10A  
MCF10.DCIS  
MCF10.Ca1d 
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Figure 5.7: Treatment of MCF10A, MCF10.DCIS and MCF10.Ca1d cells with 4-
hydroxybenzaldehyde. Differential interference contrast images of MCF10A, 
MCF10.DCIS and MCF10.Ca1d cultured in 3D rBM overlay culture in the presence of 
indicated concentrations of inhibitor or ethanol as a vehicle control for 8 days. DIC 
images at 10x magnification.  Data are representative of results from two independent 
experiments. 
 
MCF10.Ca1d 
MCF10.DCIS 
MCF10A 
Control  500 µM  1mM  
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Figure 5.8:  Treatment of MCF10.DCIS cells that express mRFP with DSF. 
Differential interference contrast (DIC) images of MCF10.DCIS-mRFP cells cultured in 
3D for 8 days in the absence or presence of the indicated concentrations of DSF or 
DMSO as a solvent control. DIC images at 10x magnification. Data are representative of 
results from three independent experiments. 
 
50 µM 20 µM DMSO Control 
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Figure 5.9: Effect of inhibitors on 3D rBM cultures of SUM102-mRFP cells.   Panel 
A) DSF; Panel B) VPA.  Cells were incubated for 8 days with the indicated 
concentrations of drugs or with DMSO as a vehicle control and DIC images are shown.  
Size bar, 90 µm.  Data are representative of results from three independent 
experiments. 
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Figure 5.10: Quantification of re-growth of SUM102-mRFP cells after drug 
exposure.  Three-dimensional rBM overlay cultures of SUM102-mRFP cells were 
treated for 8 days with the indicated concentrations of VPA (upper panel) or DSF (lower 
panel) or vehicle control.  The cells were then harvested from the matrix and re-plated in 
fresh media without inhibitors for growth in 2D over 10 days.  Results shown are mean ± 
SEM from three independent experiments. 
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Figure 5.11: Meta-analysis of normalized gene expression profiles in the 
GeneSapiens microarray database.  The highlighted designations of “Breast, ductal 
cancer” and “Breast carcinoma, NOS” include DCIS and IDC.  The boxes represent the 
quartile distribution (25-75%) range and the red horizontal lines show the median.  The 
plots also show 95% black whiskers and the individual outlier samples as small circles. 
 
 
 
 
 
 
144 
 
 
CHAPTER 6 
 
CONCLUSIONS AND PERSPECTIVES 
 
In the present study, we attempted to identify the alterations in gene expression that 
occur during the premalignant progression from normal breast to ductal carcinoma in 
situ.  We compared the gene expression profiles of DCIS mammary epithelial cells of 
various origins with the non tumorigenic mammary epithelial cells with the aim to 
elucidate significant genes and pathways underlying the premalignant transformation.  
Here, we employed a novel in vitro 3D overlay culture system that simulates the in vivo 
environment conditions.  By using this model system, we overcame the clinical issues of 
isolating the microscopic DCIS samples and were able to characterize the mammary 
epithelial cells without any contamination from the stromal components.  Also, we were 
able to obtain high quality RNA samples from the structures harvested from 3D culture 
as opposed to extraction of RNA from the formalin fixed paraffin embedded tissues that 
compromises the integrity of RNA for subsequent analysis.  At present, this is the first 
report on gene expression analysis in DCIS using the in vitro 3D culture.  
In the first part of the dissertation, we describe the identification of a common set of 
differentially expressed genes in various models of DCIS (MCF10.DCIS, SUM102 and 
SUM225) as compared to non malignant mammary epithelial cells (MCF10A) referred 
herein as ‘normal’ by Affymetrix microarray analysis.  We found that these differentially 
expressed genes are associated with a number of signaling pathways such as 
glutamate metabolism, IGF-1 signaling, integrin signaling and fatty acid biosynthesis, 
implicated and dysregulated in various cancers.  We then validated the microarray 
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findings using diverse platforms in the next chapter.  This included gene expression 
analysis by digital gene sequencing, next generation sequencing and real time PCR.  
Here, in addition to validation, we also reported the detection of low abundance and rare 
transcripts differentially expressed in DCIS.  Many differentially expressed transcripts in 
DCIS were found to be involved in cell-cell adhesion and cell proliferation implicating the 
significance of these biological processes in premalignant progression.  Furthermore, 
we identified the common promoter structures by ultra high throughput sequencing that 
may explain the functional regulation of different co-expressed genes in DCIS.  Our 
study describes the first ever application of deep sequencing technology to identify 
genetic signatures and to explore the networks and pathways that underlie DCIS of the 
breast.   
In the final chapter of this dissertation, we describe the characterization of ALDH5A1, 
an important molecular target involved in glutamate metabolic pathway that was found 
to be up-regulated in all DCIS models in microarray and sequencing studies.  We found 
that ALDH5A1 promoted cell growth and proliferation in all the three models of DCIS. 
This study is not without limitations and further studies are needed for a better 
understanding of the molecular and genetic alterations that underlie the progression 
from normal to premalignant DCIS stage.  Establishing the role of select gene products 
in driving the premalignant progression by conducting animal experiments will move this 
work forward.  Further characterization of the differentially expressed genes in various 
patient samples like tissue microarrays will strengthen the clinical significance of our 
study and may help to establish molecular markers for DCIS.  Our study characterizes 
the global transciptomic profile of breast epithelial cells, however, given the importance 
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of interactive role of stromal cells with the tumor cells in the microenvironment, future 
gene expression studies can be done with inclusion of one or more stromal components 
in the 3D culture model system.  This study lays down the basic foundation for such 
future complex studies.    
Further analysis of our deep sequencing data will be able to reveal important 
information about alternative splicing events like exon skipping, new splice junctions 
and novel isoforms in the DCIS.  Altogether, our findings move the field forward towards 
a better understanding of the gene expression changes from the normal breast 
epithelium to the premalignant DCIS stage.   
In conclusion, to the best of our knowledge, this is the first study to identify the 
transcriptional fingerprint and regulatory pathways at the whole genome level using next 
generation sequencing in the organotypic 3D overlay culture model of DCIS of the 
breast. 
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APPENDIX 
List of 295 significantly differentially expressed genes in DCIS models  
  DCIS_vs_MCF10A SUM102_vs_MCF10A SUM225_vs_MCF10A 
GeneID Symbol 
log2Fold 
Change padj 
log2Fold 
Change padj 
log2Fold 
Change padj 
12 SERPINA3 2.441 0.000 -3.206 0.000 -4.922 0.000 
125 ADH1B -Inf 0.000 -Inf 0.000 -Inf 0.000 
247 ALOX15B -3.562 0.000 -4.179 0.000 2.060 0.000 
250 ALPP -2.829 0.000 3.087 0.000 -2.956 0.000 
347 APOD 2.772 0.000 5.521 0.000 4.424 0.000 
348 APOE -7.323 0.000 -3.308 0.000 -6.379 0.000 
443 ASPA -4.969 0.000 -Inf 0.000 -Inf 0.000 
633 BGN -6.069 0.000 -8.027 0.000 -5.054 0.000 
667 DST -2.945 0.000 -3.362 0.000 -2.407 0.000 
715 C1R -4.216 0.000 -2.270 0.000 -6.984 0.000 
768 CA9 3.369 0.000 -4.963 0.000 -4.577 0.000 
810 CALML3 -8.707 0.000 -3.321 0.000 -7.863 0.000 
827 CAPN6 3.035 0.000 -7.579 0.000 -Inf 0.000 
924 CD7 -4.762 0.000 -5.703 0.000 -3.582 0.000 
970 CD70 -2.313 0.000 -3.469 0.000 -5.589 0.000 
972 CD74 2.375 0.000 -3.512 0.000 4.732 0.000 
1012 CDH13 -7.113 0.000 -3.180 0.000 -8.836 0.000 
1131 CHRM3 3.020 0.000 -Inf 0.000 -3.503 0.000 
1277 COL1A1 -4.160 0.000 -2.486 0.000 -3.065 0.000 
1280 COL2A1 -5.783 0.000 -3.170 0.000 -Inf 0.000 
1288 COL4A6 -3.427 0.000 -2.433 0.000 -7.475 0.000 
1294 COL7A1 -2.576 0.000 -2.491 0.000 -5.730 0.000 
1295 COL8A1 3.055 0.000 -2.052 0.000 -Inf 0.000 
1308 COL17A1 -3.105 0.000 -4.103 0.000 -10.474 0.000 
1356 CP 3.314 0.000 -4.829 0.000 -4.437 0.000 
1363 CPE 2.297 0.000 2.816 0.000 4.336 0.000 
1364 CLDN4 2.193 0.000 5.508 0.000 4.209 0.000 
1435 CSF1 -3.621 0.000 -2.563 0.000 -4.493 0.000 
1440 CSF3 -4.240 0.000 2.743 0.000 -3.372 0.000 
1634 DCN -6.528 0.000 -5.016 0.000 -Inf 0.000 
1796 DOK1 2.379 0.000 -3.284 0.000 -4.355 0.000 
1805 DPT -4.173 0.001 -Inf 0.000 -Inf 0.000 
1836 SLC26A2 2.359 0.000 -3.389 0.000 -5.882 0.000 
1907 EDN2 -2.138 0.000 -4.704 0.000 -4.482 0.000 
1999 ELF3 2.444 0.000 4.181 0.000 2.364 0.000 
2239 GPC4 2.578 0.000 -2.522 0.000 -Inf 0.000 
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2261 FGFR3 -7.542 0.000 -3.606 0.000 -2.700 0.000 
2281 FKBP1B -3.561 0.000 -3.721 0.000 -Inf 0.000 
2308 FOXO1 -2.927 0.000 -2.732 0.000 -3.423 0.000 
2525 FUT3 2.889 0.000 4.143 0.000 4.379 0.000 
2532 DARC -Inf 0.000 -5.146 0.000 -Inf 0.000 
2535 FZD2 -2.428 0.000 -2.542 0.000 -2.804 0.000 
2628 GATM 3.253 0.000 -Inf 0.000 5.273 0.000 
2706 GJB2 3.192 0.000 4.106 0.000 -2.180 0.000 
2737 GLI3 -3.090 0.000 -2.058 0.000 -3.839 0.000 
2741 GLRA1 -3.123 0.000 -4.439 0.000 -2.372 0.000 
3092 HIP1 -3.918 0.000 -2.218 0.000 -3.897 0.000 
3176 HNMT 2.763 0.000 2.172 0.001 3.821 0.000 
3204 HOXA7 3.178 0.000 3.372 0.000 2.373 0.000 
3382 ICA1 2.135 0.000 2.625 0.000 4.032 0.000 
3399 ID3 -3.951 0.000 -2.384 0.000 -2.785 0.000 
3492 IGH@ -Inf 0.000 -Inf 0.000 -2.723 0.000 
3635 INPP5D -3.269 0.000 -2.288 0.000 -5.240 0.000 
3691 ITGB4 2.208 0.000 -3.660 0.000 -6.051 0.000 
3745 KCNB1 -2.651 0.000 -5.289 0.000 -5.904 0.000 
3853 KRT6A -2.053 0.000 2.360 0.000 -4.099 0.000 
3854 KRT6B 2.823 0.000 2.275 0.000 -3.748 0.000 
3855 KRT7 2.694 0.000 4.091 0.000 3.736 0.000 
3861 KRT14 -7.433 0.000 -2.679 0.000 -9.086 0.000 
3912 LAMB1 -3.809 0.000 -3.968 0.000 -7.238 0.000 
3934 LCN2 2.234 0.000 6.333 0.000 3.043 0.000 
4017 LOXL2 3.013 0.000 -3.312 0.000 -3.514 0.000 
4064 CD180 2.852 0.000 -Inf 0.001 -Inf 0.000 
4129 MAOB 2.017 0.000 -2.860 0.000 -Inf 0.000 
4241 MFI2 2.698 0.000 -4.864 0.000 -4.476 0.000 
4313 MMP2 2.826 0.000 -5.679 0.000 -5.295 0.000 
4493 MT1E -6.242 0.000 -3.778 0.000 -8.621 0.000 
4684 NCAM1 2.979 0.000 -3.705 0.000 -Inf 0.000 
4776 NFATC4 2.660 0.000 3.424 0.000 3.346 0.000 
4811 NID1 -Inf 0.000 -6.183 0.000 -Inf 0.000 
4915 NTRK2 2.726 0.000 -Inf 0.000 -Inf 0.000 
5063 PAK3 2.061 0.000 -Inf 0.000 -3.541 0.000 
5067 CNTN3 3.073 0.000 -2.530 0.001 -Inf 0.000 
5099 PCDH7 -5.215 0.000 -2.127 0.000 -2.353 0.000 
5137 PDE1C 2.669 0.000 -Inf 0.000 -Inf 0.000 
5155 PDGFB 2.412 0.000 2.162 0.000 3.569 0.000 
5176 SERPINF1 -3.726 0.000 -2.540 0.000 -5.328 0.000 
5376 PMP22 2.942 0.000 -2.898 0.000 -Inf 0.000 
5603 MAPK13 2.001 0.000 2.580 0.000 3.463 0.000 
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5654 HTRA1 -3.437 0.000 -3.719 0.000 -3.027 0.000 
5909 RAP1GAP 2.261 0.000 2.015 0.000 6.110 0.000 
5990 RFX2 -4.368 0.000 -2.052 0.000 -2.083 0.000 
5997 RGS2 -2.757 0.000 3.436 0.000 -3.013 0.000 
6090 RNY5 -Inf 0.000 -Inf 0.000 -2.742 0.000 
6271 S100A1 2.899 0.000 -4.376 0.000 -2.759 0.000 
6286 S100P 2.435 0.000 4.158 0.000 2.803 0.000 
6319 SCD 2.367 0.000 2.063 0.000 3.612 0.000 
6364 CCL20 3.329 0.000 5.673 0.000 3.656 0.000 
6376 CX3CL1 2.963 0.000 -4.851 0.000 6.709 0.000 
6398 SECTM1 -4.361 0.000 -3.122 0.000 -4.039 0.000 
6441 SFTPD -2.912 0.000 -2.182 0.001 -2.379 0.000 
6542 SLC7A2 -Inf 0.000 -2.339 0.000 -4.542 0.000 
6947 TCN1 2.468 0.000 -2.744 0.000 -4.258 0.000 
7045 TGFBI -5.095 0.000 -6.042 0.000 -11.619 0.000 
7049 TGFBR3 -3.143 0.000 -6.830 0.000 -4.613 0.000 
7078 TIMP3 -4.420 0.000 -3.086 0.000 -5.973 0.000 
7092 TLL1 -Inf 0.000 -3.983 0.000 -Inf 0.000 
7097 TLR2 -4.569 0.000 3.708 0.000 2.803 0.000 
7161 TP73 -4.437 0.000 -4.972 0.000 -2.587 0.000 
7291 TWIST1 -2.128 0.000 -2.631 0.000 -8.800 0.000 
7368 UGT8 2.705 0.000 -Inf 0.000 -3.861 0.000 
7570 ZNF22 2.191 0.000 2.647 0.000 3.397 0.000 
7704 ZBTB16 -7.287 0.000 -4.061 0.000 -4.390 0.000 
7915 ALDH5A1 2.146 0.000 2.688 0.000 2.968 0.000 
8343 HIST1H2BF 2.711 0.000 3.648 0.000 3.230 0.000 
8515 ITGA10 2.571 0.000 -4.867 0.000 -5.428 0.000 
8645 KCNK5 2.642 0.000 -2.994 0.000 -2.380 0.000 
8698 S1PR4 -2.036 0.000 -5.305 0.000 -Inf 0.000 
8706 B3GALNT1 2.925 0.000 2.626 0.000 4.365 0.000 
8839 WISP2 -6.739 0.000 -6.653 0.000 -3.848 0.000 
8991 SELENBP1 -2.130 0.000 -2.666 0.000 2.362 0.000 
9080 CLDN9 2.809 0.001 3.066 0.000 4.958 0.000 
9227 LRAT 3.034 0.000 -3.331 0.000 -2.678 0.000 
9241 NOG 2.033 0.000 -2.739 0.000 -2.349 0.000 
9289 GPR56 2.687 0.000 2.396 0.000 3.387 0.000 
9435 CHST2 -3.568 0.000 -2.323 0.000 -4.735 0.000 
9586 CREB5 3.117 0.000 4.440 0.000 3.586 0.000 
9610 RIN1 -2.134 0.000 -2.229 0.000 -5.315 0.000 
9651 PLCH2 -4.224 0.000 -3.027 0.000 -5.950 0.000 
9672 SDC3 -2.707 0.000 -5.151 0.000 -2.433 0.000 
9750 FAM65B -5.709 0.000 -2.481 0.000 -3.851 0.000 
9805 SCRN1 2.248 0.000 3.101 0.000 2.684 0.000 
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9839 ZEB2 -3.903 0.000 -3.420 0.000 -4.028 0.000 
9843 HEPH 2.931 0.000 -3.106 0.000 -4.304 0.000 
9976 CLEC2B -2.019 0.000 -2.691 0.000 -3.807 0.000 
10170 DHRS9 2.139 0.000 2.184 0.000 -3.197 0.000 
10232 MSLN -6.636 0.000 -4.824 0.000 -6.784 0.000 
10388 SYCP2 2.147 0.000 -3.067 0.000 3.298 0.000 
10398 MYL9 -3.996 0.000 -7.321 0.000 -3.871 0.000 
10409 BASP1 -3.345 0.000 3.669 0.000 -2.612 0.000 
10544 PROCR -2.226 0.000 -3.217 0.000 -7.960 0.000 
10551 AGR2 3.043 0.000 5.173 0.000 6.818 0.000 
10630 PDPN -Inf 0.000 -3.270 0.000 -Inf 0.000 
10631 POSTN -4.984 0.000 -4.897 0.000 -Inf 0.000 
10656 KHDRBS3 2.442 0.000 -6.158 0.000 -2.654 0.000 
10816 SPINT3 -Inf 0.000 -Inf 0.000 -Inf 0.000 
10942 PRSS21 2.541 0.000 -2.337 0.000 -2.983 0.000 
11341 SCRG1 3.036 0.000 -Inf 0.000 -Inf 0.000 
22997 IGSF9B -3.340 0.000 -7.496 0.000 -7.112 0.000 
23043 TNIK -2.178 0.000 -3.511 0.000 -3.899 0.000 
23087 TRIM35 -2.654 0.000 -2.311 0.000 -4.489 0.000 
23105 FSTL4 -Inf 0.000 -Inf 0.000 -2.512 0.001 
23157 SEPT6 2.686 0.000 3.911 0.000 4.444 0.000 
23255 KIAA0802 -2.025 0.000 -2.107 0.000 -2.305 0.000 
23284 LPHN3 2.581 0.000 -Inf 0.000 -4.298 0.000 
23329 TBC1D30 2.240 0.000 2.995 0.000 3.613 0.000 
23507 LRRC8B 2.530 0.000 2.139 0.001 3.515 0.000 
23555 TSPAN15 2.187 0.000 2.668 0.000 4.121 0.000 
23767 FLRT3 -2.666 0.000 -3.197 0.000 -4.825 0.000 
25791 NGEF 2.779 0.000 -2.984 0.000 -2.309 0.000 
25841 ABTB2 2.019 0.000 2.541 0.000 2.685 0.000 
26018 LRIG1 2.309 0.000 -2.865 0.000 2.113 0.000 
26050 SLITRK5 -4.489 0.000 -Inf 0.000 -Inf 0.000 
26227 PHGDH 2.435 0.000 2.410 0.000 5.083 0.000 
26287 ANKRD2 -3.547 0.000 -4.160 0.000 -Inf 0.000 
26577 PCOLCE2 2.816 0.000 -5.106 0.000 -Inf 0.000 
26579 MYEOV 3.023 0.000 2.768 0.000 -3.461 0.000 
26771 SNORD102 -Inf 0.000 -Inf 0.000 -Inf 0.000 
27065 D4S234E -2.525 0.000 -3.951 0.000 -6.959 0.000 
27134 TJP3 2.058 0.000 3.298 0.000 2.751 0.000 
27293 SMPDL3B 2.346 0.000 2.777 0.000 3.074 0.000 
28513 CDH19 3.124 0.000 -Inf 0.000 -Inf 0.000 
28999 KLF15 -2.775 0.000 -Inf 0.000 -6.105 0.000 
29841 GRHL1 2.110 0.000 4.940 0.000 2.827 0.000 
51170 HSD17B11 -3.063 0.000 -2.196 0.000 -Inf 0.000 
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51330 TNFRSF12A 2.027 0.000 2.502 0.000 2.144 0.000 
53947 A4GALT -4.483 0.000 -8.590 0.000 -8.787 0.000 
54437 SEMA5B -5.613 0.000 -3.554 0.000 -Inf 0.000 
54453 RIN2 -2.088 0.000 -2.021 0.000 -2.507 0.000 
54504 CPVL 2.730 0.000 -2.780 0.000 -4.335 0.000 
54831 BEST2 -4.024 0.000 -3.540 0.000 -4.737 0.000 
54836 BSPRY 3.081 0.000 3.141 0.000 3.034 0.000 
54845 ESRP1 2.763 0.000 3.781 0.000 3.845 0.000 
54863 C9orf167 -3.087 0.000 2.709 0.000 -2.732 0.000 
55224 ETNK2 -5.539 0.000 -4.243 0.000 -3.650 0.000 
55349 CHDH 2.685 0.000 -3.598 0.000 3.350 0.000 
55653 BCAS4 -2.511 0.000 -2.115 0.000 -3.019 0.000 
56125 PCDHB11 -2.292 0.000 -4.940 0.000 -Inf 0.000 
56241 SUSD2 2.512 0.000 -2.093 0.000 3.972 0.000 
57111 RAB25 2.966 0.000 2.620 0.000 2.220 0.000 
57484 RNF150 2.770 0.000 -4.221 0.000 -Inf 0.000 
57604 C8orf79 -4.266 0.000 -4.672 0.000 -4.877 0.000 
57639 CCDC146 -2.406 0.000 -2.355 0.000 -2.380 0.000 
57863 CADM3 -7.274 0.000 -7.246 0.000 -Inf 0.000 
58473 PLEKHB1 2.936 0.000 -3.621 0.000 -2.973 0.000 
64063 PRSS22 2.451 0.000 4.864 0.000 3.057 0.000 
64218 SEMA4A 2.161 0.000 2.385 0.000 4.289 0.000 
65987 KCTD14 2.569 0.000 -4.803 0.000 -3.007 0.000 
65989 DLK2 -3.014 0.000 -5.486 0.000 -4.097 0.000 
65997 RASL11B -6.031 0.000 -3.651 0.000 -5.573 0.000 
66002 CYP4F12 -6.324 0.000 -3.236 0.000 -3.627 0.000 
78995 C17orf53 -2.335 0.000 -2.662 0.000 -2.094 0.000 
79094 CHAC1 2.283 0.000 5.749 0.000 4.450 0.000 
79148 MMP28 -3.160 0.000 -2.342 0.000 -8.417 0.000 
79156 PLEKHF1 2.223 0.000 2.515 0.000 3.162 0.000 
79603 LASS4 -Inf 0.000 -2.613 0.000 2.624 0.000 
79783 C7orf10 -2.955 0.000 -2.164 0.000 -6.571 0.000 
79919 C2orf54 2.445 0.000 5.541 0.000 4.158 0.000 
79977 GRHL2 3.063 0.000 4.669 0.000 5.573 0.000 
80023 NRSN2 2.600 0.000 -4.542 0.000 3.114 0.000 
80117 ARL14 -5.054 0.000 -3.440 0.000 -4.234 0.000 
80176 SPSB1 -2.947 0.000 -2.522 0.000 -2.585 0.000 
81606 LBH -Inf 0.000 -2.638 0.000 -4.530 0.000 
81623 DEFB126 -Inf 0.000 -Inf 0.000 -Inf 0.000 
81848 SPRY4 2.789 0.000 3.017 0.000 4.688 0.000 
83700 JAM3 -4.476 0.000 -5.389 0.000 -3.996 0.000 
84109 QRFPR 2.464 0.000 -3.506 0.000 -Inf 0.000 
84707 BEX2 2.804 0.000 2.424 0.000 4.008 0.000 
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84913 ATOH8 -6.495 0.000 -Inf 0.000 -2.271 0.000 
84940 CORO6 -4.903 0.000 -2.513 0.000 -5.036 0.000 
84969 TOX2 -4.599 0.000 -5.204 0.000 -Inf 0.000 
89932 PAPLN -4.569 0.000 -3.066 0.000 -3.549 0.000 
90226 UCN2 -3.376 0.000 -3.025 0.000 -Inf 0.000 
90362 FAM110B -Inf 0.000 -4.142 0.001 -4.328 0.000 
90525 SHF 2.716 0.000 -4.094 0.000 -4.007 0.000 
92126 DSEL -3.212 0.000 -4.991 0.000 -6.511 0.000 
94162 SNORD38A -Inf 0.000 -Inf 0.000 -Inf 0.000 
114088 TRIM9 2.939 0.000 -Inf 0.000 -Inf 0.000 
114783 LMTK3 2.533 0.000 2.532 0.000 4.652 0.000 
114897 C1QTNF1 2.579 0.000 2.253 0.000 -4.141 0.000 
117195 MRGPRX3 2.793 0.000 3.479 0.000 -4.783 0.000 
117248 GALNTL2 -3.208 0.000 -3.031 0.000 -6.024 0.000 
120892 LRRK2 -2.211 0.000 -2.310 0.000 -2.872 0.000 
124930 ANKRD13B -2.138 0.000 -2.878 0.000 -4.047 0.000 
124975 GGT6 2.480 0.000 3.418 0.000 3.922 0.000 
126433 FBXO27 3.614 0.000 3.573 0.000 3.765 0.000 
128218 TMEM125 2.468 0.000 2.061 0.000 3.430 0.000 
130497 OSR1 2.896 0.000 -5.165 0.000 -6.362 0.000 
135398 C6orf141 -2.378 0.000 -2.487 0.000 -5.232 0.000 
144195 SLC2A14 -3.762 0.000 -4.705 0.000 -Inf 0.000 
144501 KRT80 2.732 0.000 5.486 0.000 3.144 0.000 
146439 CCDC64B 2.103 0.000 4.315 0.000 4.032 0.000 
146802 SLC47A2 -4.069 0.000 -6.340 0.000 -4.536 0.000 
147920 IGFL2 -Inf 0.000 -2.562 0.000 -Inf 0.000 
151473 SLC16A14 3.631 0.000 4.073 0.000 6.321 0.000 
153346 LOC153346 -2.139 0.000 -3.796 0.000 -2.380 0.000 
161291 TMEM30B 2.547 0.000 2.036 0.000 4.281 0.000 
163259 DENND2C -2.984 0.000 2.142 0.000 -3.336 0.000 
165545 DQX1 -2.443 0.000 -3.583 0.000 -5.055 0.000 
200634 KRTCAP3 2.046 0.000 -4.032 0.000 -4.426 0.000 
200879 LIPH 2.122 0.000 4.346 0.000 5.099 0.000 
221400 TDRD6 -2.529 0.000 -5.067 0.000 -5.275 0.000 
223075 CCDC129 2.874 0.000 -Inf 0.000 -Inf 0.000 
255189 PLA2G4F -5.278 0.000 -2.672 0.000 -5.253 0.000 
257000 PLAC2 -3.129 0.000 3.075 0.000 2.297 0.000 
283174 LOC283174 -3.309 0.000 -Inf 0.000 -8.498 0.000 
284759 SIRPB2 -3.718 0.000 -3.657 0.000 -5.024 0.000 
285195 SLC9A9 -5.110 0.000 -2.987 0.000 -7.565 0.000 
285944 LOC285944 2.970 0.000 3.405 0.000 2.302 0.000 
286527 TMSB15B -3.789 0.000 -4.523 0.000 -Inf 0.000 
340359 KLHL38 -6.074 0.000 -3.846 0.000 -3.402 0.000 
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341640 FREM2 2.984 0.000 -Inf 0.000 -Inf 0.000 
388611 CD164L2 -4.286 0.000 -2.803 0.000 -3.415 0.000 
400945 FLJ41481 -3.785 0.000 -Inf 0.000 -3.513 0.000 
401827 MSLNL -5.539 0.000 -5.449 0.000 -Inf 0.000 
441869 hCG_20426 -3.645 0.000 -2.587 0.000 -4.776 0.000 
642587 LOC642587 -4.208 0.000 -3.985 0.000 -6.783 0.000 
643965 TMEM88B -3.851 0.000 -2.530 0.000 -3.990 0.000 
645027 EVPLL -5.270 0.000 -5.183 0.000 -3.378 0.000 
646543 LOC646543 -2.493 0.000 -Inf 0.000 -8.203 0.000 
692111 SNORD71 -2.111 0.000 -3.051 0.000 -3.067 0.000 
692198 SNORD78 -2.494 0.000 -2.464 0.000 -2.470 0.000 
727936 GLT8D4 2.031 0.000 -2.941 0.000 -Inf 0.000 
728196 LOC728196 -5.172 0.000 -5.142 0.000 -Inf 0.000 
100128031 LOC100128031 2.076 0.000 5.421 0.000 4.188 0.000 
100128186 LOC100128186 -Inf 0.000 -Inf 0.000 -Inf 0.000 
100128501 LOC100128501 -4.274 0.000 -2.714 0.000 -2.707 0.000 
100128703 LOC100128703 2.802 0.000 -2.357 0.000 -3.554 0.000 
100128770 LOC100128770 2.819 0.000 4.698 0.000 4.696 0.000 
100128789 LOC100128789 4.767 0.000 5.212 0.000 5.226 0.000 
100129500 LOC100129500 -7.347 0.000 -3.416 0.000 -6.607 0.000 
100130131 LOC100130131 -Inf 0.000 -2.984 0.000 -3.168 0.000 
100131825 LOC100131825 -Inf 0.000 -Inf 0.000 -Inf 0.000 
100132240 LOC100132240 2.607 0.000 -2.316 0.000 -6.213 0.000 
100192386 FLJ16779 -4.969 0.000 -4.939 0.000 -Inf 0.000 
100286923 LOC100286923 -Inf 0.000 -4.482 0.000 -3.546 0.000 
100287089 LOC100287089 -3.047 0.000 -2.669 0.000 -6.761 0.000 
100287407 LOC100287407 -2.154 0.000 -3.512 0.000 -5.293 0.000 
100287558 LOC100287558 -Inf 0.000 -4.770 0.000 -4.553 0.000 
100288023 LOC100288023 -3.341 0.000 -3.087 0.000 -3.277 0.000 
100288314 LOC100288314 2.504 0.000 2.102 0.000 3.485 0.000 
100288409 LOC100288409 -Inf 0.000 -2.860 0.000 -2.382 0.000 
100288670 LOC100288670 -2.681 0.000 -5.780 0.000 -2.276 0.000 
100288776 LOC100288776 2.615 0.000 3.669 0.000 3.610 0.000 
100288925 LOC100288925 -Inf 0.000 -Inf 0.000 -6.036 0.000 
100289165 LOC100289165 -5.790 0.000 -4.591 0.000 -4.152 0.000 
100289344 LOC100289344 -3.842 0.000 -Inf 0.000 -3.951 0.000 
100289437 LOC100289437 -2.724 0.000 -Inf 0.000 -5.107 0.000 
100289488 LOC100289488 2.465 0.000 4.144 0.000 2.317 0.000 
100289567 LOC100289567 -3.524 0.000 -2.549 0.000 -4.655 0.000 
100289603 LOC100289603 -3.837 0.000 -Inf 0.000 -Inf 0.000 
100289660 LOC100289660 -4.173 0.001 -Inf 0.000 -Inf 0.000 
100290920 LOC100290920 -5.694 0.000 -6.189 0.000 -Inf 0.000 
100293045 LOC100293045 -2.838 0.000 -7.650 0.000 -6.259 0.000 
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100294404 LOC100294404 -4.499 0.000 -2.776 0.000 -3.924 0.000 
 
 
The values in each column represent the log2 fold change in a DCIS model over 
MCF10A with adjusted p-value.  “Inf” indicates that no reads mapped to that DCIS 
model.  
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ABSTRACT 
ANALYSIS OF GENE EXPRESSION ALTERATIONS IN PREMALIGNANT 
PROGRESSION FROM NORMAL MAMMARY EPITHELIUM TO DUCTAL 
CARCINOMA IN SITU BY MULTIPLE ORTHOGONAL TOOLS 
by 
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Major: Pharmacology 
Degree: Doctor of Philosophy 
Mammary ductal carcinoma in situ (DCIS) is being found in great numbers of women 
due to the widespread use of mammography.  The molecular and genetic changes 
underlying the progression from normal breast tissue to DCIS are not clearly 
understood.  The goal of the present study was to determine gene expression changes 
in different DCIS models (MCF10.DCIS, SUM102 and SUM225) in comparison to non-
transformed breast epithelial cells (MCF10A) that may enable us to identify novel 
markers of disease progression and potential therapeutic targets. 
 We cultured the cells in three dimensional (3D) overlay cultures with reconstituted 
basement membrane (rBM) and subjected the extracted RNA to whole genome 
expression analysis by Affymetrix GeneChip® U133A 2.0 Arrays.  We found 157 genes 
that were consistently differentially expressed between MCF10A and different DCIS 
models.  Pathway analysis showed that a subset of differentially expressed genes in 
DCIS is strongly linked to glutamate metabolism and others involved in dysregulation of 
various pathways such as IGF-1 signaling, integrin signaling and fatty acid biosynthesis.  
To further enrich the expression data and identify low abundance transcripts we 
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employed next generation sequencing (RNA-Seq) using Illumina Genome Analyzer 
GAIIx.  Analysis of the sequencing data showed 295 consistently differentially 
expressed transcripts in the DCIS models.  We found that these differentially expressed 
genes encode proteins that are associated with a number of signaling pathways such as 
integrin, fibroblast growth factor and TGFβ signaling and show association with cell-cell 
signaling, cell-cell adhesion and cell proliferation.  We further mined our sequencing 
data to explore common frameworks in the promoter regions of differentially expressed 
genes.  We found significant enrichment of several common frameworks present in 
promoters of several genes like ELF3, CCL20, NFATC4, RAP1GAP, SPRY4 and 
PDGFB.  We also validated the expression data from microarray and RNA Seq with 
quantitative real-time PCR (qRT-PCR) of selected differentially expressed genes. 
We further characterized ALDH5A1, which encodes the enzyme aldehyde 
dehydrogenase 5A1 that is involved in mitochondrial glutamate metabolism.  We found 
that ALDH5A1 protein is over-expressed in all three DCIS models.  Further, two 
different drugs, disulfiram and valproic acid, that target ALDH5A1 significantly inhibited 
growth and proliferation in the DCIS models, but had minimal effect on MCF10A.   Our 
results suggest that ALDH5A1 may play an important role in DCIS and additional 
studies are warranted to evaluate the potential repurposing of disulfiram and valproic 
acid to treat DCIS. 
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